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Résumé en Français 
Rôle physiopathologique des anticorps catalytiques et des anticorps polyréactifs 
par 
Ankit MAHENDRA 
<< Biotechnologie et mise en œuvre des Fonctions Biologiques >> 
Thesis is presented at the Faculty of the Université de Technologie de Compiègne for 
obtaining the degree of Doctor of Philosophy (Ph.D) of the Université de Technologie de 
Compiègne 
Les mot-clés en Français – anticorps catalytiques, abzymes, anticorps polyréactifs, 
hémophlie acquise, transplantation rénale, facteur VIII, facteur IX 
Les anticorps sont les molécules effectrices de l’immunité adaptatrice humorale. Ils se 
lient spécifiquement et neutralisent une large panoplie d’antigènes. Au-delà de leurs 
fonctions classiques, les anticorps possèdent les propriétés moins explorées que sont 
l’activité catalytique, qui permet aux anticorps de se comporter comme des enzymes, et la 
polyréactivité, qui représente la capacité d’une molécule d’anticorps à se lier à plusieurs 
antigènes structurellement différents.  
Les anticorps catalytiques sont retrouvés dans plusieurs pathologies chez l’homme, telle 
que l’hémophilie acquise, une maladie caractérisée par la survenue d’autoanticorps anti-
facteur VIII. Dans ce travail, nous décrivons des IgG hydrolysant et activant le facteur IX 
de la coagulation chez les patients avec hémophilie acquise. Par ailleurs, nous avons 
effectué une étude longitudinale de deux ans des IgG catalytiques chez les patients 
subissant une transplantation rénale.  
Les anticorps polyréactifs représentent une proportion importante du répertoire des 
immunoglobulines circulantes. De plus, les sites inflammatoires sont abondants en 
molécules, telles que l’hème libre, capables de rendre polyréactives certaines IgG 
monoréactives. Nous avons étudié l’influence de la nature des régions constantes de la 
chaîne lourde des anticorps sur leur susceptibilité à devenir polyréactifs.  
Ce travail apporte un nouvel éclairage sur l’importance physiopathologique des anticorps 
catalytiques et polyréactifs.  
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Résumé en Anglais 
Physiopathological role of catalytic and polyreactive antibodies 
by 
Ankit MAHENDRA 
<< Biotechnologie et mise en œuvre des Fonctions Biologiques >> 
Thesis is presented at the Faculty of the Université de Technologie de Compiègne for 
obtaining the degree of Doctor of Philosophy (Ph.D) of the Université de Technologie de 
Compiègne  
Les mot clés en Anglais – Catalytic antibodies, abzymes, polyreactive antibodies, 
acquired hemophilia, renal transplant, factor VIII, and factor IX 
Antibodies are effector molecules of the humoral arm of the adaptive immune system that 
bind specifically and neutralize diverse array of antigens. Beyond the classical function 
of antibodies exist the relatively less explored properties, of “catalytic activity” that 
enable antibodies to act as enzymes and “polyreactivity” that confers the ability to bind to 
several structurally unrelated antigens. 
Catalytic antibodies have been associated with several autoimmune, inflammatory and 
infectious diseases. Acquired hemophilia is an autoimmune disease, reported with the 
presence of catalytic antibodies against coagulation factor FVIII. In the present work, we 
have investigated the presence of factor IX (FIX) hydrolyzing IgG in patients with 
acquired hemophilia. We investigated the molecular mechanism and the physiological 
relevance of FIX activation upon hydrolysis by patients’ IgG. In addition, a longitudinal 
follow-up for 2 years was done in patients undergone renal transplant to investigate the 
evolution of catalytic antibodies in the course of disease.  
Polyreactive antibodies constitute a major portion of the natural antibody repertoire. 
Additionally, sites of inflammation are abundant in protein destabilizing agents like free 
heme that can induce polyreactivity in monoreactive antibodies. We have investigated the 
effect of the antibody constant domain on heme-induced polyreactivity. 
The present work has allowed us a better understanding of the physiopathological 
relevance of catalytic and polyreactive antibodies. 
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Introduction 
 
Immunoglobulins (Ig) are glycoproteins that act as effector molecules of the humoral 
immune system. They are the end-product of humoral arm of the adaptive immune 
response. Immunoglobulins are molecules widespread among leaving species and are 
believed to be present early in ontogeny, as shown by their presence in lower vertebrates 
like sharks and birds. They are commonly acknowledged for their implication in 
eliminating pathogens and neutralizing toxins. This process is permitted by the exquisite 
specificity for single molecular structures (epitopes on antigens) and the large repertoire 
of different specificities, which in theory covers the entire array of foreign molecules that 
the organism may potentially confront. 
Beyond the classical view/understanding of immunoglobulins, lies an array of functions, 
which are still confidential to a minor portion of the scientific community. This includes 
in particular, their seminal role in innate immunity that relies on the capacity of some Ig 
to bind several structurally unrelated antigens (referred to as “polyspecific antibodies”) 
and their capacity to behave as enzymes (referred to as “catalytic antibodies”).  
The main focus of my thesis work was concentrated on the latter properties of 
immunoglobulins.  
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1. Immunoglobulins  
 
1.1.  Structure of immunoglobulins 
Immunoglobulins (Ig) are heterodimeric glycoproteins that consist of two heavy and two 
light polypeptide chains and belong to the Ig-domain superfamily (Figure 1). The 
molecular weight of the heavy chain is 50 kDa for immunoglogulins IgA, IgD and IgG, 
or 75 kDa for IgM and IgE. The molecular weight of the light chain is 25 kDa. The heavy 
and light chains interact with each other by strong covalent forces in the form of 
disulphide linkages as well as by non-covalent bonds such as hydrophobic interactions, 
salt bridges and hydrogen bonding. N-linked glycosylation is a common feature of Igs 
and is known to play an important role in Ig structure and function. However, O-linked 
glycosylation is less common and found only in the IgD and IgA1 class of antibodies (Mattu	  et	  al.,	  1998). Although glycosylation is the main feature of the constant region, it 
is often present in the variable region as well where it may affect secretion, half-life, 
antigen-binding and organ targeting. The predominant classes of immunoglobulins found 
in soluble form in the circulation are IgG>IgM>IgA>IgE. Surface-expressed 
immunoglobulins constitute the B-cell receptor (BcR). While immunoglobulins of the 
IgD, IgE and IgG class always circulate as monomers, circulating IgM are pentameric, 
and IgA primarly exist as monomer or dimer and, to a lesser extent, as trimer or 
tertramer. The multimeric form of Igs is structured by a linker polypeptide of 15 kDa, 
referred to as J-chain (Waldmann,	  1991).  
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Figure 1. Structure of immunoglobulin 
	  
Structure of the heavy chain  
The heavy chain encompasses a 110-amino acid-long, highly variable region and a 
constant region that is 330-440-amino acid-long depending on the antibody isotypes. The 
isotypes have been designated by Greek letters: γ, δ, α, µ, and ε, thus defining the IgG, 
IgD, IgA, IgM and IgE classes of the antibodies, respectively. 
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The variable region of the antibody heavy chain consists of two main parts; (1) 
hypervariable regions (HVs), which are also called complementarity-determining regions 
(CDRs) due to their complementarity towards antigen epitopes; (2) framework regions 
(FRs), that exhibit far less variations in their amino acid sequences. The constant region 
of the antibody heavy chain consists of several domains referred as CH1, CH2, CH3 and 
CH4. The antibody classes IgG, IgD, IgA contain three constant domains, whereas IgM 
and IgE consist of four constant domains. The CH1 and CH2 domains are separated by a 
hinge region that provides some flexibility to the molecule (Kuby et al, 2000).  
Structure of the light chain 
The length of the light chain is between 211-217 amino acids, of which the variable 
region is constituted of 110 amino acids. As the heavy chain, the light chain variable 
region also consists of similar number of CDRs and FRs. The light chain consists of only 
one constant domain. The constant domain is classified into two classes; kappa (k) and 
lambda (λ). The percentage distribution of kappa and lambda chains is 60% and 40% in 
humans, whereas, in mice it is 95% and 5% (Kuby et al, 2000). The light chain constant 
region is composed of only one constant domain referred as CL. 
From a functional perspective, Igs are bipolar molecules. The N-terminal end of the 
molecule (of both heavy and light chains) is implicated in antigen binding. The binding 
activity is resumed in the combined VH and VL regions. The binding part of antibodies 
can be isolated from the rest of the molecule by enzymatic digestion (Figure 2). Thus, 
digestion of IgG with pepsin generates a so-called F(ab’)2 fragments of 110 kD that 
contain two molecules each of VH-CH1-hinge and VL-Ck/λ bound by disulfide bridges. 
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Conversely, IgG digestion by papain generates Fab fragments of 50 kD that contain one 
VH- CH1 region attached to a VL- Ck/λ.  
The C-terminal half of the molecule (the CH2-CH3/4 domains) mediates interactions with 
other molecules or cells of the immune system, including complement molecules and Fc-
receptors. The C-terminal part of the molecule is referred to as the Fc portion of the 
immunoglobulin.  
Figure 2. Enzymatic digestions of immunoglobulin molecule 
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1.2.  Generation of a diverse repertoire of immunoglobulins  
The vertebrate immune system has a remarkable ability to generate antibodies against a 
enormous diversity of antigens. This capability is ensured by a dynamic genetic 
machinery that generates more than 1010 combinations of immunoglobulin gene 
arrangements. However, the number of immunoglobulin gene segments is very limited (Nemazee,	  2006). The vertebrate B cells employ several mechanisms that allow them to 
generate large array of antibodies from a relatively small number of immunoglobulin 
genes. These mechanisms include variable-region gene recombination, junctional 
diversity and random pairing.  
Variable-region gene recombination:  
The first level of generation of diversity is by random rearrangement of VDJ/VD genes. 
The variable region of the heavy chain is encoded by three genes, which are referred as 
variable (V), diversity (D) and joining (J) genes	   (Nemazee,	   2006). The light chain is 
encoded by the V and J genes. The human gene repertoire encompasses 51 VH, 27 DH 
and 6 JH genes, as well as 40 VL and 5 JL genes. The rearrangement of variable region 
genes occurs during the ontogeny of B cells in the bone marrow by random 
recombinational events that lead to the shuffling of the immunoglobulin V(D)J genes. 
This is an orderly process in which first the heavy chain rearrangement takes place 
followed by that of the light chain. The rearrangement of the V(D)J gene segments 
generates the diversity installed in the variable regions, which are otherwise referred as 
complementarity determining regions (CDRs).  
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Junctional diversity 
The second level of generation of diversity is by junctional diversity. It is a process 
followed by the V(D)J gene recombination event. The V(D)J gene rearrangement event 
leaves breaks due to cleavage of the unwanted gene segments. These breaks need to be 
filled to join the different variable region gene segments. Several proteins like the 
recombination activating gene-1 and 2 (RAG-1 and RAG-2), DNA repair protein 
Artemis, terminal deoxynucleotide transferase (TdT) and exonuclease work in concert to 
add/remove nucleotides for the proper joining of the variable region gene segments	  (Kim	  et	  al.,	  2000). The addition of nucleotide introduces a three-fold increase in the diversity 
of the variable region gene repertoire. 
Random pairing of heavy and light chains 
The third level of generation of diversity is ensured by random pairing of independently 
rearranged heavy and light chains. 
Somatic hypermutation 
Somatic hypermutation is an additional diversity generation mechanism that occurs in the 
course of an ongoing immune response, by which B cells alter their antigen specificity. It 
includes introduction or replacement of alternative nucleotides within the 
immunoglobulin VJ or VDJ segments. Somatic hypermutation of B cells occurs in 
germinal centres upon interaction with antigen-specific T cells. It is a random process, 
which may occur in the whole variable region, but is actually clustered in the CDRs. This 
unique mechanism allows selection of B cells with higher-affinity BcR for survival 
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because of their greater affinity towards antigen epitopes. The process is also referred as 
affinity maturation (Diaz	  and	  Casali,	  2002).  
Class switching 
Class switching or isotype switching is a process which occurs after the VDJ arrangement 
has completed. Under this event, the constant µ chain region (Cµ) downstream of the 
rearranged VDJ gene segment, is replaced by a new constant heavy chain (CH) gene 
segment	   (Market	   and	   Papavasiliou,	   2003). This occurs through a deletional 
recombination mechanism in the switch region that is 5’ to the CH region. Isotype 
switching is shown to be promoted by T cells, by secretion of cytokines and in a cell-to-
cell contact-dependent manner. The cytokines mainly involved in class switching are IL-
4 and TGF-β, whereas CD40 expressed on B cells influence the contact-dependent 
mechanism (Allen	   et	   al.,	   1993). The class switching procedure allows the B cells to 
produce antibodies of different isotypes, IgG, IgA and IgE, in which the antigen 
specificities of the antibodies still remain the same with changes only in the constant 
regions. The isotype determines the distribution of the antibody in the organism, by 
enabling it to diffuse through the epithelia and bind to specific cell-surface receptors, and 
hence dictates the very function of the immunoglobulin.  
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1.3.  Functions of immunoglobulins 
Antibodies are versatile molecules, which can perform a large array of functions. While 
immunoglobulin Fab regions bind to the antigen, the constant region interacts with cell 
surface receptors and other proteins for the elimination of pathogens or toxins (Figure 3). 
Figure 3. Functions of immunoglobulins 
 
Neutralization and agglutination: Antibodies can neutralize the activity of pathogens 
(microbes and viruses)	  (Crowe	  et	  al.,	  2001)	  or toxins (Chippaux) by directly binding to 
their target antigens. The ability of binding multiple antigens through the Fab region 
results in clumping of the antigens, referred to as agglutination.  
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Opsonization: Antibodies have the capacity of covering antigens or pathogens, a process 
called opsonization. The Ig in the formed complex interacts with phagocytic cells by 
means of their constant regions (Fc) with cell-surface receptors called the Fc receptors 
(FcRs). The binding of antigen-bound antibodies with multiple FcRs results in the cross-
linking of the cell-surface receptors, which then transmits a signal to the cell resulting in 
the phagocytosis of the antigen/pathogen. The ingested antigen/pathogen is then degraded 
intracellularly. 
Activation and fixation of complement: Antibodies, when bound to the surface of a 
pathogen, bind the components of the complement system. Binding of the first 
complement molecule C1q initiates the complement cascade, which finally results in the 
generation of the membrane-attack complex, resulting in the perforation of the membrane 
of the pathogen. Also, by-products of the complement cascade such as C3b can bind to 
antigen-antibody complexes and facilitate engulfment by macrophages upon interaction 
with CR1, the receptor for C3b on the cell surface (Paul, 2008).  
Effector functions of the immunoglobulin G (IgG): Immunoglobulin G is the most 
abundant class of antibodies in the serum and accounts for nearly 75% of the total 
immunoglobulin in the serum. They are divided into 4 subclasses IgG1, IgG2, IgG3 and 
IgG4, based on the number of amino acids in their hinge regions. These changes in the 
hinge region affect the biological activity of the antibody subclasses. IgG1, IgG2 and 
IgG3 are efficient in transcytosis through the placenta. Among the 4 subclasses IgG3 is 
the most efficient activator of complement, whereas IgG4 does not bind with complement 
at all. Both IgG1 and IgG3 have a good affinity to Fc receptors, IgG4 has intermediate 
affinity, and IgG2 has the least affinity. IgG molecules mediate their effector functions by 
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interaction of their Fc region with FcγRs on the cell surfaces. The two mechanisms by 
which IgGs mediate their effector functions are antibody-dependent cellular cytotoxicity 
(ADCC) and complement-dependent cytotoxicity (CDC) (Figure 3). The increasing order 
of effector function of IgG subclasses for ADCC and CDC is IgG4 < IgG2 < IgG1 ≤ 
IgG3 (Paul, 2008). 
IgG-mediated catalytic activity: The antigen-antibody interaction is in many ways similar 
to that of enzyme-substrate interaction. Like enzymes, antibodies can reduce the 
activation energy required for chemical modification, upon stabilizing the transition state 
of the bound antigen. Keeping in mind the diversity of the CDRs in the antibody 
repertoire, it seems obvious that the antigen-binding domain of some antibodies may 
resemble that of an enzyme (Pauling,	  1948). Such an antibody, upon interaction with its 
cognate antigen, may result in the chemical alteration of the antigen. In fact, antibody-
mediated catalytic activity has been reported both in diseased individuals and upon 
immunization with suitable antigens (see next chapter). 
 
 
 
 
 
	   13	  
2. Antibodies with catalytic activity 
In the late 40’s, a novel function of antibodies was postulated by Linus Pauling, which 
was later demonstrated experimentally: the capacity for antibodies to be endowed with 
enzymatic properties. Several strategies were developed to generate catalytic antibodies, 
or Abzymes, a façon, as will be explained below. The field has now evolved to the point 
where the use of “designed” catalytic antibodies may be applied to different disease 
conditions. The present chapter is dedicated to give a history of the research on catalytic 
antibodies, to describing the different approaches to generate antigen-specific catalytic 
antibodies, to discuss the physiopathological relevance of catalytic antibodies in human 
beings with a focus on antibodies with serine-protease like activity and, particularly, 
targeted towards human pro-coagulant factor VIII or human coagulation factor IX. 
Lastly, a description of the potential therapeutic usage of catalytic antibodies is 
summarized. 
2.1.  History and principles of antibody-mediated catalysis 
The history of catalytic antibodies dates back to 1946 when Linus Pauling proposed the 
hypothesis that the active centre of an enzyme is targeted against the structure of the 
transition state, rather than to the native conformation of the substrate molecule (Pauling, 
1948). He also proposed that if the antigen–binding domain of an antibody is generated 
randomly, then it is possible that the antigen–binding domain of some antibodies may 
possess structural similarity to an enzyme’s active site and thus could stabilize the 
transition state of its substrate, similar to that of an enzyme. The hypothesis proposed by 
Pauling led Jencks in 1969, to propose that antibodies generated in an anti-hapten 
immune response against chemically stable analogs of the transition state of a reaction of 
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interest could potentially display an enzymatic activity (Jencks, 1969; Satterthwait and 
Jencks, 1974). Indeed, in 1985, a general method for generating catalytic monoclonal 
antibodies (mAbs) against transition-state analogs, and a way to use those antibodies to 
accelerate chemical reactions, was first described. In 1986, using this approach, Richard 
Lerner and Peter Schultz independently reported antibody catalysis for the first time: 
monoclonal antibody-mediated hydrolysis of aryl esters and of carbonates, respectively 
(Pollack et al., 1986; Tramontano et al., 1986). Since 1986, catalytic antibodies, 
catalyzing more than 100 distinct chemical reactions have been obtained using TSA. In 
the late 80’s, the presence of spontaneously occurring catalytic antibodies in human 
beings opened new horizons and questions regarding their physiopathological relevance 
and the molecular and immune mechanisms that are at the basis of the generation of B-
cell clones producing catalytic antibodies.  
The principle of catalysis in abzymes is proposed to be mediated by the stabilization of 
the transition state of the substrate/antigen, which is then proceeded by breaking of 
chemical bonds. The catalytic activity in antibodies is conferred to the three dimensional 
spatial arrangement of amino acids, which together form either a catalytic triad (Sun	  et	  al.,	   1994) or dyad (Kolesnikov	   et	   al.,	   2000). Crystal structure of few abzymes with 
amidase activity, have shown to possess serine protease like catalytic triad (arrangement 
of serine, histidine and aspartate amino acids) with serine molecule acting as a 
nucleophile (electron-attacking group). In humans too, catalytic antibodies show the 
presence of serine protease like catalytic triad, as proposed by crystal structure of a 
catalytic monoclonal IgM obtained from a patient with monoclonal gammapathy (Ramsland	   et	   al.,	   2006). Indirect evidence for the presence of serine protease like 
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catalytic activity in human catalytic antibodies comes from their specific inhibition by 
serine protease inhibitors. However, serine protease like catalytic mechanism is not the 
whole sole mechanism of catalysis for all abzymes. An abzyme scFv derived from a 
semi-synthetic phage library with amidase activity, is known to posses tyrosine molecule 
as a nucleophile, which is very rare in nature (Reshetnyak	   et	   al.,	   2007). In addition, 
several monoclonal abzymes with similar catalytic function as their enzyme counterpart 
show less structural resemblance with each other and are known to posses’ different 
amino acid configuration in the active site (Kolesnikov	  et	  al.,	  2000).  
The location of amino acids participating in catalysis in an abzyme is not restricted to the 
antigen-binding site. Structure prediction of many monoclonal abzymes have shown that 
amino acids participating in catalysis are located in distinct regions of the variable 
domain, including the CDRs of heavy and light chains as well as the framework regions (Reshetnyak	   et	   al.,	   2007). While in some monoclonal abzymes, the amino acids 
participating in the formation of catalytic triad or dyad are contributed by close spatial 
arrangement of amino acids of both light and heavy chains, in others, either the light 
chain or the heavy chain solely contributes to the formation of an active site.  
The catalytic efficiency of enzymes is a concerted effect of several individual properties, 
such as transition state stabilization, acid-base catalysis, proximity and strain. These 
properties together influence the rate of acceleration and make enzymes proficient 
catalysts. Antibodies provide an ideal scaffold for the installation of catalytic properties, 
however the exact replication of catalytic efficiency of enzymes in catalytic antibodies 
has not been achieved. This is due to the dissimilarities in the mechanisms by which 
enzymes and abzymes catalyze their substrate. A good example comes from the study of 
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the crystal structure of the aldolase antibody 33F12 (Barbas	  et	  al.,	  1997). Although both 
the abzyme 33F12 and its natural counterpart, fructose 1,6-diphosphate aldolase, function 
through a relatively simple catalytic mechanism involving a reactive lysine, there are 
marked differences in the sensitivity and specificity of the aldol reactions performed by 
them. Unlike natural aldolase, 33F12 performs nearly 100 different aldol 
condensation/addition reactions, however with a lower turnover rate. The crystal structure 
of the abzyme reveals that the reactive lysine is situated in a hydrophobic pocket that 
does not facilitate the entry of the substrate, thus lowering the turnover. In addition, the 
promiscuity of the binding pocket allows the abzyme to perform aldol 
condensation/addition on a wide variety of substrates. In a similar way, catalytic antibody 
9A8 obtained by the anti-idiotypic approach, although possesses the catalytic dyad 
similar to its prototype enzyme acetyl- cholinesterase (AcChoE), displays relaxation in its 
specificity to substrates and inhibitors (Kolesnikov	  et	  al.,	  2000). The sequence analysis 
of 9A8 in comparison to AcChoE, revealed a striking difference in amino acids other than 
those involved in the catalysis. In the long run, the accumulation of data on the structures 
of abzymes will allow us to find the differentiating factors between enzymes and 
abzymes. This should enable generating tailor-made abzymes with fine sensitivity and 
specificity. 
	   17	  
2.2. Strategies for deliberate induction of abzymes  
2.2.1. Immunization with transition state analogs (TSA) 
Making antibodies with binding pockets complementary to transition states is 
complicated by the fact that true transition states and most reaction intermediates are 
unstable. Thus, true transition states or intermediates cannot be isolated or used as 
haptens for immunization. Instead, so-called transition-state analog (TSA) molecules are 
used. Transition-state analog molecules are stable molecules that simply resemble a 
transition state (or intermediate) for a reaction of interest in terms of stereochemistry and 
charge distribution. To the extent that the transition-state analog molecule resembles a 
true reaction transition state or intermediate, the elicited antibodies will also be 
complementary to that transition state or intermediate and thus lead to the catalytic 
acceleration of that reaction (Figure 4A). Abzymes catalyzing the hydrolysis of amides 
and esters, as well as reactions of cyclization (Janda et al., 1993; Li et al., 1994; 
Wentworth et al., 1998), decarboxylation (Smiley and Benkovic, 1994; Barbas III et al., 
1997; Hotta et al., 2000), lactonization (Napper et al., 1987), peroxidation (Ding et al., 
1998), photochemical thymine dimer cleavage, bimolecular amide-bond formation, and 
other reactions not known to be catalyzed by natural enzymes have been described. Some 
abzymes have been produced that require cofactors for activity, similar to standard 
enzymes (Iverson and Lerner, 1989). Later, in 1995 a new concept of “reactive 
immunization” emerged, wherein organisms are immunized with highly reactive haptens 
designed to make covalent link with the nucleophilic B-cell receptor (BcR) on the B cells, 
thus forming a TSA (Wirsching et al., 1995). The catalytic efficiencies of aldolase 
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abzymes, generated by reactive immunization, are only 40-fold lower than most studied 
aldolases (Wagner et al., 1995; Barbas et al., 1997).  
 
2.2.2. Manipulation of the idiotypic network 
Generation of abzymes using the idiotypic network was inspired by the “idiotypic 
network theory” proposed by Niels Jerne in 1974 (Jerne, 1974). According to this theory, 
immunization of an animal with an antigen results in the production of a 1st generation 
antibody (Ab1), with an antigen-binding site specific for an epitope on the antigen. 
Immunization with the variable region of the Ab1 induces the production of 2nd 
generation antibodies (Ab2), the antigen-binding domain of which is complimentary to 
the variable domain of Ab1 and, in some cases, possesses the internal image of the 
antigen epitope. If the initial antigen is an enzyme, some of the Ab2s will present with an 
internal image of the catalytic site of the enzyme, and will thus be catalytic (Figure 4B). 
Manipulation of the idiotypic network has led to the generation of monoclonal abzymes 
with esterase activity (Izadyar et al., 1993), amidase activity (Avalle et al., 1998), 
carboxypeptidase activity (Hu et al., 1998), protease activity (Ponomarenko et al., 2007) 
and recently allinase activity (Li et al., 2012).  
 
2.2.3. Immunization with electrophilic covalent reactive analog (CRA) 
First reported in the year 2000, phosphonate diester molecules have been extensively 
used as a bait to fish-out antibodies with catalytic activity (Tramontano et al., 2000). 
Covalent reactive analogs are haptenic phosphonates that bind covalently to a 
nucleophilic residue in the active site of an abzyme or of the BcR of the abzyme-
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producing B cells (Figure 4C). Haptenic phosphonates are reaction-based inhibitors, 
whose interaction in the active site of an abzyme is similar to that of a substrate. The only 
difference is, while a substrate molecule is released after conversion into product; the 
haptenic phosphonate makes a covalent linkage with the active site nucleophile. The 
interaction requires a nucleophilic attack by an amino acid onto the strongly electrophilic 
phosphonate in presence of a proton acceptor amino acid in close proximity. S. Paul and 
co-workers have obtained monoclonal abzymes against the gp120 coat protein of HIV-1 
virus using CRA-coupled gp120 as an immunogen (Paul et al., 2003), and against the 
amyloid-β peptide by screening an scFv library against a CRA-derivatized amyloid-β 
peptide (Taguchi et al., 2008b). Likewise, Tramontano and colleagues have successfully 
used covalently reactive phosphonate esters to isolate catalytic scFv from a semi-
synthetic scFv phage display library (Reshetnyak et al., 2007).  
 
2.2.4. Immunization with ground state antigens 
Immunization of normal or autoimmune-prone mice with ground state antigens has 
allowed to generate several monoclonal abzymes with catalytic activities against 
vasoactive intestinal peptide (Sun et al., 1994), CCR5 (Mitsuda et al., 2004), HIV-1 coat 
protein gp41 (Hifumi et al., 2002), gp120 (Durova et al., 2009), H. pylori urease (Hifumi 
et al., 2008) and TNFα (Hifumi et al., 2010). The group of Taizo Uda isolates abzymes 
among antigen specific binders by identifying the presence of serine protease-like 
catalytic triad by structure prediction of the gene sequences of heavy and light chain of 
antibodies. 
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2.2.5. De novo generation of catalytic antibodies by site-directed mutagenesis  
De novo elicitation of catalytic activity in antibodies has been performed by introduction 
of amino acid residues with known catalytic functions into the antigen-binding site of 
antibodies (Figure 4D). This approach is advantageous because the antibody, which is to 
be modified into an abzyme, is of a predetermined specificity. Fletcher	  et	  al, were able to 
introduce ribonuclease activity in an scFv variant of a Fab, which was specific for RNA. 
The authors targeted an Arg96 residue which was in close proximity of the 2’-OH of 
ribose sugar and replaced it with a histidine, in order to introduce a catalytic imidazole. 
The mutant scFv was able to hydrolyze RNA at a decent kinetic efficiency of 100	  M–
1sec–1	   with	   the	   preservation	   of	   antigen	   specificity(Fletcher et al., 1998). In another 
instance, Liu et al were able to induce protease activity in a scFv specific for the bacterial 
protein HPr. Introduction of 4 mutations in the antigen-binding domain resulted in 
induction of protease activity with no loss in specificity for HPr. The authors introduced 
three catalytic amino acids; a glutamate to augment the nucleophilicity of a water 
molecule in the vicinity, a lysine to escalate the polarity of the carbonyl group and a 
histidine as a proton donor. A glycine moiety was added as a fourth mutation in order to 
stabilize the structural integrity of complementarity determining region (CDR H3)(Liu et 
al., 1998). In a similar approach, peptidase activity has been introduced into a light chain 
expressed at the yeast cell surface, by substituting two residues Ser27a and Asp1. The 
substitutions were done for the elicitation of a serine protease-like catalytic triad with a 
His93; already present within the CDR (Okochi et al., 2007).  
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2.2.6. Isolation of catalytic antibodies by targeting specific germline genes 
Several abzymes possess variable region-encoding genes in the germline configuration 
(Le Minoux et al., 2012). In line with this observation, the presence of the Asp1, Ser27a 
and His93 catalytic triad was investigated in mouse kappa light chain of a total of 84 
clones by the group of Uda: pseudo catalytic triads were found mainly in the bb1, cr1, 
cs1, bl1, bj2 and bd2 germline kappa genes (Uda and Hifumi, 2004). In parallel, the same 
group screened genes encoding human kappa light chains, upon structural prediction 
using a strict spatial arrangement of the catalytic residues Ser, His and Asp; distance 
between His-Ser to be within 10 angstrom and that of His-Asp within 15 angstrom. Nine 
germline genes belonging to subgroup II showed a high prevalence of pseudo catalytic 
triads. Cloning and expression of these genes from circulating B cells of a healthy 
individual vaccinated against rabies virus, allowed the generation of virus-specific 
abzymes (Hifumi et al., 2012).  
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Figure 4.  
 
 
 
 
2.3. Catalytic antibodies under physiological conditions 
As explained above, the immune system is equipped with an incredible machinery of 
generating diversity. While catalytic antibodies may be induced using appropriate 
immunogens, as explained above, it has now become clear that the immune system is 
able to spontaneously generate antibodies with catalytic activity, both in health and 
disease.  
Catalytic antibodies are now considered to be a part of the natural antibody repertoire and 
act as defense against bacterial and viral pathogens. In fact, catalytic antibodies of the 
IgA isotype with anti-bacterial/viral functions have been obtained from human saliva and 
from the milk of healthy mothers (Semenov	  et	  al.,	  1998;	  Mitsuda	  et	  al.,	  2007). A set of 
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evidence shows that natural catalytic antibodies with promiscuous antigen-binding are 
encoded by the germline genes (Gololobov	   et	   al.,	   1999). Immunoglobulins M are 
considered to be the closest to the germline and data on polyclonal IgM from naïve mice 
and healthy humans show promiscuous catalytic activity of IgM against synthetic peptide 
substrates (Planque	   et	   al.,	   2004).	   Additionally, catalytic antibodies derived by 
deliberated immunization are also known to posses’ germline configuration (Kolesnikov	  et	  al.,	  2000). Further validation of the germline origin of catalytic antibodies has been 
done, by performing site-directed mutagenesis of a catalytic antibody light chain (Gao	  et	  al.,	   1995). Upon replacing the amino acids that were introduced by somatic 
hypermutation with the germline counterpart, the catalytic activity was not abrogated. 
Additional information regarding the germline origin of catalytic antibodies comes from 
the study of Le Minoux et al., analysis of the gene sequence of 23 monoclonal catalytic 
antibodies with amidase activity, revealed more than 97% resemblance in the heavy and 
light chain genes with the germline counterpart (Le	  Minoux	  et	  al.,	  2012). This suggests 
that antibody mediated catalysis is an innate property of the immune system, which is 
encrypted in the germline. The presence of antigen-specificity however, is absent in 
naturally occurring abzymes. Among naturally occurring abzymes in healthy individuals, 
IgM are known to show the highest catalytic efficiency, followed by IgA and least in IgG. 
The µ-chains of the splenic B cells are known to be the most abundant proteins that 
possess nucleophilic sites; identified by the binding of labelled electrophillic phosphonate 
inhibitors. Finally, naturally occurring catalytic antibodies are known to behave like 
serine proteases by virtue of their specificity of cleavage at the basic amino acid residues.  
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2.4. Catalytic antibodies under pathological conditions 
Experimental data on autoimmune-prone MRL/lpr or SJL mice shows that the frequency 
of catalytic clones is much higher in these strains as compared to normal mice (Tawfik	  et	  al.,	  1995). Accordingly, in 2000, the work from the group of Alexander Gabibov showed 
a higher frequency of abzymes with protease and nuclease activity in strains of 
autoimmune prone mice, MRL-lpr/lpr, NZB/NZW, SJL/J, in comparison to normal 
Balb/C mice (Ponomarenko	  et	  al.,	  2000). 
In humans too, under several autoimmune and inflammatory conditions, including asthma (Paul	   et	   al.,	   1989), acquired hemophilia A (AHA)	   (Wootla	   et	   al.,	   2008a), systemic 
lupus erythematosus (SLE)	   (Shuster	  et	   al.,	   1992), Hashimoto’s thyroiditis (HT)	   (Li	   et	  al.,	   1995), scleroderma	   (Bronshtein	   et	   al.,	   1992), multiple sclerosis (MS) (Ponomarenko	  et	  al.,	  2006), Alzheimer’s disease (AD) (Taguchi	  et	  al.,	  2008a), a high 
level of abzyme activity is witnessed against self-antigens (Table 1). Thus, a high 
prevalence of DNA/RNA-hydrolyzing antibodies has been found in patients with SLE, 
scleroderma and MS. In addition, IgG from patients with MS also show hydrolysis of 
myelin basic protein. Li et al reported the presence of thyroglobulin (Tg)-cleaving 
antibodies in serum of patients with Hashimoto’s thyroiditis. The presence of Tg-cleaving 
antibodies in HT patients was hypothesized to be beneficial in clearing-up of the 
circulating Tg, which could otherwise feed in the immune response. Patients with 
Alzheimer’s disease were reported to have amyloid beta (Aβ)-cleaving IgM antibodies. It 
has been proposed that the deposition of Aβ in the brain induces neurodegenerative 
disorders. The presence of Aβ-hydrolyzing antibodies may thus provide a feasible 
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mechanism of Aβ clearance from the body.  Acquired hemophilia A is a serious 
autoimmune disease marked by the sudden appearance of autoantibodies against 
coagulation factor VIII (FVIII). Autoantibodies against FVIII prevent its interaction with 
other molecules of the coagulation cascade thereby inhibiting its procoagulant activity. In 
a previous study, nearly 50% of the studied patients with anti-FVIII autoantibodies in 
AHA also showed the presence of FVIII-hydrolyzing IgG. The FVIII-hydrolyzing 
activity of IgG from few of these patients was also found to co-evolve with the inhibitory 
titre, suggesting that FVIII-hydrolyzing antibodies may participate to the FVIII 
inactivation process.  
In all the above-mentioned studies, the level of catalytic antibodies to the respective 
disease-specific antigen were either extremely low or absent in the serum of normal 
control subjects. Based on these findings, it was tempting to speculate that the adaptive 
improvement of innate catalysis against self-antigens is a disfavoured event in physiology 
and occurs only when there is a breakdown in the mechanisms of self-tolerance.  
 
 
 
 
 
 
 
 
 
! #7!
Table 1. Catalytic antibodies in various pathological conditions 
Pathology                                                             Target antigen 
Inflammatory disorders 
  Asthma                                                          
Sepsis 
 
Autoimmune disorders
Hashimoto’s thyridoitis 
Systemic lupus erythematosus  
Scleroderma 
Rheumatoid arthritis  
Multiple sclerosis
Acquired hemophilia  
Alzheimer’s disease 
 
Metabolic disorder 
Diabetes
Infectious disorder 
Immune thrombocytopenia 
associated with HIV-1 infection 
 
Vasoactive intestinal peptide (VIP) 
FVIII, FIX 
Thyroglobulin 
DNA, RNA 
DNA, RNA 
DNA, RNA 
DNA, RNA, MBP
FVIII, FIX 
Aß-peptide 
Grp94
Platelet GPIIIa 
Neoplastic disorder 
Multiple myeloma  Prothrombin                  
 
Alloimmune disorders
Hemophilia A
Renal transplant rejection 
FVIII
FVIII, FIX 
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2.4.1 Catalytic antibodies against coagulation factors 
Past work in the host laboratory has documented the presence of catalytic antibodies able 
to hydrolyse several coagulation factors: factor VIII and factor IX. The underlying 
hypothesis was that coagulation factor-hydrolyzing IgG may modulate the thrombotic 
profile of the patients, and thus have an outcome on disease progression. In the course of 
my PHD work, I have concentrated on two pathological situations in the human wherein 
either bleeding or thrombotic conditions are implicated: acquired hemophilia and 
rejection of renal transplant.  
 
Figure 5. Structure of FVIII: Factor VIII is released by the hepatocytes as a 
heterodimer of heavy chain (domains A1-A2-B) and a light chain (domains A3-C1-C2). 
A non-covalent divalent metal ion linkage between A1 and A3 domains associates the 
heavy and light chains.  
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2.4.2 Catalytic antibodies in patients with acquired hemophilia A 
Acquired hemophilia A (AHA) is a bleeding disorder that occurs following the 
development of a neutralizing autoimmune response against the endogenous coagulation 
factor VIII (FVIII). AHA occurs at an overall incidence rate of 1.48 per million/year and 
it mainly affects the elderly, with an incidence rate as high as 14.7 per million/year seen 
in patients above 85 years (Collins	   et	   al.,	   2007). The clinical feature of AHA is the 
occurrence of sudden bleeding episodes in individuals without previous bleeding history. 
Bleeding is life threatening in about 80% of the cases, especially in the early stage of the 
disease or in cases of excessive bleeding following trauma, surgery or cerebral 
hemorrhages (Collins	   et	   al.,	   2007). The bleeding patterns in AHA include a high 
prevalence of hemorrhages in skin, muscle or soft tissue and mucous membrane (Green	  and	  Lechner,	  1981;	  Boggio	  and	  Green,	  2001). 
In our seminal work, we had demonstrated the presence of IgG with proteolytic activity 
towards exogenous therapeutic FVIII in inhibitor-positive patients with severe congenital 
hemophilia A (Lacroix-­‐Desmazes	  et	  al.,	  1999). FVIII-hydrolyzing IgGs was detected in 
about 50% of the patients included in the study (Lacroix-­‐Desmazes	   et	   al.,	   2002). 
Further, the rates of IgG-mediated FVIII proteolysis measured in vitro were positively 
correlated to the inhibitory activity measured in the plasma of the patients (Lacroix-­‐Desmazes	   et	   al.,	   2002), although it is obvious that the different anti-FVIII IgG in the 
polyclonal antibody population of a single patient may simultaneously neutralize 
therapeutic FVIII by several means: classical steric hindrance and proteolysis. 
Importantly, the proteolysis of FVIII by IgG was demonstrated to lead to FVIII 
inactivation in vitro (Lacroix-­‐Desmazes	  et	  al.,	  2006). The protease activity was similar 
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to that of serine proteases, as more than 80% of the identified cleavage sites on FVIII 
occurred after a lysine or an arginine (Lacroix-­‐Desmazes	  et	  al.,	  2006). 
In the case of AHA, we observed that IgG from about 47% of the patients included in our 
cohort also hydrolyzed FVIII (Wootla	  et	  al.,	  2008a). A longitudinal study, performed on 
four AHA patients to evaluate the relationship between FVIII hydrolysis and FVIII 
inhibition, suggested a co-evolution of the catalytic activity with the inhibitory titer over 
time. However, despite the inhibitory potential of FVIII-hydrolyzing IgG in AHA 
patients, no correlation was found between the presence/absence of proteolytic IgG and 
the clinical parameters of the patients, or the survival status of the patients 1 year after 
diagnosis. The results of this study did not enable us to attribute the epitope specificity or 
the type I/II kinetics of FVIII inhibition to the presence of FVIII-hydrolysing IgG. 
The hydrolysis of coagulation factor VIII (FVIII) by IgG purified from the serum of 
patients with congenital and acquired hemophilia A (Lacroix-Desmazes et al., 1999; 
Lacroix-Desmazes et al., 2002; Lacroix-Desmazes et al., 2006; Wootla et al., 2008a; 
Wootla et al., 2009), suggests that catalytic antibodies may interfere with hemostasis 
under pathological conditions. Interestingly, IgG-mediated FVIII and factor (FIX) 
hydrolysis had already been documented in patients who survived septic shock (Lacroix-
Desmazes et al., 2005), with a potential of modulating disseminated vascular thrombosis. 
Furthermore, we found that IgGs from some AHA patients too were able to hydrolyze 
FIX, resulting in its activation. Hence we envisaged identifying the relevance of this 
phenomenon in the outcome of AHA. The details of this observation are attached as a 
publication in the result section.  
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2.4.3 Catalytic antibodies in patients with chronic allograft nephropathy 
Chronic allograft nephropathy (CAN) is one of the main causes of late renal allograft 
rejection. It is characterized by loss of function of the graft due to tissue destruction, 
which is substantially caused by the induction of the coagulation cascade by the stressed 
endothelium of the graft.  
The deleterious role of catalytic antibodies has been suspected in other pathological 
situations, like hemophilia, multiple sclerosis (Ponomarenko	  et	  al.,	  2006) and HIV-1-
related immune thrombocytopenia (Nardi	  et	  al.,	  2001). Under pathological conditions as 
hemophilia, where the presence of coagulation FVIII is indispensible, the presence of 
FVIII-hydrolyzing IgG is expected to be deleterious. However, under pathological 
conditions such as sepsis and CAN, which are characterized by uncontrolled activation of 
coagulation, the presence of coagulation factor-hydrolyzing antibodies, could play a 
beneficial role. In a previous retrospective study, we obtained serum at two different time 
intervals (3 months and 2 years post-transplantation) from patients that had undergone 
renal graft transplant (Wootla	  et	  al.,	  2008b). Some patients in the cohort were known to 
develop chronic allograft nephropathy (CAN) following renal transplantation. A 
surrogate synthetic peptide chromogenic substrate PFR-MCA was used to screen IgG-
mediated catalytic activity. Interestingly, IgG from patients without CAN, demonstrated 
significantly higher catalytic activity as compared to that from patients with CAN, both 3 
months and 2 years post-transplantation. In addition, the catalytic activity measured at 3 
months was predictive of CAN that developed 2 years later. The purified IgG from some 
of the patients included in the study were able to hydrolyze the coagulation factors VIII 
and/or IX. Also, IgG-mediated catalytic activity against synthetic substrate correlated 
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with FVIII hydrolysis. Thus, we postulated that the presence of catalytic IgG in CAN 
patients could be used as a prognostic marker to predict favorable outcome in renal graft 
transplant. However, the observations needed further validation in a prospective study 
with a larger cohort of patients. We designed a prospective study on 100 consecutive 
renal transplant patients and the observations are mentioned in the results section. 
	  
Figure 6. Structure of FIX: Factor IX is a vitamin K dependent coagulations factor 
secreted by the liver. The light chain of FIX is constituted of γ-carboxyglutamic acid 
residues (GLA) and a domain homologous to epidermal growth factor (EGF). The light 
chain is attached to the heavy chain through an activation peptide (AP) region, which is 
cleaved from the FIX upon activation. The heavy chain constitutes the catalytic domain 
of FIX.   
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2.5. Therapeutic potential of catalytic antibodies 
The antibody scaffold provides a unique combination of antigen specificity and 
functional activity to generate novel enzymes. Nowadays, attempts are made to take 
advantage of these synergistic properties for the treatment of human diseases. 
 
2.5.1 Catalytic antibodies against infectious agents 
Several virus-specific catalytic antibodies have been developed in the recent years. Thus, 
the HIV-1 coat proteins gp120 and gp41 have been targeted because of the key role they 
play in infecting CD4+ T lymphocytes. Three monoclonal abzymes able to cleave gp120 
in a site-specific manner were generated upon immunization of mice with a CRA-coupled 
gp120 (Paul et al., 2003). Because HIV-1 is known to escape from the host immune 
system by undergoing repeated mutations in its coat proteins, abzymes were also 
generated from a phage library established from lupus patients that cleaved the conserved 
superantigenic region 421-433 (Nishiyama et al., 2007). In parallel, the group of Uda has 
generated abzyme light chains by ground state immunization of the conserved region of 
gp41 (Hifumi et al., 2002). 
Catalytic kappa light chains have been isolated from an individual vaccinated against 
rabies virus; the light chains cleaved small peptide substrates and, in some cases, 
diminished the infectivity of rabies virus (CVS-11) in mouse NA cells and protected mice 
upon intracerebral inoculation with CVS-11 (Hifumi et al., 2012). 
Lastly, the group of Uda has isolated a light chain abzyme (UA15-L) specific for the 
urease of H. pylori (Hifumi et al., 2008). UA15-L was able to hydrolyze both 
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recombinant UreB and the whole urease, and degraded urease in the intact bacterium, 
thus significantly decreasing colonization by H. pylori in the stomach of mice. 
 
2.5.2 Abzyme prodrug therapy 
The first documentation of abzyme-mediated activation of a prodrug was provided in 
1993, when Miyashita et al showed the activation of a non-bioactive chloramphenicol 
ester by an abzyme generated against a phosphonate TSA (Miyashita et al., 1993). Later 
in 1996, Wentworth et al generated an abzyme that activated the carbamate prodrug into 
its cytotoxic form, nitrogen mustard, that was able to decrease the viability of human 
colonic carcinoma cells in vitro (Wentworth et al., 1996). The most studied abzyme for 
prodrug therapy is 38C2 that was generated by reactive immunization with the 1,3 
diketone hapten, and possesses an aldolase activity (Wagner et al., 1995). 38C2 activates 
the prodrug form of the anti-cancer drugs doxorubicin and camptothecin (Shabat et al., 
1999). It was shown to inhibit the growth of human colon carcinoma and prostrate cancer 
cell lines and to reduce tumor growth in an animal model of neuroblastoma (Shabat et al., 
2001). 38C2 also showed therapeutic potential in diabetes upon activation of an aldol-
modified insulin (Worrall et al., 2001). More recently, a catalytic nanobody with alliinase 
activity was obtained upon manipulation of the idiotypic network. The abzyme nanobody 
suppressed the growth of the B16 tumor cell line by converting the precursor prodrug 
alliin into cytotoxic allicin (Li et al., 2012).  
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2.5.3 Catalytic antibodies in inflammation  
A potential beneficial role of catalytic antibodies has been investigated in Alzheimer’s 
disease by virtue of their capacity to proteolytically degrade amyloid aggregates. 
Proteolytic cleavage of amyloid-β by recombinant light chains (Rangan et al., 2003), 
heterodimeric light chains and single chain abzymes (Taguchi et al., 2008b) was 
documented with exceptionally elevated hydrolysis rates. It was proposed that single 
chain variant abzymes may combine efficient Aβ clearance and prevention of Fc-
mediated inflammation caused by phagocytic cells. 
A monomeric heavy chain abzyme specific for the pro-inflammatory cytokine tumor 
necrosis factor-α (TNF-α) was recently developed upon immunization with the ground 
state molecule (Uda and Hifumi, 2004). In the context of the treatment of autoimmune 
and inflammatory diseases by anti-TNF therapy (Suryaprasad and Prindiville, 2003; 
Lamprecht, 2005; Atzeni et al., 2009; Rosenblum and Amital, 2011), the capacity of 
abzymes to turnover should allow to diminish the requirement for bolus doses of 
therapeutic antibodies that are usually required for the clearance of TNF-α. 
 
2.5.4 Catalytic antibodies  for gene silencing 
Gene silencing by targeting mRNA has been achieved by conventional small interfering 
RNA (siRNA) technique. Alternatively, inhibition of intracellular proteins by cell 
penetrating antibodies (TransMabs) is also being investigated (Muller et al., 2005). In a 
novel approach, Lee et al have achieved gene silencing by catalytic antibodies specific 
for the mRNA of Her2, a protein that is overexpressed in breast cancer cells (Lee et al., 
2010). The abzymes are variants of a DNA/RNA-hydrolyzing antibody light chain 3D8, 
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obtained by generating a synthetic library by randomization of amino acids. The catalytic 
antibodies variants selectively hydrolyzed the Her2 mRNA, resulting in decreased surface 
expression of Her2 and induction of apoptosis, with a cytotoxic potential greater than that 
of siRNA. 
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3. Polyreactive antibodies 
 
According to the clonal selection theory proposed by Burnet and Medawar in the 1950’s, 
single antibody molecules are specific for a single antigen. It has however become clear 
over the last 3 decades that some monoclonal antibody molecules are able to engage 
interactions with different structurally unrelated antigens, a property coined as 
“polyreactivity”. The broad binding specificity of polyreactive antibodies is conferred by 
low affinity and conformational flexibility of the antigen-binding domain. From an 
evolutionary point of view, polyreactivity in antibodies are considered to be a conserved 
feature of the immune system and are found in distantly related species, as in humans and 
sharks (Marchalonis	  et	  al.,	  2001). Thus, the repertoire of antibodies that circulates in a 
single healthy individual is composed of a substantial part of “natural” polyreactive 
antibodies. In addition to antibodies that are intrinsically polyreactive, our group and 
others have demonstrated that exposure of some monoreactive antibodies to different 
protein destabilizing agents may also impart polyreactivity to the antibodies, a 
phenomenon referred to as “induced” or “cryptic” polyreactivity and that may be 
considered as an additional level of generation of antibody-binding diversity	   (Dimitrov	  et	   al.,	   2006;	   Dimitrov	   et	   al.,	   2007;	   Djoumerska-­‐Alexieva	   et	   al.,	   2009;	   Djoumerska-­‐Alexieva	   et	   al.,	   2010). This part of the introduction is dedicated to summarizing our 
present knowledge on “natural” and “induced” polyreactive antibodies and lays the 
ground to the question I have addressed in the course of my PhD.  
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3.1.  Natural polyreactive antibodies 
Naturally occurring polyreactive antibodies are believed to be generated in the absence of 
any known antigenic stimulation. Early precursor B cells are considered to be the major 
producers of polyreactive antibodies (Wardemann	  et	  al.,	  2003). In newly born children, 
50% of the cord blood B cells exhibit the presence of polyreactive BCRs (Chen	  et	  al.,	  1998). However, in adults the percentage of polyreactive B cells are between 15-20%. B 
cells that produce polyreactive antibodies are widely distributed in the lymphoid organs 
and the repertoire consists of both the B-1+ and B-1- lymphocytes (Chen	   et	   al.,	   1998;	  Wang	  et	  al.,	  2001).  
 
While monoreactive antibodies bind to their cognate antigen following the rigid “lock 
and key” mechanism, the binding of natural polyreactive antibodies to antigens is less 
rigid and allows conformational changes within the binding pocket. Polyreactive 
antibodies have germline or near germline configuration of the variable domain. The near 
germline configuration provides greater flexibility of interactions with different antigens. 
Among the different isotypes, IgM are considered to be the most polyreactive due to 
close similarity with the germline, although some IgA and IgG also show polyreactivity. 
Another important aspect of polyreactive antibodies is their low antigen binding affinity 
(KD = 10-4 – 10-7 M) pertaining to low somatic mutations, as compared to monoreactive 
antibodies (Ternynck	  and	  Avrameas,	  1986;	  Burastero	  et	  al.,	  1988;	  Nakamura	  et	  al.,	  1988;	   Casali	   and	   Notkins,	   1989). The role of CDRs in conferring polyreactivity has 
been proved by experiments showing maintenance of polyreactivity in the Fab form, 
persistence of polyreactivity after implantation of a polyreactive CDR onto a 
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monoreactive antibody scaffold and abrogation of polyreactivity by site-directed 
mutagenesis of CDRs. However, no consensus has been observed in the composition of 
amino acids in the CDRs of polyreactive antibodies (Notkins,	   2004). It is also well 
accepted that the primary structure of the heavy or light chain is responsible in promoting 
polyreactivity of a CDR (Harindranath	  et	  al.,	  1993). This view is also backed by the 
observations that antibodies can exist in different isoforms even without binding to the 
antigen (Foote	   and	   Milstein,	   1994) and that upon interaction with antigen, 
conformational changes may allow accommodation of the antigens (James	  et	  al.,	  2003).  
Natural polyreactive antibodies are considered to play an important role in the broad anti-
bacterial activity of the normal serum. In fact, in vitro studies show that natural 
polyreactive antibodies and B-cells expressing natural polyreactive antibodies bind to a 
wide range of self and bacterial/viral antigens (Zhou	   et	   al.,	   2007). Thus polyreactive 
antibodies may play a role in preventing the dissemination of pathogens by sequestering 
them to the lymphoid organs. Moreover, the role of polyreactive antibodies in mucosal 
immunity can be pointed out by the presence of polyreactive IgA antibodies in salivary 
secretion and colostrum (Quan	   et	   al.,	   1997). Due to low affinity binding with the 
antigens the polyreactive B cells are not able to present co-stimulatory molecules B7-1 
and B7-2; however they are able to process the antigens (Wang	  et	  al.,	  2001). By virtue 
of this property polyreactive B cells may play a role in maintaining the peripheral 
immunological tolerance. 
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Figure 7. Structure of heme:                                       
                                       
 
3.2. Induced polyreactive antibodies 
In contrast to natural polyreactive antibodies, induced polyreactive antibodies are 
inherently monoreactive; they become polyreactive upon treatment with protein 
destabilizing factors, such as chaotropic agents, low and high pH, high-salt concentration, 
elevated temperature, or oxidative agents.  
Post-translational modifications of monospecific antibodies with protein destabilizing 
agents lead to conformational changes in the antibody paratopes, making them sensitive 
to form novel interactions (Bouvet	  et	  al.,	  2001). Thus, the treatment of antibodies with 
urea or ferrous ions leads to the change in the thermodynamics of the antigen-antibody 
interactions (Dimitrov	  et	  al.,	  2006;	  Dimitrov	  et	  al.,	  2007). In vitro studies have shown 
that although the affinity of antigen recognition remains the same, there is a prolongation 
in the association and dissociation kinetics, which indicates an increase in the flexiblity of 
the paratopes. The induction of plasticity in antigen recognition is considered to be due to 
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the partial denaturation of the variable regions. Among all the inducers of polyreactivity, 
heme shows a distinct mechanism of inducing polyreactivity. Unlike other inducers, 
heme does not increase the flexibility, rather makes the variable domain more rigid (Dimitrov	   et	   al.,	   2007) (Dumont	   et	   al.,	   1994). However, heme by itself establishes 
several non-covalent interactions (hydrophobic, hydrogen bonds, van der Waals, ionic 
and coordinative-interactions), by virtue of its hydrophobic macrocyclic structure (Figure 
7, 8). 
 
 
 
Figure 8. Different mechanisms of induction of polyreactivity in mono-reactive 
antibodies by protein-destabilizing agents: 
 
 
 
 
	   41	  
Sites of inflammation are a rich source of such protein destabilizing agents. In vivo, the 
sources of such agents are immune cells like phagocytes, which create a pro-oxidative 
environment by the release of reactive oxygen species (ROS). In addition, inflammatory 
sites are rich in pro-oxidative labile-iron pool and free iron containing cofactors (heme) 
that can induce polyreactivity in antibodies. Under diseased conditions such as hemolysis, 
ischemia-reperfusion, or hemorrhages, large quantities of hemoproteins are released, 
which, upon oxidation, easily release their prosthetic groups once they are outside the 
cells. The excessive release of heme saturates the heme-scavenging proteins and the 
amount of free heme can reach up to 20 µM in plasma (Balla	   et	   al.,	   2003). 
Immunoglobulins, that are one of the most abundant plasma proteins, may bind the free 
heme and acquire polyreactivity. In fact, heme-exposed immunoglobulins show reactivity 
with bacterial antigens as well as whole bacteria and show enhanced bacterial killing via 
initiation of complement cascade (Dimitrov	  et	  al.,	  2007). In vivo experiments on mouse 
model of sepsis have also shown protective effect of IVIg modified with protein-
destabilizing agents (Bouvet	  et	  al.,	  2001;	  Dimitrov	  et	  al.,	  2006). In addition, modified 
IVIg have also shown beneficial effect in treated animals by lowering the plasma levels 
of pro-inflammatory mediators (unpublished data). Thus, induced polyreactivity may 
serve as buffering agents of the immune system. However, similar observations were not 
seen in the case of pooled normal IgM (IVIgM). Upon treatment with ferrous ions, 
IVIgM did not show pronounced antigen-binding capacity (Dimitrov	  et	  al.,	  2006).  
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Figure 9. 
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4. Objectives of the present study 	  
In the introduction part of the thesis, I have presented the basic knowledge on catalytic 
antibodies, their beneficial/deleterious effect in various diseases, various methods to 
generate monoclonal catalytic antibodies and their scope as therapeutics. I have also 
presented in brief our understanding on the physiological relevance of natural 
polyreactive antibodies and mechanism of induction of polyreactivity by protein 
destabilizing agents. Based on this understanding, my main objective was to understand 
the pathophysiological relevance of catalytic antibodies in diseased conditions such as 
acquired hemophilia and renal transplant. Further, I also attempted to better decipher the 
mechanism underlying the induction of polyreactivity in antibodies. 
Objective 1. Description of FIX-hydrolyzing antibodies in acquired hemophilia A 
Our group has previously demonstrated the presence of catalytic antibodies against FVIII 
in patients with acquired hemophilia A (AHA). During our investigation, we observed 
FIX hydrolysis by IgG of some patients. The hydrolysis product was suspected to be the 
activated form of FIX. In this work, we investigated whether catalytic IgG from AHA 
patients are able to activate human FIX in vitro, whether IgG-mediated FIX activation 
has a relevance in the outcome of AHA.  
Objective 2. Investigate the evolution of catalytic antibodies in renal transplant  
Catalytic antibodies have been described in diverse autoimmune and inflammatory 
conditions. However, the physiopathological relevance of catalytic antibodies remains 
unclear. While under most disease conditions, the presence of catalytic antibodies is 
	   44	  
related to deleterious consequences, in some diseases such as sepsis, their increased 
prevalence has been associated to favourable disease outcome. We have previously 
demonstrated in a small cohort of patients with CAN, a positive association between 
higher levels of catalytic IgG and renal graft survival. I decided to revisit the 
phenomenon in a larger cohort of patients in a prospective study. My assumption was that 
the establishment of a large cohort of patients followed over several years would provide 
valuable information regarding the evolution of IgG-mediated catalytic activity under 
disease condition. 
Objective 3. Investigate the role of antibody constant domain in heme-induced 
polyreactivity 
A relatively large portion of the natural antibody repertoire is known to be polyreactive. 
Apart from the naturally occurring polyreactive antibodies, some antibodies can be 
induced to display polyreactivity by protein destabilizing agents. While most of the 
protein destabilizing agents induce polyreactivity by making the variable domain flexible, 
an iron-cofactor, heme is known to make the variable domain rigid. Interestingly, while 
some antibodies are susceptible to heme-induced polyreactivity, others are not.  In 
addition, the importance of the nature of constant domain in conferring sensitivity to 
heme-induced polyreactivity has not investigated. The investigation of the role of 
constant domain in heme-induced polyreactivity may provide greater insight into the 
possible mechanisms by which a heme induces polyreactivity.  
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Article 1- Résumé en Français 
 
Titre: Activation du facteur IX par les anticorps protéolytiques chez les patients 
atteints d’hémophilie acquise 	  
L’hémophilie acquise est une maladie hémorragique rare qui est caractérisée par 
l’apparition spontanée d’anticorps inhibiteurs dirigés contre le facteur VIII (FVIII). Les 
IgG de certains patients atteints d’hémophilie acquise hydrolysent le FVIII. En raison de 
l’étiologie complexe de la maladie, aucun paramètre clinique, y compris la présence 
d’IgG hydrolysant le FVIII, ne permet de prédire la survie ou le décès des patients. Ici, 
nous démontrons la présence d’anticorps anti-facteur IX (FIX) chez les patients avec 
hémophilie acquise. Les IgG de certains patients hydrolysent le FIX. Dans la plupart des 
cas, l’hydrolyse du FIX par les IgG résultait dans l’activation du FIX. Ainsi, l’hydrolyse 
du FIX par les IgG conduisant à une génération significative de FIX activé chez 25 des 
65 patients inclus dans l’étude. Sur la base de notre estimation des paramètres cinétiques, 
les IgG des patients activaient jusqu’à 0,3 nM de FIX par 24 heures, une quantité 
capable de restaurer le génération de thrombine in vitro, à condition que ≥3% de FVIII 
résiduel soient disponibles dans le plasma. Notre travail identifie les IgG protéolytiques 
comme de nouveaux activateurs du FIX dans les conditions pathologiques. L’activation 
du FIX par les IgG apparaît comme un phénomène prévalent au sein d’une population de 
patients avec hémophilie acquise. La présence de telles IgG pourrait compenser au 
moins en partie l’inhibition du FVIII endogène par les autoanticorps et rétablir une 
capacité de génération de thrombine.  
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Acquired hemophilia is a rare bleeding
disorder characterized by the spontane-
ous occurrence of inhibitory antibodies
against endogenous factor VIII (FVIII). IgG
from some patients with acquired hemo-
philia hydrolyze FVIII. Because of the
complex etiology of the disease, no clini-
cal parameter, including the presence of
FVIII-hydrolyzing IgG, has been associ-
ated with patient’s survival or death. Here,
we demonstrate the presence of anti-FIX
antibodies in acquired hemophilia pa-
tients. IgG from some patients were found
to hydrolyze FIX. In most cases, IgG-
mediated FIX-hydrolysis resulted in FIX
activation. IgG-mediated hydrolysis of FIX
thus led to the significant generation of
activated FIX in 25 of 65 patients. Based
on the estimated kinetic parameters, pa-
tients’ IgG activated up to 0.3nM FIX in
24 hours, an amount that restored throm-
bin generation in vitro provided the pres-
ence of more than or equal to 3% residual
FVIII activity in plasma. This work identi-
fies proteolytic IgG as novel molecules
able to activate FIX under pathologic condi-
tions. IgG-mediated FIX activation is a preva-
lent phenomenon among acquired hemo-
philia patients. The presence of FIX-
activating IgG may partly compensate for
the antibody-mediated inhibition of endoge-
nous FVIII in restoring thrombin generation.
This clinical trial was registered at www.
clinicaltrials.gov as #NCT00213473. (Blood.
2011;117(7):2257-2264)
Introduction
Acquired hemophilia is a severe hemorrhagic autoimmune disorder
that occurs in approximately 1 per 1 million persons each year. It is
characterized by the spontaneous development of autoantibodies
directed against endogenous factor VIII (FVIII), the cofactor of
activated FIX in the coagulation cascade. Clinical features include
bleeding in mucosal and soft tissues, hematuria, hematemesis, or
melena and prolonged postpartum or postoperative bleeding.1 In
most patients, anti-FVIII autoantibodies are idiopathic. However,
the disorder is associated with other conditions in approximately
40% to 50% of cases, which mainly occur in relation to postpartum,
autoimmune diseases, malignancies, and drug administration.2 The
reported mortality is between 6.2% and 44.3% one year after
diagnosis.3
Anti-FVIII autoantibodies, also referred to as FVIII inhibitors,
neutralize FVIII procoagulant activity by steric hindrance, thus
preventing the interaction of FVIII with activated FIX, von
Willebrand factor, phospholipids, thrombin, and FX.4 By binding
to FVIII, anti-FVIII antibodies may also accelerate the clearance of
FVIII. In addition to these mechanisms, IgG from some patients
with acquired hemophilia hydrolyze FVIII.5 Because of the com-
plex etiology of the disease, no clinical parameter, including the
presence of FVIII-hydrolyzing IgG, is known to predict the
outcome of the disease.
FIX inhibitors have occasionally been reported in patients with
acquired hemophilia, alone6-10 or in combination with FVIII
inhibitors.11,12 Here, we investigated the prevalence of proteolytic
IgG against FIX among patients with acquired hemophilia.
Methods
Patients
Frozen plasma samples from 65 patients with acquired hemophilia were
obtained at the time of diagnosis from Centre Hospitalier Universitaire de
Rouen (Etude Sacha: 41 patients), Centre Hospitalier Universitaire de Caen
(11 patients), Hoˆpital Cochin (Paris), Hoˆpitaux du Kremlin-Biceˆtre (Biceˆ-
tre), Nîmes, and Centre Hospitalier Universitaire de Compie`gne (France:
13 patients), in accordance with the local ethical regulation and with
informed consent in compliance with the Declaration of Helsinki. The study
protocol has been approved by the ethics and data protection committees
(Comite´ Consultatifs de Protection des Personnes se preˆtant a` des Recher-
ches Biome´dicales, Commission Nationale de l’information et des Libertes
[CCPPRB, CNIL]). “Etude Sacha” includes clinical data from 82 patients
with acquired hemophilia collected in France.13 All “Sacha” patients with
available plasma samples at the time of diagnosis (n  41) were enrolled in
our ancillary study. Criteria for inclusion of the patients were a residual
FVIII activity less than 30% (FVIII  30% in the case of 2 patients), an
inhibitory titer more than or equal to 1 Bethesda unit (BU) per milliliter, a
prolonged activated partial thromboplastin time, and normal levels of other
factors of the intrinsic pathway and of von Willebrand factor.
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Determination of FVIII-inhibitory activity
FVIII-inhibitory activity was measured in plasma using the modified
Bethesda assay.14 Plasma was heated 1 hour at 56°C. Heated plasma was
incubated with an equal volume of pooled citrated human plasma (Dade-
Behring) for 2 hours at 37°C. Residual FVIII activity was measured in a
1-stage clotting assay, as described. The detection limit of the assay was
0.3 BU/mL. Data were expressed in Bethesda units per milliliter, where
1 BU/mL corresponds to the inverse of the dilution of plasma that yields
50% residual FVIII activity.
Purification of IgG
IgG was isolated from plasma by affinity-chromatography on protein
G-Sepharose (GE Healthcare). Intravenous immunoglobulin (IVIg, San-
doglobulin, CSL-Behring) was used as a source of normal IgG. To exclude
potentially contaminating proteases, size-exclusion chromatography of
patients’ IgG and IVIg was performed on a Superose-12 column (GE
Healthcare) equilibrated with 50mM Tris (pH 7.7), 8M urea, and 0.02%
NaN3, at a flow rate of 250 L/min. IgG-containing fractions were pooled
and dialyzed against phosphate-buffered saline-0.01% NaN3 for 48 hours at
4°C, followed by dialysis against 50mM Tris (pH 7.7), 100mM glycine,
0.02% NaN3, and 5mM CaCl2 (catalytic buffer) for 24 hours at 4°C. We
have previously demonstrated that urea-treated purified IgG retain the
inhibitory activity toward FVIII.15 The purity of IgG preparations was
assessed by Western blotting under nonreducing conditions and by matrix-
assisted laser desorption/ionization-time-of-flight analysis of trypsin di-
gests of the IgG preparations. IgG was quantified by optical density
measurements at 280 nm.
Proteolysis of biotinylated factors
Human recombinant FIX (BeneFIX) and FVIII (Kogenate FS or Helixate)
were dialyzed against 100mM borate (pH 7.0), 150mM NaCl, and 5mM
CaCl2 (borate buffer) and reacted with sulfo-NHS-LC-biotin (Thermo
Scientific-Pierce Protein Research Products) for 2 hours at 4°C. Biotinyl-
ated FIX and VIII were dialyzed against catalytic buffer for 3 hours at 4°C,
aliquoted, and stored at 20°C until use. Biotinylated factors (185nM)
were incubated in catalytic buffer with IgG (10 g/mL, 67nM) for 24 hours
at 37°C. After incubation for 24 hours at 37°C, digestion profiles were
analyzed by mixing samples mixed with Laemmli buffer without -mercap-
toethanol (1:1 vol/vol), and subjecting 20 L of each sample to 10%
sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE).
Protein fragments were then transferred onto nitrocellulose membrane
(Schleicher & Schuell). After overnight blocking in Tris-buffered saline-
0.2% Tween 20 at 4°C, membranes were incubated with streptavidin-
coupled alkaline phosphatase (KPL) diluted 1:4000 in blocking buffer, for
60 minutes at room temperature. After washing in Tris-buffered saline-0.1%
Tween 20, labeled proteins were revealed using the BCIP/NBT substrate kit
(Pierce Chemical).
Calculation of rates of proteolysis from immunoblots
High-resolution images were acquired by scanning the immunoblots using
a SnapScan 600 scanner (Agfa). Black-and-white images were converted to
negatives using the Adobe Photoshop CS2 (Version 9.0.2) software. A
macro was written using the National Institutes of Health image 1.62b7 software
(OD macro, D. Heudes andA. Nicoletti, CRC, Inserm, France) to calculate mean
image densities. Briefly, the negative images were imported into the National
Institutes of Health image 1.62b7 software using the OD macro. The negative
images were converted back to the positive mode by applying an arithmetic
logarithmic process. The “log process” does not affect the image pixels. For
calculating the rates of FIX proteolysis, we measured, for each sample, the mean
density of the total area of the lane of the FIX migration profile and of the area of
the protein bands with molecular weights less than 50 kDa. The percentage of
FIX proteolyzed was calculated as the ratio of the mean density of the hydrolyzed
area over the mean density of the total area of the lane. Spontaneous hydrolysis
occurring on incubation of FIX in the presence of buffer alone was considered as
the background level and was subtracted from each analysis. Data were
expressed as millimoles of FIX proteolyzed per minute per mole of IgG. The
lowest rate of IgG-mediated hydrolysis that could be measured was 6mol/min
per mole of IgG. Significant differences between the rates of FIX proteolysis of
patients’ IgG and that of IVIg were assessed using one-way analysis of variance
post-hoc test (Dunnett multiple comparison test) using Prism Version 5.0b
(GraphPad Software). The reported P values are 2-sided. The method was
essentially similar for the calculation of IgG-mediated FVIII hydrolysis.
Activation of FIX
The IgG-mediated activation of FIX was measured by its ability to activate
FX. FIX (1M) was incubated with IgG (67nM) for 23 hours at 37°C. The
mixture was then incubated with FX (1M; Haematologic Technologies), a
saturating concentration (30M) of phospholipids vesicles and CaCl2
(5mM) for 1 hour at 37°C. Phospholipid vesicles (phosphatidylcholine/
phosphatidylserine, 3:1) of nominal 100-nm diameter were synthesized by
the membrane extrusion method.16 Phospholipid concentrations were
determined by phosphate analysis. FX activation was stopped by addition of
0.1M ethylenediaminetetraacetic acid. Activated FX formation was determined
by measuring the amidolytic activity toward the synthetic substrate S2366
(0.5mM, DiaPharma Group). During the assay, less than 5% of FX was
converted to activated FX, and activated FX formation was linear. Substrate
conversion was monitored at 405 nm. Concentrations of generated activated FX
were determined from a standard curve derived from the cleavage rate of FX by
known concentrations of activated FIX (Haematologic Technologies) under the
same conditions.
Kinetic parameters for IgG-mediated FIX proteolysis
FIX (800nM) was labeled with 125I (PerkinElmer Life and Analytical
Sciences) using iodo Gen (Pierce Chemical) as described.17 The specific
radioactivity was 0.9 Ci/g. 125I-Labeled FIX (4.5 ng) was incubated for
24 hours at 37°C with the samples (25 g/mL IgG and 0-55.8M of
unlabeled FIX) in 40 L of kinetic buffer (50mM Tris, 150mM NaCl, 5mM
CaCl2, 0.1% [wt/vol] bovine serum albumin, 0.1% [vol/vol] PEG). Samples
were mixed 1:1 with Laemmli buffer without -mercaptoethanol and were
separated by SDS electrophoresis without being boiled; 25 L of each
sample was loaded per lane. Samples were separated by 7.5% SDS-PAGE
in nonreducing conditions at room temperature in a mini-PROTEAN II
system at 25 mA/gel, until the dye front reached the bottom of the gel. The
gels were then dried and were exposed to autoradiography films (Kodak
BioMax MS-1 Autoradiography Film, PerkinElmer Life and Analytical
Sciences). Autoradiographs were scanned to allow calculation of the rate of
proteolysis of labeled FIX. The data were fitted to the Michaelis-Menten
equation by Prism Version 5.0b (GraphPad Software).
Analysis of N-terminal sequences
Unlabeled recombinant FIX (4 g) was treated for 24 hours at 37°C with
patients’ IgG (1 g) in 40 L of catalytic buffer. The resultant FIX
fragments were separated by 10% SDS-PAGE at 50 mA in nonreducing
conditions and were transferred for 2 hours at 50 mA onto a Hybond-P
PVDF membrane (GE Healthcare) in 10mM N-cyclohexyl-3-aminopro-
panesulfonic acid, 10% ethanol at pH 11.0. After being stained with amido
black, visible bands were cut and subjected to N-terminal sequencing, using
an automatic Procise 610A Protein Sequencer (Applied Biosystems). The
amount of protein sequenced ranged from 4 to 35 pmol.
Thrombin generation assay
Human plasma deficient in FVIII and devoid of platelets (PPP) (Dade-
Behring, Siemens Diagnostics) was used. FVIII was supplemented to
FVIII-deficient plasma at 0%, 3%, 10%, or 30% (0, 9, 30, and 90pM) of the
values in normal plasma. Activated FIX was used at 0 and 0.3nM diluted in
FVIII-supplemented plasma. Briefly, 80 L of each test sample was mixed
with 20L of N-2-hydroxyethylpiperazine-N-2-ethanesulfonic acid buffer or
thrombin calibrator (Diagnostica Stago) on 96-well plates. Thrombin generation
was triggered by adding 20L of fluorogenic substrate containing 102mM
CaCl2. Kinetics of thrombin generation were monitored for 120 minutes at 37°C
using a calibrated automated thrombogram (Thrombinoscope BV) and analyzed
using the appropriate software by Thrombinoscope software Version 3.0.0.29
(Synapse BV).
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Results
Proteolytic activity of IgG against biotinylated factors VIII and IX
Plasma from 65 patients was collected at the time of diagnosis of
acquired hemophilia. The mean inhibitory activity against FVIII in
plasma ranged between 1 and 1050 BU/mL (Table 1). As reported,5
IgG from some patients proteolyzed FVIII (Figure 1A, shown for
patients 1, 8, and 16). IgG did not proteolyze activated FVII,
prothrombin, or human serum albumin5,18 for patients 1, 2, 8, 10,
16, 17, 20, and 32. In contrast, we observed that IgG from some
patients proteolyzed FIX, yielding a major protein band migrating
at 45 kDa under denaturing conditions (Figure 1B) and 2 bands
migrating at 20 and 25 kDa under nondenaturing conditions
(supplemental Figure 1B-C, available on the Blood Web site; see
the Supplemental Materials link at the top of the online article).
IVIg (Figure 1B) and IgG purified from the plasma of 7 patients
with severe hemophilia B who have developed inhibitory anti-FIX
antibodies after therapeutic administration of FIX19 did not proteo-
lyze FIX (supplemental Figure 2). F(ab)2 fragments prepared from
patients’ IgG also cleaved FIX, showing that the proteolytic
activity lies within the variable regions of the antibodies (supple-
mental Figure 3). The migration profiles of FIX incubated with
patients’ IgG or with IVIg were subjected to densitometric analysis
Table 1. Characteristics of the patients at the time of diagnosis
No. of documented patients No. or mean  SD % or range
Clinical cofactors
Sex: male 65 40 66
Age, y 54 68.1  17.0 25-92
Preexisting conditions: cancer* 55 11 20
Survival at 12 mo 52 36 69.2
Standard biologic cofactors
FVIII activity in plasma, % 51 6.0  10.9 0-59
Inhibitory titer toward FVIII, BU/mL† 65 66.9  148.6 1-1050
FIX activity in plasma, % 18 117.5  55.3 64-268
aPTT (measured/physiologic value) 37 2.4  0.7 1.3-4.2
aPTT indicates activated partial thromboplastin time.
*Other preexisting conditions were allergic drug reactions (5), autoimmune disorders (4), dermatologic disorders (3), diabetes (1), postpartum (2), and idiopathic (14).
†Inhibitory titers were assessed using the modified Bethesda assay.
Figure 1. Proteolytic activity of IgG purified from the
plasma of patients with acquired hemophilia.
(A-B) IgG-mediated proteolysis of FVIII and FIX. Biotinyl-
ated human recombinant FVIII (A, 185nM) or FIX
(B, 185nM) was incubated alone for 0 or 24 hours, or in
the presence of IgG (67nM) for 24 hours at 37°C. IVIg
was used as a source of normal IgG and as a control.
Samples were subjected to 10% SDS-PAGE and trans-
ferred onto a nitrocellulose membrane, before revelation
of biotinylated fragments. Vertical lines between lanes
indicate a repositioned gel lane (A). (C) IgG-mediated
proteolysis of FVIII versus proteolysis of FIX. The graph
shows the rates of IgG-mediated proteolysis of FVIII
plotted as a function of the rates of IgG-mediated
proteolysis of FIX (values in Table 2). The correlation
between the 2 parameters was not significant as computed
using the Spearman rank correlation test. (D) Proteolysis of
125I-labeled FIX by IgG in the presence of increasing amounts
of unlabeled FIX. 125I-Labeled FIX (4.55 ng) was incubated
for 24 hours with IgG (25 g/mL) from patient 16 in the
presence of increasing concentrations of unlabeled FIX
(0-20M). Proteolysis of FIX was analyzed on a 7.5%
SDS-PAGE, and autoradiographs were scanned. Rates of
proteolysis of labeled FIX were calculated by densitometric
analysis of the 45-kDa protein band that corresponds to
activated FIX. Data are the mean of 3 independent experi-
ments (mean SEM); E indicates empirical data. Curve
indicates data fitted to the Michaelis-Menten equation
(R 0.88). (Insets) Reciprocal of the substrate concentra-
tion versus that of the velocity (R 0.99) for the 5 highest
concentrations of unlabeled FIX.
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to compute the specific rates of proteolysis (Figure 1C, y-axis,
Table 2). IVIg exhibited a marginal proteolytic activity of 0.06 
0.06 mmol/min per mole toward FIX (mean  SD). Purified IgG
from 25 of the 65 patients exhibited FIX-proteolyzing activity that
was significantly higher than that of IVIg (Table 2, P  .05).
No FIX-binding IgG was detected in a FIX-specific enzyme-linked
immunosorbent assay when whole plasma was used. In contrast, IgG
purified from the plasma of 21 of 65 patients demonstrated binding
activity with FIX, which was greater than that of the mean plus 1 SD
measured for IVIg (supplemental Figure 4). The scored anti-FIX IgG
titers did not correlate with the rates of IgG-mediated FIX proteolysis
(supplemental Figure 5, P .384). Rates of IgG-mediated FVIII
proteolysis did not correlate with rates of IgG-mediated FIX proteolysis
either (Figure 1C, P .688): purified IgG proteolyzed either FVIII or
FIX, both molecules, or none.
We then measured the proteolysis rate of 125I-labeled FIX by
IgG (167nM) from patients 16, 23, and 32 in the presence of
increasing concentrations of unlabeled FIX. The curves of the
reciprocal of the velocity plotted as a function of the reciprocal of
the substrate concentration were linear (shown for patient
16, Figure 1D inset, R  0.88), indicating that the reaction
conformed to Michaelis-Menten kinetics. The calculated average
Km and apparent Vmax for the reactions ranged between 0.94 0.25
and 7.26  3.99M, and 0.30  0.08 and 0.82  0.19nM/min,
respectively (Table 3).
Activation of FIX by patients’ IgG
We performed an electrophoretic separation under nonreduced
conditions of unlabeled FIX (Figure 2A, lane 1), IgG from patients
16 and 32 (lanes 2 and 3), activated FIX (lane 4), and FIX
preincubated in the presence of IgG from patients 16 and 32 (lanes
5 and 6) for 24 hours. Incubation of unlabeled FIX with patients’
IgG generated a protein band with a molecular weight identical to
that of activated FIX (45 kDa). N-terminal amino-acid sequencing
of the 45 kDa-protein band generated on proteolysis of FIX by the
IgG from patients 10, 14, 16, 23, and 32 revealed the presence of
2 protein sequences, as is expected because the heavy and light
chains of FIX are linked by a disulfide bridge and comigrate as a
single protein band under nonreducing conditions (supplemental
Figure 1A): YNSG, which represents the N-terminal end of FIX,
and VVGG, which corresponds to the N-terminal part of the
catalytic domain (heavy chain) of FIX, a cleavage site for
FIX-activating enzymes. The FIX fragments generated on cleavage
by activated FXI are shown in supplemental Figure 1A.
To investigate whether IgG mediate activation of FIX, we
developed a functional assay wherein the FIX proteolyzed by
patients’ IgG, was incubated in the presence of FX. The activation
of FX by the generated activated FIX was monitored using a
specific substrate. Importantly, the assay was independent of the
presence of FVIII, the cofactor of activated FIX, so as to prevent
interference by FVIII-inhibitory IgG. Incubation of FIX alone, in
the presence of IVIg or IgG from an inhibitor-positive patient with
hemophilia B, yielded marginal levels of activated FIX (Figure
2B,  0.02 mmol/min per mole). In contrast, IgG from 25 of the
65 acquired hemophilia patients demonstrated a statistically signifi-
cant activation of FIX compared with IVIg (Table 2, P  .05), with
values ranging from 0.02 to 3.49 mmol/min per mole. The specific
rates of IgG-mediated activation of FIX demonstrated a positive
and significant correlation with the rates of IgG-mediated proteoly-
sis of FIX (Figure 2C, P  .001).
Relevance of IgG-mediated activation of FIX
We then investigated the potency of activated FIX to restore
thrombin generation in the context of reduced FVIII levels.
Patients’ IgG were estimated to generate 0.3nM of activated FIX in
24 hours, based on the calculated average kinetic parameters (Table
3). Besides, because of the presence of FVIII-inhibiting antibodies,
the patients included in our study had residual levels of circulating
FVIII composed between less than 1% and 30% of the value found
in normal plasma (Table 1). In the absence of activated FIX (ie,
using plasma that contained 90nM nonactivated FIX), we did not
detect thrombin generation, even in the presence of 30% residual
FVIII (supplemental Figure 6). Conversely, the addition of 0.3nM
activated FIX to plasma restored thrombin generation provided the
presence of more than or equal to 3% residual FVIII (Figure 2D):
the time to peak was 42.5, 27.8, and 22.6 minutes when FVIII was
supplemented at 3%, 10%, and 30% to FVIII-deficient plasma,
respectively; it was infinite in the absence of FVIII.
In our cohort, the cumulative mortality one year after diagnosis
of acquired hemophilia was 30.7% (95% confidence interval,
3.0%-64.3%). Patients who were alive one year after diagnosis
had rates of IgG-mediated FIX activation that tended to be
significantly higher (0.6  0.9 mmol/min per mole) than those of
patients who passed away during that period (0.3  0.3 mmol/min
per mole, P  .067, Figure 2E), although differences did not reach
significance because of large intragroup variance.
Discussion
Acquired hemophilia is characterized by the presence of inhibitory
anti-FVIII antibodies, reduced levels of circulating FVIII, and
altered activated partial thromboplastin time.20 Our finding of
FIX-specific IgG in patients with acquired hemophilia is reminis-
cent of older work that reported acquired FIX deficiency alone or in
combination with an acquired FVIII deficiency.6-12 The presence of
FIX-specific IgG in our study was, however, not associated with
altered levels of circulating FIX. In agreement, no inhibition of FIX
activity by the purified IgG could be detected in a functional assay
(data not shown). Interestingly, detection of anti-FIX IgG by
enzyme-linked immunoassay required IgG to be purified from
plasma, suggesting low circulating levels of FIX-specific IgG.
Anti-FIX IgG may modulate the activity of FIX in different
manners. Inhibitory anti-FIX IgG that may develop in patients with
hemophilia B after the administration of therapeutic FIX to control
bleedings, neutralize FIX by steric hindrance.19,21 Although never
reported in patients, some monoclonal anti-FIX IgG enhance the
catalytic efficiency of activated FIX by increasing its affinity for
activated FVIII.22 We demonstrate here that IgG from some
patients with acquired hemophilia significantly proteolyze and
activate FIX.
Circulating activated FIX has been reported in the blood of
healthy subjects. Increased levels have recurrently been associated
with thrombotic conditions.23 In physiology, FIX is hydrolyzed and
activated by activated FXI and by the tissue factor/activated FVII
complex; it may be cleaved and inactivated by granulocyte and
neutrophil elastase,24,25 and by plasmin.26 Our work identifies
circulating IgG with proteolytic properties as novel molecules able
to hydrolyze and activate FIX under pathologic conditions. Al-
though the estimated enzymatic kinetics of proteolytic IgG are low
compared with those of classic enzymes, this may be compensated
by the long half-life and substantially higher concentration of IgG
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Table 2. FVIII inhibitory titers, mortality and specific rates of hydrolysis, and activation of coagulation factors by IgG purified from the
plasma of 65 patients with acquired hemophilia
Patient no.
Inhibitory titer,
BU/mL*
Mortality of
patients†
Hydrolysis of FVIII,‡
mmol/min per
mole IgG
Hydrolysis of FIX,§
mmol/min per
mole IgG
Activation of FIX,
mmol/min per mole IgG
1 40 D 0.45  0.2¶ 0.03  0.01 0.29  0.05
2 63 A 0.15  0.0 0.29  0.45 0.96  0.10¶
3 128 D 0.14  0.1 0.44  0.38¶ 0.07  0.00
4 114 D 0.13  0.1 0.37  0.06 0.03  0.02
5 380 ND 0.17  0.0 0.35  0.19 0.03  0.01
6 32 A 0.12  0.1 0.37  0.18 0.23  0.02
7 49.4 ND 0.08  0.0 0.49  0.29¶ 0.02  0.01
8 3.1 D 0.38  0.2¶ 0.42  0.14¶ 0.95  0.32¶
9 42 A 0.13  0.0 0.33  0.26 1.33  0.34¶
10 6 A 0.17  0.0 0.64  0.42¶ 2.01  0.56¶
11 14 D 0.08  0.0 0.01  0.01 0.33  0.12
12 2 A 0.12  0.1 0.17  0.13 0.70  0.15¶
13 40 A 0.16  0.1 0.21  0.02 0.21  0.05
14 2 A 0.22  0.0¶ 0.73  0.02¶ 3.43  0.48¶
15 80 A 0.18  0.0¶ 0.32  0.02 0.28  0.06
16 52 A 0.14  0.0¶ 1.04  0.14¶ 3.49  0.59¶
17 100 A 0.36  0.1¶ 0.17  0.08 0.42  0.04
18 10 A 0.09  0.0 0.36  0.27 0.13  0.03
19 1.4 D 0.10  0.0 0.38  0.29¶ 0.05  0.02
20 18 D 0.08  0.0 0.54  0.61¶ 0.19  0.06
21 1050 ND 0.15  0.1¶ 0.35  0.16 0.05  0.03
22 330 D 0.14  0.1¶ 0.28  0.05 0.59  0.07¶
23 18 A 0.30  0.1¶ 0.97  0.13¶ 1.78  0.17¶
24 1.3 D 0.05  0.0 0.50  0.17¶ 0.59  0.00¶
25 60 D 0.06  0.0 0.16  0.05 0.04  0.00
26 1 A 0.06  0.0 0.18  0.07 0.20  0.04
27 4 A 0.10  0.1 0.27  0.09 0.42  0.04
28 56 ND 0.07  0.0 0.08  0.05 1.98  0.17¶
29 4.5 A 0.13  0.0¶ 0.17  0.07 0.14  0.04
30 1.5 A 0.08  0.0 1.10  0.04¶ 0.89  0.28¶
31 3 A 0.11  0.1 0.34  0.08¶ 0.07  0.03
32 7 A 0.19  0.0¶ 0.39  0.23¶ 2.13  0.71¶
33 362.7 A 0.08  0.0 0.10  0.10 0.04  0.01
34 249.2 ND 0.09  0.1 0.19  0.18 0.06  0.03
35 62 A 0.32  0.0¶ 0.41  0.22¶ 0.31  0.03¶
36 54 A 0.21  0.1¶ 0.13  0.11 0.02  0.01
37 1 ND 0.13  0.1 0.11  0.07 0.07  0.03
38 105.4 ND 0.10  0.0 0.05  0.04 0.04  0.01
39 92.5 ND 0.09  0.0 0.14  0.11 0.03  0.01
40 26.6 D 0.10  0.1 0.09  0.08 0.03  0.00
41 10 D 0.17  0.0 0.33  0.02¶ 0.85  0.13¶
42 29.9 ND 0.10  0.0 0.15  0.12 0.03  0.01
43 4.9 A 0.30  0.2¶ 0.24  0.16 0.12  0.03
44 13 A 0.10  0.0 0.34  0.17¶ 0.26  0.09¶
45 58.2 ND 0.17  0.0 0.25  0.14 0.03  0.01
46 25 A — 0.08  0.03 0.08  0.03
47 35 D — 0.62  0.08¶ 0.38  0.03¶
48 190 D — 0.07  0.01 0.07  0.00
49 6.2 A — 0.02  0.01 0.05  0.02
50 50 A — 0.32  0.12¶ 0.22  0.02¶
51 5.5 A — 0.14  0.06 0.09  0.02
52 13.6 A — 0.07  0.02 0.10  0.05
53 8 A — 0.17  0.03¶ 0.16  0.06¶
— indicates not documented.
*Inhibitory titers were measured in plasma using the modified Bethesda assay.
†Mortality was documented in the case of 52 of the 65 patients over a period of 365 days. A indicates alive; D, deceased; and ND, not documented.
‡The results are mean  SD of 4 independent experiments. Rates of FVIII hydrolysis were calculated by densitometric analysis of Western blots. Spontaneous hydrolysis
that occurred on incubation of FVIII in the presence of buffer alone was subtracted from each analysis. The mean coefficient of variation was 0.53  0.22 (range, 0.09-1.15).
§The results are mean  SD of 3 or 4 independent experiments. Rates of FIX hydrolysis were calculated by densitometric analysis of Western blots. Spontaneous
hydrolysis that occurred on incubation of FIX in the presence of buffer alone was subtracted from each analysis. The mean coefficient of variation was 0.47  0.32 (range,
0.01-1.58). The detection limit in our assay was 0.6 nM of hydrolyzed protein, equivalent to a rate of hydrolysis of 6 mol/min per mole IgG.
The results are mean  SD of 3 independent experiments. Rates of FIX activation were calculated in a functional assay as described (“Activation of FIX”). The mean
coefficient of variation was 0.26  0.15 (range, 0.00-0.55).
¶P  .05 for the comparison with intravenous immunoglobulins, using 1-way analysis of variance post-hoc test (2-tailed test).
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in the circulation. Of note, under our experimental conditions, IgG
activated up to 0.3nM of FIX in 24 hours, a value in the same range
as the estimated levels of circulating activated FIX in healthy
donors (ie, 0.1-0.5nM).27 Further, given that concentrations of IgG
and FIX in plasma are 10 mg/mL (67M) and 90nM, respectively,
the molar ratio of IgG antibody against FIX in plasma is 740. These
molar ratios in our experiments were 0.07 to 0.36. Thus, hydrolysis
was observed when these molar ratios in the experimental samples
were 0.01% to 0.05% of those in normal plasma, suggesting that
IgG-mediated hydrolysis is a mechanism of FIX activation by the
antibodies of the patients in vivo. Activation of FIX requires
proteolytic cleavage at 2 different sites. It remains to be determined
whether IgG-mediated FIX activation results from a synergy
between different IgG molecules each cleaving at a single location,
or whether single proteolytic IgG molecules hydrolyze the
2 different sites and hence harbor promiscuous cleavage specificity.
In addition to our previous observations,5,28,29 several pieces of
evidence in the present study make it unlikely that the proteolysis
of coagulation factors was caused by contaminating proteases: IgG
purified from the plasma of different patients demonstrated differ-
ent proteolyzing behaviors (Figure 1B); notably, IgG purified from
hemophilia B patients with FIX inhibitors failed to proteolyze and
activate FIX; the different purified IgG preparations selectively
proteolyzed FVIII and/or FIX (Figure 1C), although they failed to
proteolyze albumin, prothrombin, activated FVII,5 or the synthetic
peptide substrate for activated FX, and did not activate FX; F(ab)2
fragments of patients’ IgG hydrolyzed FIX, similar to the whole IgG
counterparts (supplemental Figure 3). Lastly, matrix-assisted laser
desorption/ionization-time-of-flight analysis of purified IgG did not
reveal traces of activated FXI or other adventitious protease.
The physiopathologic relevance of proteolytic antibodies re-
mains a debated issue. Antibody-mediated proteolysis has been
associated with pathogenesis in asthma,30 multiple sclerosis,31-33
autoimmune thyroiditis,34 and hemophilia A.15,28 Conversely, el-
evated levels of IgG with amidolytic activity have been associated
with positive outcome in severe sepsis,35 or with delayed chronic
allograft nephropathy in renal transplantation.36 Here, we observe
that IgG from 38.5% of the patients significantly activate FIX
compared with IVIg. In our cohort, the cumulative mortality was
30.7%. Interestingly, patients who were alive 12 months after
diagnosis statistically tended to have higher levels of FIX-
activating IgG than patients who were deceased (P  .1), although
the difference did not reach significance. Taken together, the data
suggest that, in certain underlying pathologies, IgG-mediated FIX
activation may be beneficial and represents an antihemorrhagic
mechanism that compensates, at least in part, for the inhibition of
endogenous FVIII by the patients’ anti-FVIII autoantibodies. In
support, in vitro addition of picomolar levels of activated FIX to
plasma partly restores thrombin generation, provided that residual
FVIII in plasma was more than or equal to 3%. Because the
IgG-mediated FIX activation is reflected in marginally improved
thrombin generation, it may be appropriate to analyze the effect of
thrombin generation on patients’ mortality in the future.
Hemorrhages in patients with acquired hemophilia are treated
with FVIII, activated FVII, or activated prothrombin complexes,
all of which are hampered by short half-life and/or risks for
thromboembolic complications. Our results raise the issue of the
Table 3. Kinetic parameters of the hydrolysis of FIX by IgG of
patients with acquired hemophilia
No. of patients Vmax, nM/min Km, M
16 0.82  0.19 7.26  3.99
23 0.41  0.03 0.94  0.25
32 0.30  0.03 1.81  0.61
Mean 0.51  0.08 3.34  1.62
FIX was incubated at increasing concentrations (0-20M) with IgG (167nM) of
3 patients with acquired hemophilia for 24 hours at 37°C. Hydrolysis rates were
computed, and the data were fitted to the Michaelis-Menten equation to derive the
apparent Vmax and average Km. Data are the mean  SE of 3 independent
experiments.
Table 2. FVIII inhibitory titers, mortality and specific rates of hydrolysis, and activation of coagulation factors by IgG purified from the
plasma of 65 patients with acquired hemophilia (continued)
Patient no.
Inhibitory titer,
BU/mL *
Mortality of
patients†
Hydrolysis of FVIII,‡
mmol/min per
mole IgG
Hydrolysis of FIX,§
mmol/min per
mole IgG
Activation of FIX,
mmol/min per mole IgG
54 3 A — 0.10  0.02 0.12  0.03¶
55 1.5 ND — 0.02  0.01 0.06  0.02
56 28 ND — 0.04  0.03 0.08  0.02
57 27 A — 0.19  0.07¶ 0.04  0.00
58 1.7 D — 0.12  0.05 0.11  0.04
59 4.4 D — 0.10  0.02 0.07  0.03
60 98 A — 0.04  0.01 0.05  0.02
61 45 A — 0.29  0.06¶ 0.29  0.05¶
62 2 A — 0.28  0.05¶ 0.20  0.04¶
63 1 ND — 0.25  0.02¶ 0.26  0.07¶
64 11.5 A — 0.39  0.01¶ 0.38  0.09¶
65 9 A — 0.17  0.02¶ 0.16  0.06¶
IVIg 0 — 0.06  0.03 0.06  0.06 0.01  0.00
— indicates not documented.
*Inhibitory titers were measured in plasma using the modified Bethesda assay.
†Mortality was documented in the case of 52 of the 65 patients over a period of 365 days. A indicates alive; D, deceased; and ND, not documented.
‡The results are mean  SD of 4 independent experiments. Rates of FVIII hydrolysis were calculated by densitometric analysis of Western blots. Spontaneous hydrolysis
that occurred on incubation of FVIII in the presence of buffer alone was subtracted from each analysis. The mean coefficient of variation was 0.53  0.22 (range, 0.09-1.15).
§The results are mean  SD of 3 or 4 independent experiments. Rates of FIX hydrolysis were calculated by densitometric analysis of Western blots. Spontaneous
hydrolysis that occurred on incubation of FIX in the presence of buffer alone was subtracted from each analysis. The mean coefficient of variation was 0.47  0.32 (range,
0.01-1.58). The detection limit in our assay was 0.6 nM of hydrolyzed protein, equivalent to a rate of hydrolysis of 6 mol/min per mole IgG.
The results are mean  SD of 3 independent experiments. Rates of FIX activation were calculated in a functional assay as described (“Activation of FIX”). The mean
coefficient of variation was 0.26  0.15 (range, 0.00-0.55).
¶P  .05 for the comparison with intravenous immunoglobulins, using 1-way analysis of variance post-hoc test (2-tailed test).
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therapeutic relevance of the passive administration of proteolytic
FIX-activating antibodies; proteolytic antibodies would advanta-
geously combine the capacity for “turnover” that characterizes
enzymatic activities, low risk for thrombotic complications be-
cause of their low catalytic rates of FIX activation, with long
half-life typical of IgG molecules.
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Figure S1. Factor IX activation by activated factor XI and IgG from patient 17 
(A) Depiction of the activation of factor IX by activated factor XI. The figure represents the 
sequential cleavage between amino acid positions R145-A146 and R180-V181 of factor IX by 
activated factor XI. Cleavage at the first bond (R145-A146) generates a single band migrating at 
56 kDa (referred to as FIXα) under non-reducing condition, whereas under reducing condition it 
leads to two polypeptides of sizes 20 kDa and 36 kDa. The cleavage of the second bond (R180-
V181) releases the activation peptide of 11 kDa and leads to the formation of activated FIX 
(FIXaβ), which migrates as a 45 kDa fragment under non-reducing condition and as two 
polypetides of 20 kDa (light chain) and 25 kDa (heavy chain) under reducing condition. (B) 
Dose-dependent proteolysis of factor IX by IgG from patient 17. To identify different factor IX 
intermediates generated during activation by IgG, biotinylated factor IX (185 nM) was incubated 
with increasing concentrations of IgG (0 to 40 µg/ml) from patient 17 for 24 hr at 37°C. Samples 
were separated by 10% SDS-PAGE under reducing conditions and transferred to nitrocellulose, 
prior to revelation of biotinylated fragments. (C) Time-dependent proteolysis of factor IX by IgG 
from patient 17. IgG (67 nM) from patient 17 were mixed with biotinylated factor IX (185 nM) 
for 0 to 48 hours at 37°C. Proteolysis of FIX was examined by SDS-PAGE and Western blot. 
 
Figure S2. Investigation of IgG-mediated proteolysis of factor IX in patients with 
hemophilia B 
Biotinylated human recombinant factor IX (185 nM) was incubated alone or in the presence of 
IgG (67 nM) purified from the plasma of 7 inhibitor-positive patients with hemophilia B, for 0 or 
24 hr at 37°C. Intravenous immune globulin (IVIg) was used as a source of normal IgG and as a 
control (Ctl). Samples were subjected to 10 percent SDS-PAGE and transferred onto a 
nitrocellulose membrane, prior to revelation of biotinylated fragments. 
 
Figure S3. Hydrolysis of FIX by F(ab’)2 fragments prepared from the IgG of patient 16. 
F(ab’)2 fragments were prepared upon digestion of purified IgG with pepsin in 0.2 M Na acetate 
buffer (pH 4.1) for 18 hr at 37°C. The digestion was stopped on adding Tris to adjust the pH to 
7.4. The preparation was dialyzed in the presence of PBS. To obtain a pure fraction of F(ab’)2 
fragments, and to exclude potentially contaminating proteases, size-exclusion chromatography of 
the preparation was performed on a Superose-12 column (Amersham) equilibrated with 50 mM 
Tris (pH 7.7), 8 M urea and 0.02% NaN3, at a flow rate of 250 µl/min. F(ab’)2-containing 
fractions (tested by an ELISA) were pooled and dialyzed against PBS-0.01 percent NaN3 for 
48 hr at 4°C, followed by dialysis against 50 mM Tris (pH 7.7), 100 mM glycine, 0.02 percent 
NaN3, 5 mM CaCl2 (catalytic buffer) for 24 hr at 4°C. Biotinylated human recombinant factor IX 
(185 nM) was incubated alone for 0 or 24 hr, in the presence of IgG (67 nM) or F(ab’)2 
preparation (67 nM) from patient 16, for 24 hr at 37°C. Intravenous immune globulin (IVIg) was 
used as a source of normal IgG and as a control. Samples were subjected to 10 percent SDS-
PAGE and transferred onto a nitrocellulose membrane, prior to revelation of biotinylated 
fragments. 
 
Figure S4. Titers of anti-factor IX IgG from patients with acquired hemophilia 
An ELISA was performed using recombinant human factor IX. Plates (Nunc, Maxisorb) were 
coated with recombinant human factor IX (2 µg/ml, 1 hr) in phosphate-buffered saline (PBS, 10 
mM sodium phosphate/0.14 M NaCl, pH 7.4) and blocked (1 hr) with PBS, BSA (1 percent, 
W/V). Purified IgG (0 to 67 nM, 50 µl) were incubated for 1 hr and the plates were washed with 
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PBS-tween 20 (0.01 percent V/V). The plates were then incubated for 1 hr with peroxidase-
linked mouse anti-human immunoglobulin antibodies (Jackson ImmunoResearch, Suffolk, UK). 
After washing with PBS-0.01 percent tween 20, the o-Phenylenediamine dihydrochloride 
(SIGMAFAST™ OPD, Lyon, France) substrate was added and the absorbance at 492 nm was 
measured using a UV-vis spectrophotometer (GENios, Tecan Trading AG, Switzerland). The 
optical density obtained in the case of wells lacking IgG was considered to represent the 
background level and was subtracted from the values obtained for each well incubated with 
purified IgG. ELISAs on different plates were standardized using the purified IgG from a 
hemophilia B patient who had developed anti-factor IX IgG following replacement therapy with 
exogenous factor IX (Patient HJC). IgG purified from the plasma of 21 of 65 patients 
demonstrated binding activity with factor IX, which was greater than that of the mean+1 SD 
measured for IVIg. 
 
Figure S5. Binding of IgG to factor IX versus IgG-mediated proteolysis of factor IX 
The binding of purified IgG (23 nM) from 65 patients with acquired hemophilia was tested by 
enzyme-linked immuno assay against human recombinant factor IX (2 µg/ml). The optical 
density values measured at 492 nm for IgG were plotted as a function of the calculated rates of 
IgG-mediated proteolysis of factor IX. The correlation between the two parameters was not 
significant as computed using the Spearman rank correlation test. 
 
Figure S6. Generation of thrombin by activated factor IX in the presence of factor VIII 
The thrombin generation assay probes the whole intrinsic coagulation cascade from contact 
activation to the formation of thrombin as well as the inactivation of activated coagulation 
factors by plasma protease inhibitors. Tissue factor-independent thrombin generation curves 
were determined in human plasma that is devoid of platelets (PPP). The generation of thrombin 
was monitored during 120 min in factor VIII-deficient plasma supplemented with exogenous 
factor VIII at 30% of the level found in normal plasma, and in the presence of 0, 0.3 and 3 nM of 
activated factor IX. The time to reach the peak of thrombin generation (referred to as time-to-
peak) was computed. Results are representative of two independent experiments. Indicated 
percent values represent adjusted factor VIII levels in test plasma. 
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Article 2- Résumé en Français 
Titre: Evolution des niveaux d’anticorps catalytiques chez les patients ayant subi une 
transplantation rénale 
La transplantation rénale est le traitement de choix pour les patients en insuffisance rénale 
terminale. Nous avons montré que de faibles niveaux d’IgG catalytiques sont un 
marqueur pronostique potentiel de la néphropathie chronique d'allogreffe. L’origine et 
l’importance physiopathologique des anticorps catalytiques sont mal connues en partie 
parce que ces anticorps ont été étudiés dans des cohortes relativement petites de patients 
atteints de maladies rares et/ou sans suivi systématique. Ici, nous avons suivi pendant 
deux années l’évolution des niveaux d’anticorps catalytiques dans une large cohorte de 
patients ayant subi une transplantation rénale. Nos résultats montrent que, avant 
transplantation, les patients en insuffisance rénale terminale ont des niveaux hétérogènes 
d’IgG hydrolysant le PFR-MCA, un substrat générique. L’hydrolyse du PFR-MCA est 
plus importante dans le cas des IgG des patients que dans celui d’un mélange d’IgG de 
donneurs sains. La transplantation rénale est marquée par une baisse drastique du niveau 
des IgG catalytiques en 3 mois, suivie par une augmentation progressive les 21 mois 
suivants. Les patients ayant de forts niveaux d’IgG catalytiques avant transplantation 
récupéraient des niveaux élevés d’IgG catalytiques au bout de deux ans. Par ailleurs, 
l’hydrolyse par les IgG d’un substrat protéique modèle, le facteur VIII de la coagulation, 
n’était pas corrélée à celle du PFR-MCA avant transplantation, mais l’était 24 mois plus 
tard. Dans leur ensemble, nos résultats suggèrent que le niveau d’IgG catalytiques 
circulantes en conditions pathologiques est une propriété intrinsèque du système 
immunitaire de chacun, et que la récupération des IgG catalytiques après transplantation 
est accompagnée par des modifications du répertoire des antigènes cibles.  
	   64	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Abstract 
Renal transplant is the treatment of choice for patients with end-stage renal disease. We 
have previously identified low levels of catalytic IgG as a potential prognosis marker for 
chronic allograft rejection. The origin and physiopathological relevance of catalytic 
antibodies is not well understood owing to the fact that catalytic antibodies have been 
studied in relatively small cohorts of patients with rare diseases and/or without systematic 
follow-up. In the present study, we have followed the evolution of levels of catalytic IgG 
in a large cohort of renal transplant patients over a period of 2 years. Our results 
demonstrate that, prior to transplant, patients with renal failure present with 
heterogeneous levels of IgG hydrolyzing the generic PFR-MCA substrate. PFR-MCA 
hydrolysis was greater in the case of patients’ IgG than in that of a preparation of pooled 
IgG from healthy donors. Renal transplant was marked by a drastic decrease in levels of 
catalytic IgG over three months followed by a steady increase during the next 21 months. 
Patients who displayed high levels of catalytic IgG pre-transplant recovered high levels 
of catalytic antibodies 2 years post-transplant. Interestingly, IgG-mediated hydrolysis of a 
model protein substrate, pro-coagulant factor VIII, did not correlate with that of PFR-
MCA prior transplantation, while it did 24 months post-transplant. Taken together, our 
results suggest that the level of circulating catalytic IgG under pathological conditions is 
an intrinsic property of each individual’s immune system, and that recovery of pre-
transplant levels of catalytic IgG is accompanied by changes in the repertoire of target 
antigens.  
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Introduction 
Catalytic antibodies are immunolglobulins with enzyme-like properties. The advent of 
hybridoma technology fuelled a remarkable progress and in the past 26 years catalytic 
antibodies with more than 100 tailor-made specificities have been made. From the late 
80’s, scientists have also investigated the pathophysiological association of catalytic 
antibodies in several diseased conditions. Thus, IgG with catalytic activity against 
vasoactive intestinal peptide, thyroglobulin, myelin basic protein, DNA/RNA and 
coagulation factor VIII, have been reported in pathological conditions including asthma (1), Hashimoto’s thyroiditis (2), multiple sclerosis (3), systemic lupus erythmatosus (4), 
and hemophilia A (5). Recent findings however, suggest the presence of naturally 
occurring catalytic antibodies in physiology. The naturally occurring catalytic antibodies 
display promiscuity in antigen/substrate-specificity and are believed to act in defence 
mechanism against viral/bacterial pathogens. In fact, immunoglobulins of the IgA and 
IgM type isolated from healthy individuals are shown to possess nuclease and/or protease 
activity against bacterial or viral antigens (6-­‐8). In this context, catalytic antibodies have 
been proposed to participate in maintaining immune homeostasis and clearing of 
biological wastes. Whether catalytic antibodies are a feed-back control mechanism aimed 
at re-establishing immune homeostasis under diseased conditions still remains elusive. In 
this line, our earlier investigations provide some hints. We have observed that high levels 
of circulating catalytic IgG correlates with a favourable outcome in some diseases. 
Patients with high IgG-mediated catalytic activity had a better survival rate in sepsis and 
a tendency towards better survival was observed in the case of patients with acquired 
hemophilia, that possess factor IX-activating antibodies in plasma (9, 10). Moreover, in 
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patients undergoing renal transplant, better graft survival correlated with the presence of 
high levels of IgG-mediated catalytic activity. High IgG-mediated catalytic activity as 
early as at 3 months was predictive of absence of chronic allograft rejection (CAN) 2 
years post-transplant (11).  
Despite the efforts invested to date, our understanding of the physiopathological 
relevance of catalytic antibodies in human health remain poor. We know that patients 
with different diseases generally exhibit heterogeneous levels of catalytic antibodies. We 
also know that the levels of catalytic antibodies may evolve with time, although not 
necessarily in a manner that correlates with disease progression. However, it is not clear 
whether high levels of catalytic antibodies in some individuals are an intrinsic property of 
their very immune system or are associated with peculiar disease conditions. In the 
present study, we followed a large cohort of patients with renal transplant for a period of 
2 years, with regular and systematic blood sampling prior to transplantation as well as 3, 
12 and 24 months later. 
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Patients and methods 
Study population 
From October 2008 to August 2009, we prospectively collected plasma from 100 
consecutive patients 3 months following renal transplant at the Renal Transplantation 
Department of the Necker Hospital (Paris, France). Patients were followed-up and we 
also collected plasma at 12 months (92 patients) and 24 months (73 patients) post-
transplant. Frozen pre-transplant plasma samples were retrieved retrospectively in the 
case of 59/100 patients. Clinical characteristics of the patients are depicted in Table 1. 
Written informed consents were obtained from each patient according to the Declaration 
of Helsinki.  
 
Plasma collection 
Blood was collected in citrate vacutainer tubes (BD biosciences), and centrifuged at 1500 
rpm for 10 min at 20°C. Plasma was stored in aliquots at -20°C until use. 
 
Purification of IgG 
IgG were isolated from plasma by affinity-chromatography on protein G-Sepharose 
(Amersham Pharmacia Biotech). In brief, IgG was incubated with protein G-Sepharose 
overnight at 4°C, eluted using 0.2M glycine-HCl pH 2.8, dialyzed against PBS-0.02% 
NaN3 overnight at 4°C, and concentrated using Amicon (Millipore). A therapeutic 
preparation of pooled normal human IgG (intravenous Ig (IVIg); Sandoglobulin) was 
used as a source of control IgG. Size-exclusion chromatography of patients’ IgG and 
IVIg was performed on a Superose-12 column (GE Healthcare Europe) equilibrated with 
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urea-containing buffer (50 mM Tris pH 7.7, 8 M urea and 0.02% NaN3), at a flow rate of 
0.5 ml/min to exclude potentially contaminating proteases. IgG-containing fractions were 
then pooled and dialyzed against PBS-0.02% NaN3 for 2 days with four changes in 
buffer at 4°C, followed by dialysis against catalytic buffer containing 5 mM CaCl2 (pH 
7.7) for 1 days with two changes in buffer at 4°C. The purity of IgG preparations was 
confirmed by SDS-PAGE and immunoblotting under non-reducing conditions. IgG was 
quantified by Bradford assay. 
 
IgG-mediated hydrolysis of PFR-MCA 
IgG (66.67 nM) were mixed with 100 µM PFR-MCA (Peptide Institute, Inc.) in 40 µl of 
catalytic buffer containing 5 mM CaCl2 (pH 7.7) in white 96-well U-bottom plates 
(Thermo Scientific) and incubated in the dark for 24 h at 37°C. Hydrolysis of the PFR-
MCA substrate was determined by the fluorescence of the leaving group 
(aminomethylcoumarin; λem 465 nm, λex 360 nm) using a spectrofluorometer (GENios; 
Tecan Trading). Fluorescence values were compared with a standard curve of free MCA 
and the corresponding quantities of released MCA were computed. At each time point, 
background release of MCA, measured in wells containing the substrate alone, was 
subtracted from the value observed in the presence of the Abs. Data are expressed as the 
quantity of released MCA computed at time 0 subtracted from the quantity of released 
MCA computed at a given time point per amount of time per amount of IgG.  
 
Biotinylation of FVIII 
Recombinant human factor VIII (FVIII, Kogenate FS, BayerPharma, Lille, France) was 
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reconstituted in distilled water to a final concentration of 600 µg/ml, desalted by 
dialyzing against borate buffer (100 mM borate (pH 7.0), 150 mM NaCl, and 5 mM 
CaCl2). Sulfo-NHS-LC-biotin (440 µl at 25 µg/ml) was allowed to react with 600 µg of 
FVIII with gentle agitation in the dark for 2 h at 4°C. Biotinylated FVIII was dialyzed 
against catalytic buffer containing 5 mM CaCl2 for 3 h at 4°C, aliquoted, and stored at -
20°C until use.  
 
Hydrolysis of biotinylated FVIII 
Biotinylated FVIII (185 nM) was incubated in 40 µl of catalytic buffer containing 5 mM 
CaCl2 with the purified patients’ IgG (10 µg/ml, 66.67 nM) in the dark for 24 h at 37°C. 
Samples were mixed with Laemmli’s buffer without 2-ME (1:1, v/v) and 25 µl of each 
sample was subjected to 10% SDS-PAGE. Protein fragments were then transferred onto 
nitrocellulose membranes (Schleicher & Schuell’s Microscience). Following overnight 
blocking in TBS containing 0.2% Tween 20 at 4°C, membranes were incubated with 
streptavidin-coupled alkaline phosphatase (Southern Biotech) diluted 1:3000 in blocking 
buffer, for 60 min at room temperature. After washing in TBS containing 0.1% tween-20 
and TBS, labeled FVIII was revealed using the BCIP/NBT kit (Kirkegaard & Perry 
Laboratories). Blots were scanned using a scanner (EPSON Perfection V10) and rates of 
hydrolysis were calculated by densitometric analysis. 
 
Statistics 
The statistical comparisons of groups of patients were performed using the non- 
parametric Mann-Whitney test, with two-tailed P values, unless indicated.  
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Results 
IgG from pre-transplant patients show heterogeneous levels of catalytic activity, 
which is not related to particular underlying pathology 
We collected plasma from 100 consecutive renal-transplant patients after 3 months of 
transplant and followed-up to obtain plasma at 12 (92 patients) and 24 months (73 
patients) post-transplant. Pre-transplant plasma samples from 59 patients were retrieved 
retrospectively. Overall, 27 patients were lost during the 24 months of the study period. 
The cohort included as many men as women, with a mean age of 48.3±1.5 years 
(mean±SEM; range: 21 to 83). Causes for end-stage renal dysfunction included diabetes 
(4% of the patients), vasculopathy (8%), glomerulopathy (24%), uropathy (23%), 
interstitial nephropathy (15%) or were not known (26%). Fifteen and 2 patients had had 
one or two previous transplants, respectively. Fifteen and 2 patients had had one or two 
previous transplants, respectively.  
IgG was purified and tested for hydrolysis of the peptide PFR-MCA, a surrogate substrate 
for catalytic antibodies with serine protease-like activity (12). The absence of 
contamination of the IgG samples by adventitious proteases was ensured by the use of a 
double-step purification procedure that involves a step of purification based on affinity 
and a step of purification based on protein size under denaturing conditions. Incubation of 
patients’ IgG with PFR-MCA resulted in hydrolysis of the peptide and release of the 
fluorescent MCA moiety. The released fluorescence allowed for the calculation of rates 
of hydrolysis.  
Hydrolysis of PFR-MCA was dose- and time-dependent (data not shown). Pooled IgG 
from healthy individuals (IVIg) demonstrated a marginal hydrolysis of PFR-MCA with 
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an activity of 0.65±0.03 fmol/min per pmol (mean±SEM for 29 repeats). Irrespective of 
the time-point considered, IgG from renal-transplanted patients demonstrated 
significantly higher hydrolysis rates of PFR-MCA than IVIg (Figure 1A). There was no 
significant difference in the levels of PFR-MCA-hydrolyzing IgG at any time point with 
respect to the sex, the age, the transplantation rank, the cause for end-stage renal failure 
and the time of dialysis prior to transplant (data not shown and Table 1).	  	  
The levels of PFR-MCA hydrolyzing IgG were extremely heterogeneous prior to 
transplantation, with a mean activity of 6.6±0.9 fmol/min/pmol (mean±SEM; coefficient 
of variation: 1.04, Figure 1A). To investigate whether high or low levels of PFR-MCA 
hydrolyzing IgG were associated with a particular disease condition, we compared the 
hydrolysis rates between patients with different causes for end-stage renal failure. IgG 
from patients with uropathy displayed the lowest mean rate of PFR-MCA hydrolysis, that 
was statistically different from that of IgG from patients with interstitial nephropathy 
(3.7±0.7 vs 7.9±1.2 fmol/min/pmol, P=0.003, Figure 1B). Of note, several underlying 
pathologies had only a low number of cases, thus hampering powerful statistical 
comparison.  
 
IgG-mediated catalytic activity varies overtime in renal-transplant patients 
A longitudinal follow-up of the levels of PFR-MCA-hydrolyzing IgG was performed to 
determine the evolution of IgG-mediated catalytic activity during the course of the 
disease. The number of patients at each time point (0, 3, 12 and 24 months) was 59, 100, 
92 and 73, respectively. The differences in the rates of IgG-mediated catalytic activity 
between each group were evaluated using the two-tailed Mann Whitney test. As 
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compared to the rates of IgG-mediated catalytic activity pre-transplant, the rates 
decreased sharply 3 months post-transplant  (6.6±0.9 vs 2.4±0.2 fmol/min/pmol, 
P<0.0001, Figure 1A). However, an increase in the rates of hydrolysis of PFR-MCA was 
observed at 12 months post-transplant as compared to 3 months (3.2±0.3 vs 2.4±0.2 
fmol/min/pmol, P=0.008). The rates of hydrolysis further increased significantly at 24 
months (5.1±0.6 fmol/min/pmol) in comparison to 3 months (P<0.0001) and 12 months 
(P=0.016). There was no difference in the rates of IgG-mediated catalytic activity 
between patients prior to transplant and 24 months later (6.6±0.9 vs 5.1±0.6 
fmol/min/pmol), indicating that the pre-existing levels of PFR-MCA-hydrolyzing IgG 
had been recovered in the due course of time.  
Linear regression analysis between the groups of patients pre-transplant and 24 months 
post-transplant, showed a significantly positive correlation in the rates of IgG-mediated 
PFR-MCA hydrolysis (P<0.001, R2=0.23, Figure 1C). No correlation in IgG-mediated 
catalytic activity was observed between the groups of patients at other time points. To 
confirm that patients with elevated levels of catalytic antibodies before transplant recover 
elevated levels two years later, we divided the patients into quartiles based on the rates of 
IgG-mediated PFR-MCA hydrolysis measured in pre-transplant samples. At each time 
point, the IgG-mediated catalytic activity of the upper quartile was compared with the 
rates of catalytic activity of the cumulated lower three quartiles (Figure 1D). The rate of 
IgG-mediated catalytic activity in the upper quartile of patients was significantly high 
both pre-transplant (12.03±1.6 vs 2.7±0.2 fmol/min/pmol, P<0.0001) and 24 months post 
transplant (6.8±1.2 vs 4.6±0.7, fmol/min/pmol, P=0.009). 
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IgG-mediated FVIII and PFR-MCA hydrolysis correlate at 12 months but not prior 
to transplant 
IgG from patients’ plasma prior to transplant, and 3 and 12 months post-transplant were 
tested for their ability to hydrolyze human recombinant FVIII. Patients’ IgG were 
incubated with biotinylated FVIII and profiles of FVIII hydrolysis were revealed by 
Western blotting (Fig 2A). The rates of IgG-mediated FVIII hydrolysis were calculated 
by densitometric analysis after subtracting the amount of FVIII hydrolysed spontaneously 
in the absence of IgG. Patients’ IgG demonstrated heterogeneous profiles of FVIII 
hydrolysis (Fig 2A). The rates of hydrolysis of FVIII among pre-transplant patients were 
highly heterogeneous. As observed for PFR-MCA hydrolysis, the rate of IgG-mediated 
FVIII hydrolysis decreased significantly 3 months post-transplant (157±9.8 vs 43.8±10.2 
µmol/min/mol, P<0.0001, Fig 2B), and recovered after 12 months (113.7±17.6 
µmol/min/mol). Pooled IgG from healthy individuals demonstrated a marginal hydrolysis 
of FVIII with an activity of 11.1±1.2 µmol/min/mol (mean±SEM for 22 repeats).  
While the mean rate of hydrolysis of PFR-MCA and FVIII by patients’ IgG was 
relatively high prior to transplant, no correlation was observed between IgG-mediated 
PFR-MCA hydrolysis and IgG-mediated FVIII hydrolysis (P=0.17, R2=0.03, Figure 2C). 
The longitudinal follow-up however demonstrated a correlation tendency at three months 
(P=0.053, R2=0.01), which became significant 12 months post transplantation (P<0.0001, 
R2=0.4, Figure 2D). 
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Discussion 
The results are discussed in the main discussion part of the thesis. 
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Tables 
Table 1. Patients’ characteristics 
 Nb (%) or median [range] 
Age (years) 100 
 48 [21-83] 
Sex 100 
Females 50 
Males 50 
Cause for end-stage renal failure 100 
Diabetes 4 
Vascular diseases 8 
Glomerulopathy 24 
Uropathy 23 
Interstitial nephropathy 15 
Unknown 26 
HLA reactive antibodies 68 
HLA1 18 (27) 
ND 32 
HLA2 29 (43) 
ND 32 
Both HLA1 and HLA2 10 (15) 
ND 34 
HLA mismatch 98 
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0 5 
1 10 
2 22 
3 12 
4 32 
5 16 
6 1 
Risk group 99 
1 15 
2 40 
3 44 
Previous kidney transplant 100 
None 82 
1 15 
2 2 
ND 1 
ND: not documented 
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Figure legends. 
Figure 1. Longitudinal analysis of catalytic IgG in patients undergoing renal 
transplant. Panel A. Evolution of IgG-mediated catalytic activity in patients with renal 
transplant. IgG were purified from the plasma of patients collected prior to kidney 
transplant (n=59), as well as 3 (n=100), 12 (n=92) and 24 (n=73) months following 
transplantation. Purified IgG (66.67 nM) were incubated with the PFR-MCA substrate 
(100µM) at 37°C for 24 hr. PFR-MCA hydrolysis was quantified by measuring the 
fluorescence of the leaving fluorescent MCA moiety, and is expressed in fmol of 
hydrolyzed substrate as a function of time per pmol of IgG. The hydrolysis of PFR-MCA 
by pooled IgG from healthy donors is depicted by a dotted line. Hydrolysis was compared 
between groups using the two-tailed Mann Whitney U test: *: P=0.015; **: P=0.004; 
***: P<0.0001). Panel B. Catalytic IgG in patients with different causes for end-stage 
renal failure. The study cohort included 2 patients with diabetes, 3 with vasculopathy, 13 
with glomerulopathy, 15 with uropathy, 11 with interstitial nephropathy and 15 with 
unknown cause for end-stage renal failure. Statistical significances were assessed using 
the two-tailed Mann Whitney U test. Panel C. Correlation between IgG-mediated PFR-
MCA hydrolysis prior to transplantation and 24 months later. The rates of IgG-mediated 
PFR-MCA hydrolysis measured prior to renal transplant and after 24 months were 
positively correlated as analyzed by linear regression. Panel D. Longitudinal follow-up of 
the patients displaying high levels of catalytic IgG. The pre-transplant patients were 
divided into quartiles and the mean rates of PFR-MCA hydrolysis of the upper quartile 
was compared with that of the pooled remaining quartiles. Hydrolysis was compared 
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between groups using the two-tailed Mann Whitney U test (*: P=0.03; ***: P<0.0001 or 
P= 0.0004).  
Figure 2. Hydrolysis of FVIII by IgG from renal-transplant patients. Panel A. IgG-
mediated FVIII hydrolysis. Biotinylated recombinant human FVIII (185 nM) was 
incubated alone (lane 1) or in the presence of IgG (66.67 nM) from 7 randomly selected 
renal-transplanted patients (lanes 1-7) for 24 hr at 37°C. Pooled normal IgG from healthy 
donors (IVIg) was used as control IgG. FVIII was subjected to 10% SDS-PAGE and 
transferred onto a nitrocellulose membrane before revelation of biotinylated fragments. 
Panel B. Longitudinal follow-up of FVIII-hydrolyzing IgG. Rates of IgG-mediated FVIII 
hydrolysis were obtained by densitometric analysis of the blots (Panel A). Results are 
expressed as µmol of hydrolyzed FVIII per min per mol of IgG. Statistical differences 
where assessed using the two-tailed Mann Whitney U test: ***: P<0.0001 or P=0.0004; 
**: P<0.001. Panels C and D. Correlation of rates of PFR-MCA hydrolysis and FVIII 
hydrolysis by IgG prior transplant (Panel C; ns: not significant) and 24 months later 
(Panel D). 
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Article 3- Résumé en Français 
 
Titre: Réduction du titre des anticorps catalytiques chez les patients traités aux 
IgIV ayant subi une transplantation rénale 
Les anticorps catalytiques sont des immunoglobulines dotées d’activité enzymatique. 
Les IgG catalytiques ont été décrites dans différentes pathologies inflammatoires et 
autoimmunes chez l’homme. En particulier, de faibles niveaux d’IgG catalytiques ont 
été proposés comme marqueur pronostique du rejet chronique d’allogreffe chez les 
patients subissant une transplantation rénale. La transplantation rénale est le traitement 
de choix pour les patients en insuffisance rénale terminale. Chez les patients possédant 
des anticorps spécifiques du donneur, les immunoglobulines intraveineuses, une 
préparation thérapeutique d’IgG humaines normales (IVIg), sont utilisées, seules ou avec 
d’autres traitements immunosuppresseurs, pour désensibiliser les patients et prévenir le 
rejet de greffe aigu. Dans cette étude, nous avons suivi sur une période de 24 mois les 
niveaux d’IgG catalytiques dans une large cohorte de patients subissant une 
transplantation rénale. Vingt-quatre pourcents des patients avaient reçu des IVIg au 
moment de la transplantation. Nos résultats démontrent une réduction marquée des 
niveaux d’IgG catalytiques chez tous les patients trois mois après transplantation ; la 
diminution étant significativement plus marquée chez les patients traités avec les IVIg. 
Ces travaux suggèrent que la prévention du rejet aigu à l’aide des IVIg induit une baisse 
transitoire des niveaux d’IgG catalytiques, qui pourrait remettre en cause l’utilisation de 
la mesure des niveaux d’IgG catalytiques comme marqueur pronostique de la 
néphropathie chronique d'allogreffe.  	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Abstract  
Catalytic antibodies are immunoglobulins endowed with enzymatic activity. Catalytic 
IgG has been reported in several human autoimmune and inflammatory diseases. In 
particular, low levels of catalytic IgG have been proposed as a prognostic marker for 
chronic allograft rejection in patients undergoing kidney transplant. Kidney allograft is 
treatment of choice for patients with end-stage renal failure. Intravenous 
immunoglobulins, a therapeutic pool of normal human IgG, is used in patients with 
donor-specific antibodies, alone or in conjunction with other immunosuppressive 
treatments, in order to desensitize the patients and prevent the development of acute graft 
rejection. In the present study, we followed for a period of 24 months the levels of 
catalytic IgG in a large cohort of patients undergoing kidney transplantation. Twenty-four 
percent of the patients received IVIg at the time of transplantation. Our results 
demonstrate a marked reduction in the levels of catalytic antibodies in all patients three 
months following kidney transplant. The decrease was significantly more pronounced in 
patients receiving adjunct IVIg therapy. The results suggests that prevention of acute 
graft rejection using intravenous immunoglobulins induces a transient reduction in the 
levels of catalytic IgG, thus potentially jeopardizing the use of levels of catalytic 
antibodies as a prognosis marker for chronic allograft nephropathy.  
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Introduction 
Catalytic antibodies are immunoglobulins that are endowed with enzymatic activity (1). 
The first examples of catalytic antibodies were obtained following the active 
immunization of experimental animals with appropriate immunogens, referred to as 
transition state analogs (1-3). Since then, a series of approaches has been elaborated to 
generate antibodies with desired enzymatic activities (4-6). Antibodies with enzymatic 
properties however also develop spontaneously in vivo. Thus, IgG able to hydrolyze the 
vasoactive intestinal peptide, DNA, thyroglobulin or pro-coagulant factor VIII have been 
described in patients with asthma, systemic lupus erythematosus, Hashimoto’s thyroiditis 
and hemophilia A, respectively (7-11). Because catalytic antibodies in the human had 
been reported under pathological conditions, it was long thought that they are endowed 
with a pathogenic role, or that, at least, they are a hallmark of immune dysregulation and 
uncontrolled inflammation (12). However, catalytic antibodies of the IgM, IgG and IgA 
isotypes have since been reported in normal blood, in the milk of healthy mothers and in 
saliva (13-15). Under physiological conditions, the antigen/substrate specificity of 
catalytic antibodies is unknown and the latter are generally probed using surrogate 
synthetic peptide substrates (16). It was proposed that catalytic antibodies may participate 
in immune homeostasis and in clearance of biological wastes (17, 18), in line with the 
hypothesis proposed by P Grabar regarding naturally occurring antibodies (19). 
Interestingly, we have recently demonstrated a correlation between the increased 
prevalence of catalytic IgG and positive outcome in several human diseases. Thus, 
increased levels of IgG capable of hydrolyzing the synthetic tri-peptide substrate for 
serine proteases - proline-phenylalanine-arginine-methyl-coumarinamide (PFR-MCA), 
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were found at the time of diagnosis in patients who had survived septic shock three 
weeks later (20). Similarly, we documented the presence of PFR-MCA-hydrolyzing IgG 
in the plasma of patients undergoing renal transplant (21). Low levels of catalytic IgG 3 
months following transplantation were predictive of chronic allograft nephropathy (CAN) 
2 years down the lane, suggesting that IgG-mediated PFR-MCA hydrolysis may be used 
as a prognosis marker for CAN in renal-transplanted patients (21).  
Kidney allograft is treatment of choice for patients with end-stage renal failure (22, 23). 
Short and long-term renal graft survival is particularly compromised in patients 
transplanted across the HLA barrier (24). In particular, some patients, referred to as 
“sensitized” patients possess anti-HLA antibodies, also referred to as “donor-specific 
antibodies” (DSA), of either natural origin, or induced by multiple pregnancies, blood 
transfusion and/or previous transplant. Because sensitized patients are at a higher risk of 
developing humoral acute graft rejection, several strategies have been developed in the 
last decades to desensitize the patients. Among these, the use of intravenous 
immunoglobulins for therapeutic use (IVIg), either alone or in conjunction with 
plasmapheresis and/or monoclonal anti-CD20 antibody-mediated B-cell depletion 
(Rituximab), has allowed to increase the rate of transplant of highly sensitized patients, 
while reducing the time to transplant and the risk of acute rejection (24-26). IVIg 
represents a pool of normal human IgG purified from the plasma of several thousands of 
healthy donors. It is endowed with immuno-regulatory and anti-inflammatory properties, 
justifying their use in a plethora of pathological conditions (27).  
Fluctuations with time of levels of catalytic antibodies in the human population and under 
pathological state have never been studied in a systematic manner (20, 28, 29). Likewise, 
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the size of the cohorts of individuals included in studies on catalytic antibodies has 
always been limited, mostly owing to the fact that catalytic antibodies had been described 
in patients with rare diseases originating from varied clinical centers (28, 29). In the 
present intermediate study, we followed the levels of catalytic IgG in a large cohort of 
patients with renal transplant for a period of 24 months post-transplant. The results 
document higher levels of PFR-MCA-hydrolyzing IgG in patients prior to transplant, as 
compared with pooled IgG from healthy individuals. A drastic reduction in the levels of 
catalytic antibodies is observed in all patients three months following kidney transplant. 
The decrease is significantly more pronounced in patients receiving adjunct IVIg therapy. 
Taken together, the results suggests that the treatments dedicated at preventing acute graft 
rejection induce a transient reduction in the levels of catalytic, thus potentially 
jeopardizing the use of levels of catalytic antibodies as a prognosis marker for CAN.  
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Patients and methods 
Study population 
From February 2008 to August 2009, we prospectively collected plasma from 
consecutive patients 3 months following renal transplant at the Renal Transplantation 
Department of the Necker Hospital (Paris, France). Plasma was also collected 12 months 
and 24 months post-transplant. Frozen pre-transplant plasma samples were retrieved 
retrospectively when available (n=59). Clinical characteristics of the patients were 
collected at the same time-points during physical examination and are depicted in Table 
1. Written informed consents were obtained from each patient according to the 
Declaration of Helsinki. Some patients had received IVIg at the time of renal transplant. 
The protocol for IVIg treatment consisted in 2g per kg body weight Endobulin® (Baxter, 
Maurepas) over a 96-hr period of time on the day of transplant, on day 21, 42 and 63 after 
kidney.  
Plasma collection 
Blood was collected in citrate Vacutainer® tubes (BD biosciences), and centrifuged at 
1500 rpm for 10 min at 20°C. Plasma was stored in aliquots at -20°C until use. 
 
Purification of IgG 
IgG were isolated from serum by affinity-chromatography on protein G-Sepharose 
(Amersham Pharmacia Biotech). In brief, IgG was incubated with protein G-Sepharose 
overnight at 4°C, eluted using 0.2M glycine-HCl pH 2.8, dialyzed against PBS-0.02% 
NaN3 overnight at 4°C, and concentrated using Amicon (Millipore). A therapeutic 
preparation of pooled normal human IgG (intravenous Ig (IVIg); Sandoglobulin®) was 
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used as a source of control IgG. Size-exclusion chromatography of patients’ IgG and 
IVIg was performed on a Superose-12 column (GE Healthcare Europe) equilibrated with 
urea-containing buffer (50 mM Tris pH 7.7, 8 M urea and 0.02% NaN3), at a flow rate of 
0.5 ml/min to exclude potentially contaminating proteases. IgG-containing fractions were 
then pooled and dialyzed against PBS-0.02% NaN3 for 2 days with four changes in 
buffer at 4°C, followed by dialysis against catalytic buffer containing 5 mM CaCl2 (pH 
7.7) for 1 days with two changes in buffer at 4°C. The purity of IgG preparations was 
confirmed by SDS-PAGE and immunoblotting under non-reducing conditions. IgG was 
quantified by Bradford assay. 
IgG-mediated hydrolysis of PFR-MCA 
IgG (66.67 nM) were mixed with 100 µM PFR-MCA (Peptide Institute, Inc.) in 40 µl of 
catalytic buffer containing 5 mM CaCl2 (pH 7.7) in white 96-well U-bottom plates 
(Thermo Scientific) and incubated in the dark for 24 h at 37°C. Hydrolysis of the PFR-
MCA substrate was determined by the fluorescence of the leaving group 
(aminomethylcoumarin; λem 465 nm, λex 360 nm) using a spectrofluorometer (GENios; 
Tecan Trading). Fluorescence values were compared with a standard curve of free MCA 
and the corresponding quantities of released MCA were computed. At each time point, 
background release of MCA, measured in wells containing the substrate alone, was 
subtracted from the value observed in the presence of the Abs. Data are expressed as the 
quantity of released MCA computed at time 0 subtracted from the quantity of released 
MCA computed at a given time point per amount of time per amount of IgG.  
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Statistics 
The statistical comparisons of groups of patients treated with IVIg and of patients not 
treated with IVIg were performed using the non parametric Mann-Whitney test, with 
two-tailed p values.  
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Results 
Circulating IgG from renal-transplanted patients hydrolyze PFR-MCA  
Plasma was collected from 100 consecutive renal-transplanted patients 3, 12 and 24 
months post-transplant between February 2008 to September 2011. Fifty-nine pre-
transplant plasma samples were retrieved retrospectively. Overall, 27 patients were lost 
during the 24 months of the study period. The cohort included as many men as women, 
with a mean age of 48.3±1.5 years (mean±SEM; range: 21 to 83). Causes for end-stage 
renal dysfunction included diabetes (4% of the patients), vasculopathy (8%), 
glomerulopathy (22%), interstitial nephropathy (15%), uropathy (25%) or were not 
known (26%), in agreement with other cohorts (30). Fifteen and 2 patients had had one or 
two previous transplants, respectively. A large majority of the patients were under 
classical tri-therapy using Tacrolimus, Mycophenolate mofetil and steroids. Fifty-three 
patients received Basilixumab as adjuvant therapy (including 9 who also received IVIg) 
and 28 patients received anti-thymocyte globulins (including 16 with IVIg) and 18 
patients did not receive any adjunct therapy. Ten patients received Rituximab alone (1 
case), with Basiliximab (1 case), with anti-thymocyte globulins (7 cases) or with both (1 
case).  
IgG was purified and tested for hydrolysis of the peptide PFR-MCA, a surrogate substrate 
for catalytic antibodies with serine protease-like activity (16). The absence of 
contamination of the IgG samples by adventitious proteases was ensured by the use of a 
double-step purification procedure that involves a step of purification based on affinity 
and a step of purification based on protein size under denaturing conditions. Incubation of 
patients’ IgG with PFR-MCA resulted in hydrolysis of the peptide and release of the 
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fluorescent MCA moiety. The released fluorescence allowed for the calculation of rates 
of hydrolysis. Hydrolysis of PFR-MCA was dose- and time-dependent (data not shown). 
Pooled IgG from healthy individuals demonstrated a marginal hydrolysis of PFR-MCA 
with an activity of 0.65±0.03 fmol/min per pmol (mean±SEM for 29 repeats). 
Irrespective of the time-point considered, IgG from renal-transplanted patients 
demonstrated significantly higher hydrolysis rates of PFR-MCA than pooled IgG from 
healthy individuals (Figure 1). The levels of PFR-MCA hydrolyzing IgG were extremely 
heterogeneous prior to transplantation, with a mean activity of 6.6±0.9 fmol/min/pmol 
(mean±SEM; coefficient of variation: 1.04, Figure 1). They decreased during the first 
three months that followed renal transplant to reach 2.4±0.2 fmol/min/pmol, and 
increased gradually during the 21 following months (3.2±0.3 and 5.1±0.6 fmol/min/pmol 
at 12 and 24 months post-transplant, respectively).  
There was no significant difference in the levels of PFR-MCA-hydrolyzing IgG at any 
time point with respect to the sex, the age, the transplantation rank, the cause for end-
stage renal failure, the time of dialysis prior to transplant, and the use of Basiliximab, 
anti-thymocyte globulins or Rituximab (data not shown and Table 1).  
 
Treatment of patients with IVIg at the time of transplant is associated with a 
marked reduction of PFR-MCA hydrolyzing IgG 3 months post-transplant 
Twenty-four patients (11 men and 13 women) had been treated with IVIg at the time of 
renal transplant. Treatment consisted in 4 cycles of administration of IVIg from the day 
of renal transplant and every three weeks thereafter. There was no difference between 
IVIg-treated patients and the remaining patients in terms of age, male to female sex ratio, 
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dialysis time prior to transplant and HLA mismatch score (Table 1). There was also no 
statistical difference in the distribution of the reasons for end-stage renal failure, although 
patients with uropathy tended to be more prevalent among IVIg-tretad patients. In 
contrast, and as expected, 47.8 % of the IVIg-treated patients had been transplanted 
previously as compared to 7.1% in the group of patients not treated with IVIg 
(P<0.0001). Likewise, 81.8% of the IVIg-treated patients had anti-HLA1 and anti-HLA2 
antibodies, as compared to 48.2% for the remaining patients. Fifteen of the IVIg-treated 
patients received anti-thymocyte globulins and 8 received Basiliximab (one additional 
patient received both). There was no statistical difference in treatment protocols between 
IVIg-treated patients and patients not treated with IVIg (Table 1).  
Patients treated and patients not treated with IVIg demonstrated similar rates of IgG-
mediated PFR-MCA hydrolysis prior to renal transplant (6.1±1.0 vs 6.8±1.2 
fmol/min/pmol, respectively, mean±SEM, Figure 1A). In contrast, the two groups of 
patients presented with statistically different rates of PFR-MCA hydrolysis by patients’ 
IgG 3 months post-transplant: 1.5±0.3 fmol/min/pmol and 2.7±0.2 fmol/min/pmol for 
IVIg-treated and non-treated patients (P=0.004, using the two-tailed Mann-Whitney test). 
While both groups of patients experienced a decrease in catalytic activity during the first 
3 months post-transplant, the decrease was more marked among IVIg-treated patients 
than in patients who did not receive IVIg: 4.0 vs 2.5-folds reduction, respectively. Levels 
of catalytic IgG were not different between the two groups of patients 12 months (3.5±0.6 
vs 3.0±0.3 fmol/min/pmol, respectively) and 24 months (5.4±1.1 vs 5.0±0.7 
fmol/min/pmol, respectively) post-transplant. Except in the case of the use of IVIg, there 
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was no difference in the levels of catalytic IgG according to the type of adjuvant 
immunotherapy (data not shown).  
 
Levels of PFR-MCA-hydrolyzing IgG are not associated with the presence of anti-
HLA antibodies 
Because IVIg are generally administered to patients with high levels of anti-HLA 
antibodies in order to desensitize the patients (31), we investigated a possible bias 
between patients treated or not with IVIg with respect to the levels of PFR-MCA-
hydrolyzing IgG. Patients were categorized based on the presence of either anti-HLA1 or 
anti-HLA2 antibodies, of both anti-HLA1 and anti-HLA2 antibodies or on the absence of 
anti-HLA antibodies. As is depicted in Figure 2, levels of PFR-MCA-hydrolyzing IgG 
were identical, irrespective of the presence or absence of anti-HLA1 and/or anti-HLA2 
antibodies. This was true both prior to renal transplant and 3 months after transplant.  
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Discussion 
In the present work, we investigated in an intermediate analysis the changes with time in 
levels of catalytic antibodies in patients receiving kidney transplants. To this end, we 
studied a large cohort of 100 consecutive patients followed in the same transplantation 
center. Patients included in the study were thus homogeneous in terms of clinical follow-
up, treatment for prevention of graft rejection and origin of the drugs used in the 
treatment protocols. At the present time, data on CAN have not been obtained for all 
patients; CAN and rejection are thus not end-points of the present intermediate analysis.   
The pathophysiological role of catalytic antibodies in the human is yet unclear. We and 
others had initially reported the presence of naturally occurring catalytic antibodies in 
human immunological and inflammatory diseases (8, 10, 11, 32), leading to the 
hypothesis that these antibodies may be deleterious. However, the description of catalytic 
IgM, IgG and IgA under physiological conditions (13-15), the finding that levels of PFR-
MCA hydrolyzing IgG were elevated in patients surviving from septic shock (20), and 
the discovery in some patients with acquired hemophilia, a disease characterized by the 
presence of neutralizing anti-factor VIII autoantibodies, of factor IX-activating IgG (33), 
encouraged to revisit the initial hypothesis. Notably, we demonstrated in renal-
transplanted patients that patients who did not develop CAN two years after 
transplantation had more elevated levels of PFR-MCA-hydrolyzing IgG (21). Our data 
highlighted the predictive value of measuring levels of catalytic IgG on the occurrence of 
CAN. The present work shows that patients with renal failure exhibit higher level of 
catalytic IgG than pooled normal IgG from healthy individuals (pre-transplantation data, 
Figure 1). It also reveals an extreme heterogeneity among patients in terms of level of 
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PFR-MCA-hydrolyzing IgG. The heterogeneity appears more as a general feature of 
pathological states than resulting from any particular cause for end-stage renal failure.  
Our data document a reduction in the levels of catalytic antibodies after kidney 
transplant, followed by a progressive and slow restoration of the repertoire of catalytic 
IgG over time. Fluctuations in levels of catalytic IgG have rarely been studied earlier. 
Previous reports concentrated only on small numbers of patients in a retrospective 
manner, with low number of time points studied using serum or plasma that had not been 
systematically collected at pre-defined time points (28, 29). In contrast, one of the 
strength of the present study is the collection of plasma from a large number of 
consecutive patients in a prospective manner, and at different pre-determined time points: 
3, 12 and 24 months following kidney transplant. Only the pre-transplant plasma samples 
were retrieved retrospectively. Of note, PFR-MCA-hydrolyzing IgG were tested at a 
constant IgG concentration for all the patients’ samples (i.e., 67 nM). Hence, the changes 
in levels of catalytic IgG represent changes of the amount of catalytic IgG within the total 
IgG pool, and are thus independent from possible fluctuations of total IgG levels. 
Reasons for a drop in the levels of PFR-MCA-hydrolyzing IgG are probably linked to the 
immuno-suppressive treatment of the patients. Indeed, all patients received classical 
treatment using different combinations of steroids, cyclosporin, tacrolimus and/or 
mycophenolate mofetil. Furthermore, about 90% of the patients received adjunct 
immuno-suppressive therapy under the form of Basiliximab, anti-lymphocyte rabbit 
serum, Rituximab, plasmapheresis and/or IVIg.  
In our cohort, 24 of 100 patients received IVIg therapy at the time of kidney transplant. 
Generally, IVIg is being used, either alone or in conjunction with plasmapheresis and/or 
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Rituximab, in patients undergoing transplantation across HLA barriers (24, 25, 31, 34-
37). Thus, pre-conditioning patients “sensitized” to HLA with high-dose IVIg presents 
with short-term advantages, notably increasing transplantation rates, reducing the waiting 
time to transplantation and reducing acute humoral graft rejection. Accordingly, IVIg-
treated patients in our cohort had significantly higher occurrence of previous graft and 
had a greater prevalence of anti-HLA1 and/or anti-HLA2 antibodies (Table 1). We 
observe here that the drop in the levels of PFR-MCA-hydrolyzing IgG 3 months 
following kidney transplant was statistically significantly more pronounced for patients 
treated with IVIg, as compared to patients who did not receive IVIg as adjunctive 
therapy. Mean levels of catalytic IgG in IVIg-treated patients were 55% that of the other 
patients. Jordan et al had previously documented a reduction of “panel reactive antibody” 
values following IVIg infusion to renal transplanted patients (24, 31). Although 
statistically significant in the studies by Jordan et al, the decrease in donor-specific 
antibodies among IVIg-treated patients was not as marked and consistent as the one we 
observe in the case of catalytic IgG.  
Two explanations may account for the further reduction in levels of catalytic IgG 3 
months post-transplant in IVIg-treated patients. The dose and timing of IVIg 
administration to the patients are compatible with a direct dilution effect of patients’ IgG 
by the infused immunoglobulins. Indeed, considering that the patients received 2 g IVIg 
per kg body weight, that the average patient weight was 68 kg, that the blood volume 
may be estimated to approximately 5 liters, that the half-life of IVIg is 3 weeks (not 
considering the fact that some patients present with large proteinuria), and that the last 
administration of IVIg occurred 3 weeks  prior to the 3-month sampling, one may broadly 
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estimate a 2 to 3-fold dilution of the endogenous IgG by IVIg, which incidentally 
corresponds to the observed further 2-fold reduction in levels of catalytic IgG. 
Alternatively, IVIg are endowed with immuno-regulatory effects on several innate and 
adaptive immune cells. In particular, IVIg have been shown in vitro to impact on B-cell 
proliferation, survival and differentiation, as well as modulate immunoglobulin secretion 
(38-44). Investigating putative changes in the levels of catalytic IgM might be a strategy 
to delineate between the two possibilities.  
Our earlier work performed in a retrospective study that implicated 20 patients with 
kidney transplant, described that higher levels of catalytic IgG, both 3 and 12 months 
post-transplantation, were associated with a reduced incidence of chronic allograft 
nephropathy. The receiver operating characteristic curve derived from the levels of IgG-
mediated PFR-MCA hydrolysis indicated that the hydrolytic activity of circulating IgG 
was a potential predictive marker for CAN, superior to the widely used biological 
parameters such as glomerular filtration rate (45) or proteinuria (46). The patients in the 
latter study had received similar immunosuppressive regimen as the patients included in 
the present cohort. Taken together, our data suggest that the reduction, associated with 
IVIg administration, in the levels of catalytic IgG in the patients 3 months post-transplant 
may jeopardize the use of catalytic antibodies as prognosis markers for chronic allograft 
nephropathy.  
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Table 1. Characteristics of the study population 
 IVIg-treated No IVIg P value* 
Number of patients 24 76  
Sex - M/F 11/13 39/37  
Age - years† 46.9±3.1 (21-73) 48.8±1.7 (22-83) ns 
Weight – kg 68.0±2.9 (51-109) 66.4±1.7 (39-114) ns 
ND 0 1  
Previous transplant - % 47.8 7.1 <0.0001 
ND 1 6  
Cause of Nephropathy – Nb (%)#    
Diabetes 1 (4.2) 3 (4.0) ns 
Vascular 0 (0) 8 (10.5) ns 
Glomerulopathy 3 (12.5) 19 (25.0) ns 
Uropathy 10 (41.7) 15 (19.7) 0.056 
Interstitial nephropathy 2 (8.3) 13 (17.1) ns 
Unknown 8 (33.3) 18 (23.7) ns 
Dialysis time prior to transplant - 
m† 
65.2±9.4 (7-148) 50.2±5.5 (0-214) 0.091 
ND 1 13  
HLA mismatch - score : 1 to 6 
(range) 
4 (0-5) 3 (0-6) ns 
ND 0 2  
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Anti-HLA1 and anti-HLA2 Abs - 
% 
81.8 48.2 0.006 
ND 13 20  
Adjuvant immunotherapy - Nb‡     
Anti-thymocyte globulins 16 12  
Basiliximab 9 45  
Rituximab 7 3  
Plasmapheresis 2 3  
None 11  
* Two-tailed Mann-Whitney test; † Mean±SEM (range); ND : Not Documented; # 
Fisher’s exact test 
‡ All patients received Steroids, Cyclosporin, Tacrolimus and/or Mycophenolate Mofetil; 
one patient received both Basiliximab and anti-thymocyte globulins 
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Figure Legends 
 
Figure 1. Treatment of renal transplant patients with IVIg is associated with a transient 
decrease in levels of PFR-MCA hydrolyzing IgG. IgG was purified from the plasma of 
patients who received IVIg therapy prior to transplantation (full circles) and from patients 
who did not received IVIg (empty circles). Plasma had been collected prior to renal 
transplant (D0) and 3 (M3), 12 (M12) and 24 (M24) months after renal transplant. IgG 
(66.67nM) was incubated with PFR-MCA (100 µM), a peptide chromogenic substrate, 
for 24 hr at 37°C. The amount of hydrolysis was quantified by measuring the 
fluorescence of the leaving MCA moiety, and is expressed in femtomoles of substrate 
hydrolyzed per minute per picomoles of IgG.  IVIg was used as a control source of 
normal human IgG. Panel A depicts the raw results as scatter dot plots. Panel B depicts 
the evolution of the mean ± SEM levels of PFR-MCA-hydrolyzing IgG in the two groups 
of patients with time (*: P=0.004). The dotted line represents the hydrolysis of PFR-
MCA by IVIg (mean of 29 measurements; Coefficient of variation: 0.29).  
 
Figure 2. Levels of IgG-mediated hydrolysis of PFR-MCA among patients with anti-
HLA antibodies. Patients were divided into three groups based on the presence of anti-
HLA antibodies: no anti-HLA antibodies (circles); presence of either anti-HLA1 or anti-
HLA2 antibodies (squares), and presence of both anti-HLA1 and anti-HLA2 antibodies 
(triangles). The graphs depict the rates of hydrolysis of PFR-MCA by IgG from each 
groups of patients purified from plasma collected prior to renal transplant (D0) or 3 
months after transplant (M3).  
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Figure 1. 
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Figure 2. 	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Article 4- Résumé en Français 
 
Titre: Importance de l’isotype des immunoglobulines dans la sensibilité à 
l’induction de polyréactivité par exposition à l’hème 
 
Les immunoglobulines circulantes comprennent des anticorps dotés d’une spécificité 
unique envers leur antigène cible, appelés anticorps monoréactifs, et des anticorps 
capables de se lier à plusieurs structures antigéniques différentes et appelés anticorps 
polyréactifs. Une fraction des anticorps monoréactifs acquière des propriétés 
polyréactives après exposition in vitro à des agents redox tels que les ions ferreux, 
l’hème ou les dérivés réactifs de l’oxygène. L’injection d’IgG normales à un organisme 
inflammé induit la génération d’anticorps polyréactifs. Des études antérieures indiquent 
que, contrairement aux IgG polyclonales, les IgM polyclonales ne sont pas sensibles aux 
ions ferreux, alors que les deux préparations polyclonales sont sensibles à l’hème. Dans 
l’étude présente, nous avons étudié l’importance de la nature de la partie constante de la 
chaîne lourde des immunoglobulines dans la sensibilité à l’induction de polyréactivité. 
Nous avons isolé l’IgM circulante d’un patient avec lymphome B de la zone marginale 
de la rate. En parallèle, nous avons cloné les gènes codant les régions variables de l’IgM 
circulante sur un structure d’IgG. Les réactivités de l’IgM purifiée et de l’IgG 
recombinante ont été comparées avant et après exposition à l’hème par ELISA, dot blot, 
Western blot et ‘surface plasmon resonance’. Les deux anticorps étaient également 
sensibles à l’induction de polyréactivité par l’hème. L’affinité à l’équilibre de l’IgM 
« induite » était 10 fois plus élevée que celle de l’IgG « induite ». Ces résultats 
contribuent à notre compréhension des mécanismes moléculaires en jeu dans l’induction 
de polyréactivité par les agents redox.  
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Title: Relevance of immunoglobulin isotype for sensitivity to polyreactivity 
induction upon exposure to heme 
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Running title: Effect of Ig isotype on sensitivity to polyreactivity induction 
 
Capsule: 
1. Background: A fraction of circulating immunoglobulins acquires polyreactive 
behavior following exposure to redox agents, but the influence of the nature of the 
constant region on this effect remains ill-defined.  
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2. Results: The purified circulating IgM from a patient with splenic marginal zone B-cell 
lymphoma and the corresponding cloned recombinant IgG1 both demonstrated sensitivity 
to exposure to heme and acquire polyreactive behaviors.  
3. Conclusion: The nature of the Fc portion does not dictate sensitivity to induction of 
antibody polyreactivity upon exposure to heme.  
4. Significance: While the physiopathological relevance of the induction of polyreactive 
antibodies under oxidizing conditions remains unclear, our results suggest that all 
circulating antibodies that penetrate a pro-oxidative microenvironment may undergo 
alteration of their antigen-binding specificity.  
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Summary 
Circulating immunoglobulins encompass antibodies with single specificity for their 
cognate antigens, referred to as monoreactive antibodies, and antibodies with polyspecific 
binding behavior that are able to bind several structurally unrelated molecular targets. We 
and others have demonstrated that a fraction of the circulating monoreactive antibodies 
acquire polyreactive behavior following in vitro exposure to redox agents such as ferrous 
ions, heme or reactive oxygen species. Likewise, introduction of normal IgG into 
inflamed organisms results in the generation of polyreactive antibodies. Previous studies 
have indicated that, in contrast to normal polyclonal IgG, polyclonal IgM are not 
sensitive to ferrous ions but exhibit sensitivity to heme. In this work, we addressed the 
relevance of the nature of the constant part of the heavy chain of immunoglobulins for the 
sensitivity to induction of polyreactivity. We isolated the circulating IgM from a patient 
with splenic marginal zone B-cell lymphoma. In parallel, we cloned the V region genes 
encoding the circulating IgM into an IgG scaffold. The reactivity of the purified IgM and 
of the recombinant IgG was compared before and after in vitro exposure to heme by 
ELISA, dot blot, Western blot and surface plasmon resonance. Both antibodies 
demonstrated equal sensitivity to heme-induced polyreactivity. The equilibrium affinity 
of the “induced” IgM was 10 folds that of the “induced” IgG. The present results 
contribute to our understanding of the molecular mechanisms at play at the time of redox 
agent-induced antibody polyreactivity.  
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Introduction 
Repertoires of immunoglobulins in healthy individuals represent an enormous diversity 
of antigen-binding specificities. This allows the immune system to generate high-affinity 
receptors specific for any potential antigenic structure. Based on their antigen-binding 
characteristics, immunoglobulins in a complete immune repertoire may be divided in two 
broad categories – monoreactive antibodies and polyreactive antibodies. 
A polyreactive antibody is an antibody molecule that is capable of specific binding to 
several structurally unrelated molecular targets; these include proteins, nucleic acids, 
carbohydrates, phospholipids, peptides and haptens (1-3). Such antibodies represent a 
significant fraction (about 20 %) of healthy immune immunoglobulin repertoires. The 
genes encoding the variable regions of polyreactive antibodies are thought to be in germ-
line configuration or to have a low number of somatic mutations (1,4). However, recent 
studies revealed that, in healthy individuals, a significant number of memory B cells 
express polyreactive B-cell receptors that have undergone affinity maturation and 
accumulate a high number of somatic mutations in the genes encoding their variable 
regions (5,6). These studies actually indicate that acquisition of polyreactivity by some 
immunoglobulins is the very result of the somatic hypermutation process. Polyreactive 
antibodies belong mostly to the IgM isotype, but polyreactive antibodies from other 
immunoglobulin isotypes (IgG, IgA and IgE) are also present (1,2). The interaction of 
polyreactive antibodies with multiple antigens is usually characterized by lower binding 
affinities (KD values of 10-4-10-7 M) as compared to the interaction of monoreactive 
antibodies with their cognate antigen (KD values of 10-8-10-11 M). The lower antigen-
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binding affinity is compensated by enhanced functional affinity (avidity) in the case of 
decavalent IgM antibodies.  
The molecular mechanisms underlying polyreactive antigen-binding are not completely 
understood. It was demonstrated that the binding of antigen by germ-line gene-encoded 
antibodies is accompanied by significant structural changes in their antigen-binding sites, 
especially in the CDR3 loop of the heavy chain (7-10). These antibodies demonstrated 
also high antigen-binding polyreactivity. Thus, the presence of a pliable antigen-binding 
site that can adapt to the molecular features of different antigens appears as the main trait 
of polyreactivity (11,12). However, there are case of polyreactive antigen-binding that are 
not accompanied by significant structural changes in the antibody paratope (13). 
Different functions of polyreactive antibodies or polyreactive B-cell receptors have been 
proposed. The most important one could be a further diversification of the immune 
repertoires (11). Polyreactive antibodies can also participate in immune defense by 
establishing an innate-like first line of defense against pathogens (14,15). Interestingly, 
the concentration of such antibodies was found to increase in cases of some viral or 
bacterial infections (16,17). Moreover, some of the broadly neutralizing HIV antibodies 
show antigen-binding polyreactivity (18,19). The promiscuous antigen binding of natural 
IgM antibodies may contribute to the clearance of senescent or apoptotic cells or 
damaged macromolecules (20-22). Polyreactive antibodies were also proposed to exert 
immunomodulatory effects and, at the level of B cells, to participate in the maintenance 
of immune tolerance (1).  
The above described polyreactive antibodies express their polyreactivity constantly from 
the time of their entry in circulation to the time of their catabolism. In addition to these 
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natural polyreactive antibodies, the normal immune repertoire contains a fraction of 
antibodies that can acquire antigen-binding polyreactivity post-translationally. Indeed, the 
temporary exposure of some monoreactive antibodies to conditions that can alter protein 
structure such as low pH, chaotropic agents or high-salt concentrations, results in 
acquisition of polyreactive antigen-binding characteristics (23-27). Usually, 
immunoglobulins are exposed to such conditions during their purification from plasma or 
cell culture supernatants. Thus, the phenomenon of induced polyreactivity could at least 
in part explain the different binding behavior that is observed in the immunoreactivity of 
antibodies when evaluated before and after purification from serum (28,29). 
In addition to protein destabilizing agents that are used in laboratory practice for 
immunoglobulin purification, the induction of cryptic immunoglobulin polyreactivity 
occurs after exposure to agents that are present in vivo and can be released in large 
quantities at sites of inflammation and/or tissue damage. Indeed, in vitro and in vivo 
exposure of human immunoglobulins to reactive oxygen species, heme, ferrous ions or 
other pro-oxidative agents and conditions, have been shown to result in acquisition of 
polyreactive antigen-binding potential of antibodies (30-36). Cryptic polyreactive 
antibodies were detected in evolutionary distinct species such as human, mouse and 
chicken (31,33,37). Importantly, only a fraction of the antibodies from the normal Ig 
repertoire is sensitive to redox agents and the acquisition of polyreactivity occurs at 
concentrations of redox agents that are not influencing the overall Ig molecular integrity 
(38). Despite the potential biological importance of inducible antibody polyreactivity for 
the regulation of immune responses or as a first line of defense against pathogens (3), its 
molecular mechanism is not well understood. Thus, the molecular features that 
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distinguish monoreactive antibodies with cryptic polyreactivity from monoreactive 
antibodies or from naturally polyreactive antibodies are ill-defined. Likewise, the site on 
the immunoglobulin molecule that is affected by the redox agents, or whether the effect 
directly targets the antigen-binding site or residues outside the paratope remains to be 
elucidated.  
Antibodies with different immunoglobulin isotypes are susceptible to induction of 
polyreactivity by redox agents. Thus, antibodies of the IgG, IgM and IgA isotypes may 
acquire antigen-binding polyreactivity after exposure to redox agents (32,33,39). 
However, these studies utilized antibodies from different isotypes that also differ in their 
antigen-binding specificity. Hence, the role of the constant immunoglobulin region on the 
susceptibility to induction of polyreactivity of antibodies that have identical variable 
regions is also not known. Recent studies have revealed the important role of the constant 
portion of immunoglobulin molecules for determining the affinity, specificity and 
functional activity of variable-region identical antibodies (40,41). In the present study, we 
explored the influence of the nature of the constant region of an antibody for induction of 
polyreactive binding. We generated a human monoclonal IgG antibody with identical 
variable region as a circulating monoclonal IgM isolated from a patient with splenic 
marginal zone lymphoma. We then compared the sensitivity to polyreactivity induction 
of the recombinant monoclonal IgG and purified monoclonal IgM, as well as the 
mechanisms underlying polyreactive antigen binding. The results contribute to our 
understanding of the molecular mechanisms of induced polyreactivity of antibodies, of 
the mechanism of functional pairing of variable and constant portions in 
immunoglobulins, and of the role of antibody valency in polyreactive antigen binding.  
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Material and methods 
Sequencing of variable region gene sequences and gene analysis. 
Bone marrow was obtained from a 57 year-old female patient (patient 47) with a 
circulating IgM diagnosed to have splenic marginal zone B-cell lymphoma, and after 
informed consent. Mononuclear cells were isolated by fractionation on Ficoll-Hypaque 
gradients (PAA, Velizy-Villacoublay, France) as described by the supplier. After 
centrifugation, the mononuclear cells ring was recovered and the cells were washed in 
PBS (Life technologies, Saint Aubin, France) and initially stored in liquid nitrogen with 
DMSO. For this study, cells were thawed rapidly and washed in PBS. High-molecular-
weight DNA was extracted from mononuclear cells using the QIAamp DNA Mini Kit 
(QIAGEN, Courtaboeuf, France). 
The rearranged variable genes encoding the heavy chain (VH) and encoding the light 
chain (VL) were amplified from genomic DNA (1 µg) using a mixture of forward primers 
annealing to the peptide leader region of the VH and VL genes, in combination with a 
single (for VH) or mixture (for VL) of primers specific for the joining genes as previously 
described (42-44). The PCR mixture contained 1x Taq buffer, 200 µM of each dNTP, 1.5 
mM of MgCl2, 10%, 1 U of Taq polymerase (Ampli-Taq Gold, Life Technologies), and 
0.2 µM of each primer in a final volume of 50 µl. PCR amplification consisted of an 
initial denaturation step at 94° C for 10 minutes, followed by 35 cycles at 94° C for 30 
second, 64° C for 1 minute, and 72° C for 1 minutes, with a final extension step at 72° C 
for 10 minutes. All PCR reactions were performed using appropriate positive (clonal and 
polyclonal) and negative controls. PCR products were subsequently analysed either by 
GeneScan profiling on ABI 3730 DNA Analyzer (Applied Biosystems, California, USA) 
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for VH rearrangements (using a fluorochrome-labeled IGHJ primer), or by standard 
polyacrylamide gel electrophoresis (for VL rearrangements) according to the Biomed 2 
protocols (44). 
Monoclonal bands corresponding to VH and VL tumor gene rearrangements were excised 
from 1.5% low-melting agarose gels and the PCR products were purified from the gel 
with the QIAEX II kit (Qiagen). Thereafter, they were sequenced directly on both strands 
using the ABI 3730 DNA Analyzer (Applied Biosystems). Sequence data analysis, 
including identification of V, D and J genes as well as mutational status assessment, was 
done by comparing the tumor’s VH and VL gene sequences to those of the corresponding 
human germline sequences  presenting the highest homology using the IMGT® databases 
and the IMGT/V-QUEST tool (http://www.imgt.org). 
 
Purification of the circulating IgM 
The serum from patient 47 was subjected to affinity-chromatography on anti-human IgM 
agarose antibodies (Sigma-Aldrich, Lyon, France). The purity of the purified IgM was 
confirmed by SDS-PAGE and Western blotting.  
 
Cloning, transfection and expression of variable region gene sequences. 
The sequences of the variable region genes obtained from the bone marrow aspirates 
were re-synthesized commercially (Geneart AG, Regensburg, Germany). The restriction 
sites EcoR1 and Nhe1 were introduced in the sequence encoding the heavy chain variable 
gene (VH) and restriction sites Age1 and Bsi W1 in the sequence of the light chain 
variable gene (VL). The VH sequence was cloned into the pFUSE expression vector 
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(Invivogen, Toulouse, France) that possesses a sequence encoding the constant region of 
the human IgG1 heavy chain. The VL sequence was cloned into the pFUSE2 expression 
vector (Invivogen) that contains the sequence encoding the constant region of the human 
kappa light chain.  
For expression of the recombinant antibody in eukaryotic system, human embryonic 
kidney cells (HEK-293) were used. Cells were first grown in HYPER flask (Corning, 
New York, USA) in Dulbecco’s modified Eagle’s medium (DMEM) containing 10% 
FBS and non-essential amino acids (Life Technologies). The cloned expression vectors 
were mixed (350 µg of each) in 35 ml of 150 mM NaCl2 and further treated at a ratio of 
1:3with polyethleneimine (2.1 mg). The reaction mixture was let to stand for 10 min, was 
mixed in 500 ml of serum-free DMEM, containing non-essential amino acids and 1% 
nutridoma (Roche, Boulogne-Billancourt, France), and was added to the cells. Four days 
post-transfection, culture supernatant was collected and the recombinant IgG (rIgG47) 
were isolated by affinity chromatography on protein G sepharose (Amersham 
Biosciences, GE Healthcare Lifesciences, Velizy-Villacoublay, France). The purity of the 
IgG preparation was assessed on a 10% SDS-PAGE under reducing and non-reducing 
conditions.  
 
Immunoreactivities of antibodies by ELISA. 
Ninety-six well plates (Corning) were coated with human factor IX (10 µg/ml, Benefix; 
Baxter, Vienna, Austria), myelin basic protein (10 µg/ml, Sigma-Aldrich), human factor 
H (5 µg/ml, Complement Technologies Inc., Tyler, Texas, USA) and Apo-hemoglobin 
(10 µg/ml, Sigma-Aldrich). After 2 hr incubation at room temperature, the wells were 
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blocked with 0.2% PBS-Tween 20 (PBST). rIgG47 (100 µg/ml) was treated with hematin 
(0 to 16 µM) for 30 min on ice, and was diluted to a final concentration of 10 µg/ml prior 
to being incubated with antigen-coated plates for 2 hr at room temperature. Plates were 
washed and incubated with a peroxidase-conjugated goat anti-human IgG (Southern 
Biotech, Birmingham, Alabama, USA) for 1 hr at room temperature. Bound IgG were 
revealed by measuring the absorbance at 492 nm after addition of peroxidase substrate, 
o-Phenylenediamine dihydrochloride (Sigma-Aldrich).  
 
Immunoreactivities of antibodies by Western blots. 
Immunoreactivities on cross blots were investigated using cell lysates, including human 
endothelial cell (HUVEC), human liver and on recombinant human factor IX (FIX). Cell 
lysates (100 µg/ml) and recombinant antigen (10 µg/ml) were directly adsorbed on 
nitrocellulose membranes in individual slots of miniblotters 28 SL (Immunetics, 
Cambridge, MA, USA). After 1 hour incubation, the membranes were blocked with TBS-
Tween 0.1%.  
In the case of preparative Western blots, HUVEC lysates (100 µg) were 
electrophoretically separated on 10% preparative SDS-PAGE, and then transferred on 
nitrocellulose membranes. Membranes were blocked with TBS-Tween 0.1% overnight. 
The purified IgM and recombinant IgG from patient 47 (IgM47 and rIgG47) at 10 µg/ml 
were treated with varying concentrations of hematin (0 to 16 µM) for 30 min on ice. The 
membranes were then introduced perpendicularly in the miniblotters and the antibodies 
were incubated in individual slots. After 1 hr at room temperature, the blots were washed 
for 1 hr with TBS-Tween 0.1%. Fixed IgM and IgG were revealed using alkaline 
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phosphatase conjugated anti-human IgM or anti-human IgG antibodies (Southern 
Biotech, Birmingham, Alabama, USA) and the BCIP-NBT substrate (KPL Laboratories, 
Gaithersburg, Maryland, USA). 
 
Binding of hematin to rIgG47 and IgM47 by absorbance spectroscopy.  
The binding of hematin to IgM47 and rIgG47 was studied by UV-visible spectroscopy. 
Hematin was added at varying concentrations (0 to 6.4 µM) to IgM47 or rIgG47 
(100 µg/ml in PBS, pH 7.4) and incubated in the dark for 5 min. Absorption spectra were 
measured at a wavelength range of 350-700 nm, with a scanning speed of 1500 nm/min. 
The absorption spectra of hematin alone were obtained at similar concentrations. The 
binding curves of hematin interaction with IgM47 and rIgG47 were obtained by 
subtracting the absorbance maxima in the Soret region of hemin in the presence of Ig by 
the absorbance maxima of hemin diluted in PBS alone (Aheme-IgG- Aheme) at 390 nm.  
Surface Plasmon resonance analysis.  
The kinetics of the interaction of hematin-treated IgM47 or rIgG47 with different 
antigens was measured by surface Plasmon resonance on a BIAcore 2000 (Biacore AB, 
GE healthcare Life Sciences). Myelin basic protein, Factor IX and Factor H were coupled 
to research grade CM5 sensor chip (GE Healthcare Life Sciences), as per the 
manufacturers instructions. Density of adsorbed antigens were 2.6, 1.8 and 5.0 ng/mm2, 
respectively. IgM47 (111 µg/ml, 100 nM) and rIgG47 (100 µg/ml, 670 nM) were first 
treated with 8 µM of hematin in PBS for 5 min on ice. Hematin-treated rIgG47 and 
IgM47 were further diluted to 20 and 100 nM in HBS-EP buffer (10 mM HEPES, 
150 mM NaCl, 3 mM EDTA, 0.005% tween 20, pH 7.2) and injected in serial dilutions 
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on the immobilized antigens for 5 min at a flow rate of 10 µl/min at 25°C. The 
dissociation was then monitored for an additional 5 min. The surface of the chip was 
regenerated using 0.1 M glycine and 0.3% triton X-100, pH 12. The kinetic rate constants 
were calculated using the BIAevaluation version 4.1 software (Biacore).  
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Results. 
Sensitivity of a recombinant IgG from a patient with SMZL to heme. 
Patient 47 was characterized by a circulating IgM and by a monoclonal B-cell infiltrate in 
the bone marrow. DNA from the B-cell lymphoma was obtained by bone-marrow 
aspirate. The genes encoding the variable regions of the heavy (VH) and light (VL) 
chains of the monoclonal immunoglobulin were amplified and sequenced. VH and VL 
genes were then synthesized and cloned into human IgG1 and kappa expression vectors. 
The recombinant IgG (rIgG47) was produced in HEK293 cells and purified from 
supernatant by chromatography on protein G-Sepharose. We then investigated the 
reactivity of rIgG47 incubated alone or following exposure to hematin. rIgG47 
demonstrated a marginal baseline binding to a series of self-antigens including factor IX 
(FIX), myelin basic protein (MBP), factor H (FH) and apo-hemoglobin (Figure 1), as 
well as factor VIII and calreticulin (data not shown). The binding of rIgG47 incubated 
with varying amounts of hematin increased in a dose-dependent manner. Two-hundred 
percents increase binding to self-antigens were obtained for hemin concentrations as low 
as 0.5 to 1 nM, i.e., a 7 to 15 molar excess of heme over IgG. Saturation of binding was 
obtained for hematin concentrations comprised between 4 and 10 µM, depending on the 
antigen. At saturation, IgG binding increased by at least 4-fold as compared to native 
rIgG47.  
 
Sensitivity of rIgG47 and IgM47 to polyreactivity induction by heme.  
Because rIgG47 was found to be sensitive to heme treatment, we decided to compare the 
capacity of both rIgG47 and of the circulating IgM purified from the plasma of patient 47 
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(IgM47) to become polyreactive following exposure to hematin. rIgG47 and IgM47 were 
incubated alone or in the presence of increasing amounts of hematin. Ig reactivity was 
tested with antigen extracts from HUVEC and human liver tissue (Figure 2A). Pooled 
human IgG and IgM from healthy donors were used as positive controls. As indicated in 
ELISA, rIgG47 demonstrated marginal autoreactivity with both tissue extracts in the 
absence of exposure to hemin; IgG reactivity increased in a dose-dependent manner with 
increasing heme concentrations. Interestingly, while native IgM did not react with both 
sources of self-antigens, it started binding following exposure to 0.5 µM heme. The 
binding intensity of IgM reached saturation at 2 µM heme, while that of IgG reached 
saturation at 5 µM heme.  
We then compared the reactivity of rIgG47 and IgM47 with protein extracts of HUVEC 
separated in a preparative SDS-PAGE prior to transfer onto nitrocellulose membrane 
(Figure 2B). In both cases, there was a dose-dependent increase in the binding to HUVEC 
antigens with increasing heme concentrations.  
 
Binding of heme to rIgG47 and to IgM47.  
We applied steady-state absorbance spectroscopy in order to investigate the ability of 
heme to bind to rIgG47 and to IgM47. Steady state absorbance spectroscopy revealed 
changes in the UV-visible spectra of hemin upon incubation with Ig (Figure 3). The 
absorbance maxima in the Soret region increased when hemin was incubated in the 
presence of rIgG47 and IgM47, as compared to heme incubated alone. Changes in the 
low energy part of the spectrum (α and β regions of the spectrum: 500-600 nm) were also 
evidenced, suggesting a specific binding of the macrocyclic compound to the protein. The 
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absence of a significant shift in the Soret region of UV-visible spectra suggested that the 
binding of hemin to rIgG47 and IgM47 is not accompanied by the coordination of the 
central iron by amino-acid residues of the Ig molecules. Differential spectra analyses 
(insets) indicated that saturations of Ig with hemin were achieved above a 15-molar 
excess of hemin in the case of IgM47 and above 8 in that of rIgG47. This suggests the 
presence of approximately 10 binding sites for heme on both IgM47 and rIgG47. Fitting 
the data with a single binding site hyperbolic equation allowed calculation of the mean 
apparent affinity at equilibrium, which was equal to 2.5±0.2 nM in the case of IgM47, 
and 1.1±0.3 nM in that of rIgG47.  
 
Kinetic parameters of the binding of heme-exposed IgM47 and rIgG47 to self 
antigens.  
To obtain quantitative data about the influence of the Ig class on the polyreactive 
interactions of antibody 47, we used surface plasmon resonance-based real time 
interaction analyses. Different autoantigens were immobilized on sensor chips, including 
plasma-derived human factor H, human factor IX, bovine myelin basic protein and 
porcine tubulin. The real-time interaction profiles indicated that native IgG47 and IgM47 
tested at 100 and 20 nM, respectively, did not bind to the immobilized proteins (Figure 4 
and Supplement Figures S1, S2 and S3), thus supporting our data obtained by ELISA. 
Exposure of both Ab47 isotypes to heme resulted in considerable increase in the binding 
response (Figure 4 and Supplement Figure S1, S2 and S3). By applying global analyses 
to the interaction profiles, we evaluated the kinetic parameters of the interactions (See 
Table 1). The exposure of antibody 47 to heme resulted in acquisition of physiologically 
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relevant values of the binding affinity for different antigens. Thus, the determined values 
of equilibrium dissociation constant (KD) for binding to different antigens for heme-
exposed IgM47 and IgG47 ranged from 7.6 to 15.3 nM and 41.3 to 76.1 nM, 
respectively. The obtained values of the kinetic rate constants (Table 1) indicated that the 
relatively elevated values of binding affinity for the polyreactive Ab47 originate from 
high values of the association rate constant (Table 1), implying that the antibody-antigen 
complex is formed rapidly. The values of the association rate constant for the 
polyreactive IgM47 were marginally higher than that of the polyreactive IgG47 (Table 1). 
The values of dissociation rate constant for both IgG47 and IgM47 heme-exposed 
polyreactive antibodies were relatively high and in the same range, indicating a relatively 
poor stability of the complexes.  
Further, we investigated whether the induction of polyreactivity by heme affects the 
binding of IgG47 to protein G. The real time interaction profiles of native IgG47 and 
heme-exposed IgG47 showed that both forms of the antibody bind strongly to 
immobilized protein G (Figure 5). Calculated binding affinities indicate that the binding 
of heme to the IgG molecule and ensuing transition to polyreactive antigen-binding 
behavior does not influence the binding affinity to protein G. 
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Discussion 
In this work, we investigated the influence of the nature of the constant portion of 
antibodies in the sensitivity to induction of antibody polyreactivity by redox agents. To 
this end, we cloned the variable regions of the circulating IgM from a patient (patient 47) 
with a splenic marginal zone B-cell lymphoma after isolating DNA by bone morrow 
aspirate. The variable regions of the IgM were expressed on an human IgG1 scaffold. In 
parallel, we purified the IgM by affinity-chromatography from the serum of patient 47. 
We thus generated a recombinant antibody that has identical antigen-binding sites as the 
endogenous circulating IgM but different constant portions. The recombinant IgG and 
purified IgM forms of the antibody in their native states showed low binding activity to 
various autoantigens or to bacterial antigens. However, the exposure of the antibody to 
heme resulted in a dramatic increase in immunoreactivity. Antibody 47 acquired 
polyreactivity and started to recognize various self- and foreign antigens as evaluated by 
ELISA, immunoblot and Biacore binding analyses. The ability to acquire polyreactivity 
did not depend on the immunoglobulin isotype. The quantitative data obtained by kinetic 
analyses revealed that the polyreactive form of antibody 47 bind with relatively high 
affinity (KD in low nM range, see Table 1) to all studied autoantigens. The high values of 
the association rate constants observed in the binding to antigens by both the IgG and 
IgM forms of antibody 47 indicated that the antigen-binding site of the polyreactive 
antibody form is pre-optimized for interaction with the protein antigens. The estimated 
binding affinity of IgM47 was 5 to 7-fold higher in case of all studied antigens as 
compared with the binding affinity of IgG47. This difference may be explained either by 
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the contribution of avidity effects in the case of a pentameric IgM molecule, or by effect 
of different isotypes on the configuration of the antigen-binding site (see below). 
Accumulating evidence reveals the important role of the constant portion of 
immunoglobulin molecule for the fine-tuning of the antigen-binding properties of 
antibodies. It was demonstrated that the antigen-binding affinities of antibodies that 
possess identical V region sequences but different heavy chain isotypes differ 
significantly (45). Thus, the V region of the anti-tubulin antibody PER was expressed in 
an IgA and an IgG scaffolds. The binding affinity of monomeric intact IgA, F(ab’)2 IgA 
or Fab IgA fragments was considerably higher as compared to the binding affinity of the 
IgG variant (45). This observation highlights the modulation the antigen binding affinity 
of an antibody by the CH1 region of its heavy chain. The studies in the laboratory of 
Arturo Cassadevall clearly delineated the importance of the constant portion of 
immunoglobulins for determining antigen specificity and affinity. Thus, kinetic and 
thermodynamic analyses demonstrated that different IgG subclasses influence energetic 
changes and the overall affinity of an antibody against the Cryptococcus carbohydrate 
antigen (46,47). Moreover, this investigation revealed that the subclass of the heavy chain 
determinates the tendency for binding to multiple autoantigens, i.e., the polyreactivity of 
the antibody. The role of the nature of constant Ig regions in the antigen-binding 
properties of antibody paratopes was further confirmed by using a variety of biophysical 
approaches (48,49). It was proposed that the constant portion affects the antigen-binding 
site of antibody by long-range electrostatic interactions and conformational signaling 
through the VH-CH1 interface (40). Indeed, circular dichroism analyses during antibody 
interaction with cognate antigen revealed variations in the secondary structure in 
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antibodies that have identical variable regions but different constant regions (48). 
Moreover, NMR analyses demonstrated that the constant region of an antibody influences 
the electronic structure of the variable region and consequently its hydrolytic activity 
(49). The structural constraints exerted by different constant regions modulate the antigen 
binding sites and change not only the fine specificity and affinity of antibodies but also 
their functional properties (50). Thus, it was shown that the pathogenic potential of anti-
DNA antibodies that possess the same variable regions strongly depends on the type of 
the constant region: recognition of DNA, binding to cells, binding to isolated glomeruli 
and potential to exert kidney-damaging effects strongly correlated with the Ig subclass 
and class (50). Another study revealed that the constant Ig region influences the 
functional activities of broadly neutralizing antibodies to HIV (51). 
All these findings prompted us to investigate the role of the Ig constant region in 
determining the sensitivity to induction of antibody polyreactivity. Previous works 
demonstrated that cryptic polyreactive antibodies belong to different Ig classes – IgG, 
IgM and IgA (32,33,39). However, in these studies, Ig molecules with different variable 
regions were used. In the present work, we observed that, independently of the isotype, 
the exposure of antibody 47 to heme resulted in acquisition of polyreactivity. The breadth 
of the induced polyreactivity however may differ, which could be explained by the 
specific effect exerted by the different constant Ig regions on defining the fine specificity 
of antibodies. The sensitivity of both IgG and IgM isotypes to heme suggests that cryptic 
antibody polyreactivity is a property that depends on the interaction of the redox-active 
agents with the variable regions of the immunoglobulins. Our previous data had indeed 
demonstrated that heme induces polyreactivity by direct binding to the immunoglobulins 
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(34). Heme-binding restrains the conformational flexibility of the antibody paratope. 
Therefore, we hypothesized that antibodies exploit the inherent promiscuity of this 
compound as a cofactor for binding to multiple antigens (52). Here, absorption 
spectroscopy indicated that heme binds to both IgG47 and IgM47. The binding to both 
isotypes was characterized with similar spectral changes and the estimated binding 
affinities for heme were in a similar range (KD values in low µM range). This result 
suggested that the binding of heme to cryptic polyreactive antibody is specific to the V 
region. The small differences in the affinity for heme to molecule with different isotype 
again may be explained by an influence of the constant portion on the fine specificities of 
antigen binding regions. 
The interaction of antibodies with their cognate antigens may result in induction of 
conformational changes at long distance from the paratope. Indeed, a recent study 
demonstrated the presence of consistent structural alterations in the constant domain of 
various immunoglobulins upon antigen binding (53). This finding further supports the 
notion that the V and C regions of the immunoglobulins are functionally coupled. The 
binding of haptens by antibodies was shown to result in allosteric changes in the IgG 
molecule that modify its constant portion and hamper interaction with protein A and 
protein G molecules (54,55). In the present study, the kinetic data indicate that induction 
of polyreactivity by heme does not influence the binding affinity of IgG47 to protein G. 
This observation rules out putative heme-induced changes in the constant portion of the 
IgG molecule or heme-induced formation of IgG aggregates.  
In contrast to the effect of heme on IgG, the exposure to ferrous ions – another agent 
previously demonstrated to reveal the cryptic antibody polyreactivity – did not induce 
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significant changes in the antigen-binding characteristics of either isotypes of antibody 
47. This observation implies that cryptic polyreactive antibodies express differential 
sensitivities to different redox agents – a finding that can be explained by the existence of 
different mechanisms of induced antibody polyreactivity. Indeed, previous studies 
demonstrate that the mechanism of polyreactive binding by heme and ferrous ion-treated 
antibodies is different (33,34). The exposure of antibodies to ferrous ions results in an 
increase in the structural flexibility of the antigen binding sites. The increase pliability of 
paratopes may explain the better adaptability of the antibodies to multiple antigenic 
determinants. In contrast, heme rigidifies the antibody paratope and its binding seems 
indispensible for the antibody polyreactivity. Moreover, there are some differences in the 
sets of antigens recognized by heme and iron ion-induced polyreactive antibodies (56). 
Interestingly, our previous data indicated that pooled human IgM antibodies, in contrast 
to pooled human IgG, show only marginal sensitivity to induction of polyreactivity by 
ferrous ions (33). Taken together, these data indicate that revealing of cryptic 
polyreactivity occurs by different mechanism depending on the chemical nature of the 
redox agent.  
Cryptic polyreactive antibodies have been shown to exert powerful anti-inflammatory 
effects in vivo. Thus, the treatment of animals with polyreactive heme- or ferrous ion-
exposed IgG was found to protect from sepsis and autoimmune diabetes (33,57,58). In 
addition, cryptic polyreactive antibodies have been proposed as a biomarker for 
neurodegenerative diseases (59). The study of the molecular mechanisms underlying the 
cryptic nature of antibody polyreactivity is of uttermost importance to understand the 
physiopathological role of this antibody fraction and to explore its therapeutic potential. 
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The present study suggests that cryptic polyreactivity is a property dependent only on the 
unique amino-acid sequence and spatial rearrangement of the variable region; the 
constant region of the immunoglobulin molecule appears not to influence susceptibility to 
polyreactivity induction. However, based on the available literature, we can not rule out 
the possibility that the constant region participates in the fine-tuning of the repertoire of 
the recognized antigens and the binding affinities, once polyreactivity has been induced. 
Furthermore, whether induction of polyreactivity occurs spontaneously in vivo as a 
strategy to maintain homeostasis remains to be deciphered. 
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Table 1 
 
Kinetic parameters of the binding of hematin-treated IgM47 and rIgG47 to self-
antigens.  
 
 IgM47 rIgG47 
Antigen kon x 104 
M
-1 
S
- 1 
koff  x 10-3 
S
-1 
KD x 10-9 
M 
kon x 104 
M
-1 
S
- 1 
koff  x 10-3 
S
-1 
KD x 10-9 
M 
Factor H 53 5.7 10.8 5.8 4.0 69.3 
Factor IX 75 7.0 9.4 10.7 4.7 43.8 
MBP 56 4.3 7.6 7.2 3.0 41.3 
Tubulin 50 7.7 15.3 8.6 6.5 76.1 
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Legends to figures. 
 
Figure 1. Binding of hematin-treated rIgG47 to self-antigens by ELISA. Native or 
hematin-treated (0.25 to 16 µM) rIgG47 (10 µg/ml, 67 nM) were incubated with 
insolubilized factor IX (FIX), myelin basic protein (MBP), factor H (FH) and apo-
hemoglobulin in ELISA plates. After washing, bound IgG were revealed using a HRP-
coupled anti-human IgG antibodies and substrate. Data represents the mean absorbance ± 
SD of triplicate wells. 
 
Figure 2. Binding of hematin-treated IgM47 and rIgG47 to self-antigens by 
immunoblot. Panel A. Cross blot analysis for immunoreactivities of native and hematin-
treated (0.5 to 10 µM) IgM47 (left panel, 20 µg/ml) and rIgG47 (right panel, 20 µg/ml) 
with HUVEC and liver cell lysates. As a control, we used pooled normal IgM (IVIgM, 
100 µg/ml) or IgG (IVIgG, 100 µg/ml) treated with hematin (0, 10, 20 µM). Intensity of 
dots was computed and mean values (±SD) are plotted versus the heme concentration and 
are expressed as arbitrary units. Panel B. A protein extract from HUVEC was separated 
on a 10% preparative SDS-PAGE. The binding of native and hematin-treated (0.125 to 
16 µM) IgM47 (left panel, 20 µg/ml) and rIgG47 (right panel, 10 µg/ml) to HUVEC 
proteins was detected by Western blot. Immunoreactivities of native or hematin-treated 
(10 µM) IVIgM and IVIgG were analyzed as controls.  
 
Figure 3. Binding of hematin to IgM 47 and rIgG47 by absorbance spectroscopy. 
IgM47 and rIgG47 (100 µg/ml) were titrated with hemin (0 to 6400 nM). Corresponding 
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aliquots of hemin were also added to a reference cuvette, containing buffer alone. The 
absorbance spectra of increasing concentrations of hemin alone (dashed line curves) and 
hemin in the presence of IgM47 (left panel, plain line curves) or of rIgG47 (right panel, 
plain line curves) were recorded in the range of 350-700 nm. Insets: the specific binding 
of hemin to IgM47 and rIgG47 was estimated by subtracting the absorbance maxima in 
the Soret region of hemin in the presence of Ig by the absorbance maxima of hemin 
diluted in PBS alone. Plotted data represent the excess of hemin over a concentration of 
Ig of 1 nM. Data were fitted using the single binding site hyperbolic equation (R2=0.96 
for both IgM47 and rIgG47, respectively). 
Figure 4. Kinetics of interaction of native and hematin-exposed IgM47 and rIgG47 
with MBP. IgM47 (20 nM, top panels) and rIgG47 (100 nM, bottom panels) were 
incubated alone (left panels) or with 8 µM hematin (right panels). The binding of the 
heme-IgM47 and heme-rIgG476 complexes to MBP was then measured in real-time by 
surface plasmon resonance using serial dilutions with initial Ig concentrations of 20 and 
100 nM, respectively. The intensity of binding is depicted as resonance units (RU).  
The binding profiles were fitted using the by BIAevaluation software (full red curves, 
Biacore AB). 
Figure 5. Kinetics of interaction of native and hematin-exposed rIgG47 with Protein 
G. rIgG47 (100 nM) was incubated alone (left panel) or with 8 µM hematin. The binding 
of the heme-rIgG476 complexes to protein G was measured in real-time by surface 
plasmon resonance using serial dilutions with initial IgG concentrations of 100 nM. The 
intensity of binding is depicted as resonance units (RU).  
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Legends to supplemental data 
 
Figure S1. Kinetics of interaction of native and hematin-exposed IgM47 and rIgG47 
with factor H. IgM47 (20 nM, top panels) and rIgG47 (100 nM, bottom panels) were 
incubated alone (left panels) or with 8 µM hematin (right panels). The binding of the 
heme-IgM47 and heme-rIgG476 complexes to factor H was then measured in real-time 
by surface plasmon resonance using serial dilutions with initial Ig concentrations of 20 
and 100 nM, respectively. The intensity of binding is depicted as resonance units (RU).  
 
Figure S2. Kinetics of interaction of native and hematin-exposed IgM47 and rIgG47 
with tubulin. IgM47 (20 nM, top panels) and rIgG47 (100 nM, bottom panels) were 
incubated alone (left panels) or with 8 µM hematin (right panels). The binding of the 
heme-IgM47 and heme-rIgG476 complexes to tubulin was then measured in real-time by 
surface plasmon resonance using serial dilutions with initial Ig concentrations of 20 and 
100 nM, respectively. The intensity of binding is depicted as resonance units (RU).  
 
Figure S3. Kinetics of interaction of native and hematin-exposed IgM47 and rIgG47 
with factor IX. IgM47 (20 nM, top panels) and rIgG47 (100 nM, bottom panels) were 
incubated alone (left panels) or with 8 µM hematin (right panels). The binding of the 
heme-IgM47 and heme-rIgG476 complexes to factor IX was then measured in real-time 
by surface plasmon resonance using serial dilutions with initial Ig concentrations of 20 
and 100 nM, respectively. The intensity of binding is depicted as resonance units (RU).  
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Discussion 
I my thesis work, I have focussed on two relatively less studied properties of antibodies. 
The first is antibody catalytic activity and second is polyreactivity. In this section, I will 
first discuss our observations on catalytic antibodies. This will then be followed by a 
discussion on polyreactive antibodies.  
 
1. The origin of catalytic antibodies 
The origin of catalytic antibodies had been a puzzling question ever since catalytic 
antibodies have been found in the human, that is in a situation when catalytic antibodies 
had not been “induced” upon deliberate immunization, but develop “spontaneously”. The 
term “origin” covers actually two different aspects of the generation of catalytic 
antibodies: that of the genetic origin of catalytic antibodies, and that of their ontogenic 
origin: how are the B-cell clones producing catalytic antibodies generated during the 
ontogeny of the immune system and/or in the course of an immune response. In this first 
part of my discussion, I will concentrate on discussing the hypotheses proposed to 
explain the “spontaneous” presence of such antibodies in human beings.  
 
1.A.Genetic origin of catalytic antibodies 
The genetic origin of catalytic antibodies may be seen in two different ways. A first 
possibility is that some sets of genes, which are “dedicated” to encoding variable regions 
with a catalytic site, pre-exist in the gene repertoire of every individual. If this were true, 
it would mean that the catalytic function of antibodies has been evolutionary conserved - 
	   158	  
if not selected for, a possibility that is justified by the fact that catalytic antibodies may be 
found in different species, such as human and mice. We believe that the lack of 
systematic research of spontaneously occurring catalytic antibodies in distant species 
such as chicken or sharks, prevents us from concluding on these lines. In collaboration 
with Dr Padiolleau-Lefevre, we performed an analysis of 23 monoclonal antibodies with 
amidase activity reported in the literature (Annexe. Article-1). Interestingly, our analysis 
pointed towards a high prevalence of catalytic antibodies using the rare antibody light 
chain variable gene subgroups IGKV2, IGKV9 and IGKV19 (Le	  Minoux	  et	  al.,	  2012).	  
Another group headed by Dr Uda highlighted a preferential presence of serine protease-
like catalytic triads in the antibody variable kappa gene subgroups bb1, cr1, cs1, bl1, bj2 
and bd2 (Uda	   and	   Hifumi,	   2004). It should be noted that both of these studies were 
based on the analysis of monoclonal antibodies that, by definition, result from the 
stimulation of the immune system, which thus does not exclude possible bias in the 
analysis. Of note, Uda et al identified catalytic triads with spatial arrangement of Ser-
Asp-His similar to that found in the active site of proficient serine proteases (Hifumi	  et	  al.,	  2012), in the 3D structure of available monoclonal antibodies. They then cloned the 
corresponding germline genes and showed catalytic activity in the produced light chains. 
Thus, the light chains derived from germline genes A3/A19, A5, A17, A18, A23 of 
subgroup II, a relatively less expressed subgroup, was demonstrated to preferentially 
posses catalytic activity (Hifumi	  et	  al.,	  2012).  
Another strategy to address the question of the origin of catalytic antibodies is to study 
the germline or mutated conformation of the genes encoding their variable regions. 
Historical studies in the 90’s had compared the extent of germline mutations in induced 
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catalytic antibodies with esterase, oxy-cope rearrangement, Diels-Alder or VIPase 
activities (Table 1). Interestingly, the antibodies had been “demutated” to the germline 
configuration by site-directed mutagenesis. The catalytic activities of the germline and 
mutated antibodies had then been compared. The number of replacement mutations 
ranged between 3 and 14, which is not surprising given the fact that the antibodies had 
been induced by active immunization. Surprisingly however, there was no general rule as 
whether germline or matured antibodies are better catalysts or not. Indeed, the 
monoclonal antibody 48G7 was a better catalyst in the mature configuration, while clone 
AZ-28 displayed better catalytic efficiency in its germline configuration (Table 1). 
Conversely, clone C23.5 with VIPase activity displayed identical catalytic efficiencies, 
whether in its germline or matured configuration. In our review of the published data on 
catalytic antibodies (Annexe. Article-1), the variable regions of the heavy chains and 
light chains of the reported antibodies had more than 97% similarity with the 
corresponding germline genes, suggesting very low amount of somatic mutations. 
Mutations were more prevalent in the heavy chains than in the light chains, and light 
chains were more frequently involved in the catalytic process. Of note, in 50% of the 
cases, the mutation targeted an amino-acid that was presumed to be involved in the 
catalytic site.  
As a conclusion of this part, it is clear that some “induced” catalytic antibodies are 
encoded by germline genes, which means that conserved amino-acids from the 
framework regions of the antibodies participate to the critical amino-acids of the catalytic 
site, while other “induced” catalytic antibodies result from a process of affinity 
maturation. In the latter case, whether the somatically mutated amino-acids are directly 
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part of the catalytic triad (in the case of antibodies with serine protease activity) or 
“shape” the 3D structure of the variable region to bring in close contact conserved amino-
acids that make the catalytic site, remains to be determined. It is most probable that no 
general rule applies and that each case may be found. Nevertheless, it appears difficult to 
conclude with respect to the genetic origin of the catalytic antibodies that 
“spontaneously” develop on human beings, would it be under physiological or 
pathological conditions, because a systematic analysis of the variable region genes 
encoding these antibodies is still lacking, an might be difficult to achieve.  
 
Table 2. 
 
Clone Activity Nb replacements 
Activity of 
Germline 
encoded 
Activity 
germline vs mature References 
48G7 Esterase 9 + (low) germline <<<mature Lesley 93,  Patten 96 
AZ-28 Oxy-cope rearragement 6 + germline >> mature Ulrich 97 
39-A11 Diels-Alder 3 + germline << mature Romesberg 98 
1E9 Diels-Alder 14 + germline << mature Xu 99 
C23.5 VIPase 4 + germline  ≈ mature  
Gao 94, 
Gololobov 99 
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1.B. Ontogenic origin of catalytic antibodies 
The ontogenic origin of catalytic antibodies relates to the immune mechanisms that allow 
the production of B cells producing catalytic antibodies. A paradigm pointed out 
previously by S Paul is the necessity, for a B-cell clone to be selected, of a strong B-cell 
receptor (BcR) signalling. Contrarily, in the case of catalytic antibody-producing B cells, 
where the BcR is presumably catalytic and has a turnover, the binding stage of the BcR 
with the target antigen is very short since the antigen is catalysed and released. S Paul 
and others have thus derived strategies to “induce” catalytic antibodies, for instance using 
covalently reactive analogues (described in the introduction). The central question here 
however is the selection process of catalytic antibodies in an individual without deliberate 
immunization using “manipulated” immunogens. Hypothetically, the catalytic antibody 
response may be either antigen-driven, or may occur as a bystander response. In this 
second option, B cells possessing catalytic BCRs may spontaneously escape negative 
selection processes in bone marrow or at the periphery, or B cells may take advantage of 
a peculiarly low threshold of sensitivity for activation and benefit from ongoing immune 
activation in nearby microenvironment and be thus induced to produce catalytic 
antibodies. These hypotheses however remain unclear and require more investigation. In 
disagreement with the second option however, the generation of catalytic antibodies in 
physiology seems to be tightly regulated. Indeed, experimental data in autoimmune-prone 
MRL/lpr or SJL mice show a higher frequency of catalytic antibodies than in normal 
mice (Tawfik	   et	   al.,	   1995). Accordingly, protease and nuclease activity of antibodies 
from strains of autoimmune prone mice, MRL-lpr/lpr, NZB/NZW, SJL/J, have been 
reported to be very high in comparison to that of normal Balb/c mice. Of note, catalytic 
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antibodies of the IgM, IgA and IgG class, present in body fluids such as blood, saliva or 
mothers milk, have been reported (Semenov	  et	  al.,	  1998;	  Planque	  et	  al.,	  2004;	  Mitsuda	  et	  al.,	  2007). The presence of isotype switched catalytic antibodies again pleads in favour 
of a regulated generation of antibody catalysts.  
S Paul and co-workers have shown the importance of the nature of the antibody constant 
heavy chain in the catalytic potency. Thus, data on human catalytic antibodies suggests 
that normal IgM express the highest catalytic activity, followed by IgA and IgG that are 
considered to be the least catalytic. The reason for IgM bearing the highest catalytic 
efficiency has been related to their tendency to be germline encoded. The germline 
configuration provides greater flexibility, relatively lower affinity for antigen and 
ultimately better turnover, properties that are a hallmark of efficient catalysts. Recent 
findings indicate that the constant domain plays an important role in the overall superior 
catalytic efficiency of IgM. Thus, variable regions cloned from a catalytic antibody were 
expressed in different scaffolds: single chain fragment variable (scfv), IgG and IgM: the 
recombinant IgM displayed the highest catalytic activity. In contrast, isotype switching 
(eg. from IgM to IgG), which is generally accompanied by somatic hypermutation, is a 
feature of mature humoral immune responses, and specializes antibodies towards 
efficient binding rather than turnover.  
In humans, several autoimmune and inflammatory conditions are known for the sudden 
spontaneous generation of catalytic antibodies. Thus catalytic antibodies to self-antigens 
like vasoactive intestinal peptides (VIP), coagulation factor VIII (FVIII), DNA/RNA, 
myelin basic protein, thyroglobulin, and amyloid beta occur spontaneously in asthma, 
acquired and congenital hemophilia A, systemic lupus erythematosus, scleroderma, 
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multiple sclerosis, Hashimoto’s thyroiditis and Alzheimer’s disease. The reasons for an 
exacerbated generation of catalytic antibodies in diseases remains unclear. Given the 
complexity of some of the diseases in terms of the underlying conditions that causes the 
disease, it becomes difficult to identify the trigger that induces the catalytic antibody 
response. In this line, we recently tried to associate the levels of catalytic antibodies in 
patients receiving renal transplant, with the underlying diseases that were the cause for 
end-stage renal failure (Article 2). Among the different underlying conditions, that 
include diabetes, vasculopathy, glomerulopathy, uropathy and interstitial nephropathy, 
the lowest catalytic activity was found in patients with congenital defects (uropathy) as a 
cause for renal failure. Interestingly, kidney failure due to congenital defect is 
presumably not resulting from a global alteration of inflammatory, immune or 
cardiovascular processes. Besides, once treated by kidney replacement, patients with 
uropathy are not supposed to relapse. Taken together, our observation of higher levels of 
catalytic antibodies in renal transplant patients with diabetes, vasculopathy, 
glomerulopathy and interstitial nephropathy as compared to patients with uropathy is one 
additional piece of evidence that the trigger for higher levels of catalytic antibodies is 
associated with a dysregulated immuno-inflammatory status. 
Under physiological conditions, catalytic antibodies have a promiscuous substrate 
specificity: they are generally revealed using substrates for amidases, such as the 
synthetic PFR-MCA peptide which we have used in our studies, and they fail to 
hydrolyze larger more complex antigens such as thyroglobulin, FVIII or FIX (Li	  et	  al.,	  1995;	  Wootla	   et	   al.,	   2008a). Whether the exacerbated catalytic antibody response in 
pathology is antigen-driven remains unclear. Our finding that the repertoire of catalytic 
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IgG changes with time in patients undergoing renal transplant, and acquire the capacity to 
hydrolyze FVIII (Article 2-3), is suggestive of a positive selection of the catalytic clones. 
Likewise, our finding of FIX-activating catalytic IgG in some patients with acquired 
hemophilia, but not in all patients, suggests an influence on the generation of catalytic B-
cell clones, of the disease the pre-exists to the occurrence of anti-FVIII autoantibodies – a 
hypothesis not confirmed in our small cohort of patients. Alternatively, it may reflect the 
fact that patients wit the same disease are not equal in their capacity to mount a catalytic 
immune response.  
 
2. The physiopathological relevance of catalytic antibodies 
Historically, catalytic antibodies were studied by chemists and enzymologists. It is only 
in 1989 that catalytic antibodies were described for the first time in a context where the 
immune system had not been stimulated deliberately in order to boost the Ig catalytic 
response: spontaneously occurring IgG able to hydrolyze VIP were found in patients with 
asthma (Paul	  et	  al.,	  1989). Immediately, the catalytic activity of antibodies was proposed 
as a property to distinguish natural antibodies that circulate in physiological state from 
antibodies that are present in patients with different pathological conditions. Indeed, the 
list of diseases where catalytic antibodies are found extended rapidly from patients with 
Hashimoto’s thyroiditis, to patients with systemic lupus erythematosus or with 
hemophilia A (Shuster	   et	   al.,	   1992;	   Li	   et	   al.,	   1995;	   Lacroix-­‐Desmazes	   et	   al.,	   2002). 
These antibodies were also found to spontaneously arise in some animal models of 
human disorders (Ponomarenko	  et	  al.,	  2000). A general concept emerged according to 
which catalytic antibodies were associated with pathology, either as a hallmark of 
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immune dysfunction or as actors of the pathogenic processes. Simultaneously however, 
catalytic antibodies were described in the milk, blood and saliva of healthy individuals (Semenov	   et	   al.,	   1998;	   Planque	   et	   al.,	   2004;	   Mitsuda	   et	   al.,	   2007). In parallel, 
monoclonal human light chains endowed with catalytic activity were described in 
patients with Bence-Jones proteins (Paul	   et	   al.,	   1995)	   as well as monoclonal IgM in 
patients with Waldenström’s macroglobulinemia (Planque	   et	   al.,	   2004). In the latter 
examples, it is probable that the catalytic activity was not responsible for the tumorigenic 
process and that the clonal catalytic light chains result from the expansion of 
spontaneously catalytic antibody-producing B-cell clones. A major difference between 
disease-associated catalytic antibodies and antibodies found in healthy donors was the 
specificity of the catalytic antibodies: while disease-associated antibodies hydrolyzed 
molecules related to the pathogenic process, i.e., VIP in patients with asthma, 
thyroglobulin in patients with Hashimoto’s thyroiditis, FVIII in patients with hemophilia 
A, DNA in patients with lupus, naturally occurring catalytic antibodies had promiscuous 
amidase-like cleaving specificity and did not hydrolyze protein antigens.  
The work which I have performed during my PhD, together with some of our anterior 
findings, opens a novel prospective as far as the physiopathological relevance of catalytic 
antibodies is concerned. Taken together, our work indicates that the levels of catalytic 
antibodies are always greater under the pathological conditions studied to date, that is 
hemophilia A (Lacroix-­‐Desmazes	   et	   al.,	   2002), acquired hemophilia (Wootla	   et	   al.,	  2008a), sepsis (Lacroix-­‐Desmazes	  et	  al.,	  2005),	  renal transplant (articles 2 and 3), than 
in healthy donors. In most of the cases, higher levels of catalytic antibodies are associated 
with positive outcome form the disease – this was demonstrated in sepsis, in chronic 
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allograft nephropathy (Wootla	   et	   al.,	   2008b),	   and suggested in acquired hemophilia (Wootla	   et	   al.,	   2011) (article 1). The closest case where catalytic activity could have 
been claimed to be pathogenic, i.e., anti-FVIII IgG in allo-immunized patients with 
congenital hemophilia A, has recently been revisited by Grosbois et al – the authors have 
depicted FVIII-hydrolyzing IgG in patients without anti-FVIII allo-antibodies, and an 
inverse evolution of the levels of catalytic antibodies and of anti-FVIII IgG in patients 
treated by high dose FVIII to induce specific tolerance (Grosbois	   et	   al.). More 
importantly, we demonstrate that catalytic IgG that hydrolyze and activate FIX are able to 
restore some levels of thrombin generation in vitro. Our current hypothesis is that, for 
reasons which are yet unclear, the B cells that produce catalytic antibodies are activated 
under pathological conditions. Such an activation could result either from a loss of 
negative control as proposed by Tawfik (Tawfik	  et	  al.,	  1995)	  or from a positive selection 
by a yet unknown antigenic trigger. It is tempting to speculate that the increased levels of 
circulating antibodies represent an attempt of the unbalanced organism to re-establish the 
homeostasis of the immune system. It could however simply be that increased levels of 
circulating catalytic antibodies are a hallmark of inflammation/hyper-immunity as it is 
the case for C-reactive protein (CRP).  
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3. FVIII as a preferential target for catalytic antibodies 
Since the late 80s, scientists have investigated the presence of catalytic antibodies against 
a plethora of disease-associated target molecules. The results of most of the studies 
indicated that indeed, catalytic antibody response in the diseases was associated to the 
antigen that is central to pathology of the disease, for example, catalytic antibodies 
against thyroglobulin in Hashimoto’s thyroiditis or amyloid beta in the case of 
Alzheimer’s. We were the first group that demonstrated the generation of catalytic 
antibodies in an alloimmune response to the exogenous FVIII in patients with congenital 
hemophilia A. Factor VIII hydrolysis by purified IgG was observed in the case of 54 
percent (i.e. 13 of 24) of patients with severe congenital hemophilia A. Later, we also 
observed the presence of FVIII-hydrolyzing catalytic autoantibodies in patients with 
acquired hemophilia. In the study cohort of 45 patients, 21 (47%) patients’ IgG displayed 
significant hydrolysis of FVIII. Growing evidences however suggest that the presence of 
FVIII-hydrolyzing catalytic antibodies is associated in other diseases where FVIII is not 
directly implicated in the pathogenesis. In this line, we have earlier reported the presence 
of catalytic antibodies to FVIII in patients with sepsis and in patients that have undergone 
renal transplant. Thus, our observations indicate that the context in which FVIII-
hydrolyzing antibodies emerge is far more complex. 
The clues to understand the different context, in which FVIII-hydrolyzing antibodies may 
be generated, could be found through the structure or function of FVIII. Structurally, 
FVIII is considered to be an inherently unstable molecule. In addition, the stability of 
FVIII in vivo depends upon it’s binding to various plasma proteins or antibodies, 
proteolytic-inactivation and non-proteolytic degradation. The occurrence of FVIII-
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inhibitory antibodies has been proposed to be due to the increased immunogenicity that 
occurs because of the presence of the FVIII degradation products. The question however 
arises as, why does FVIII become a target for catalysis in diseases whose pathogenesis is 
not even distantly related. The probable answer lies in the central role played by FVIII in 
coagulation and/or coagulation-induced inflammation. In the coagulation cascade, FVIII 
plays an important role as a co-factor for activated FIX (FIXa) and FX, thereby 
increasing the velocity of FX activation by FIXa by several thousand folds. Interestingly, 
there are ample evidences of an extensive cross-talk between coagulation and 
inflammation. The importance of this cross-talk has been reported in several thrombotic 
complications. Indeed, one of the major causes of complication in sepsis is disseminated 
intravascular coagulation. In addition, in patients with renal transplant, activation of the 
stressed endothelium results in the amplification of the coagulation cascade - a major 
cause of chronic allograft nephropathy. 
These observations suggest that due to the central role played by FVIII in coagulation and 
inflammation, it is possible that the inflammatory microenvironment favours an anti-
FVIII immune response that includes generation of catalytic antibodies to FVIII. It can 
also be inferred that catalytic antibodies against FVIII can be deleterious or beneficial 
depending on the type of disease they are associated with. Thus, FVIII-hydrolyzing 
antibodies in hemophilia can be deleterious, however, in prothrombotic conditions such 
as sepsis or CAN the presence of catalytic antibodies against FVIII may be beneficial. 
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4. Factor IX-hydrolyzing IgG in different diseases 
Our initial work on FVIII-hydrolyzing IgG in congenital hemophilia A failed to detect 
hydrolysis of other self-antigens, such as human serum albumin and human recombinant 
FIX used as controls (Lacroix-­‐Desmazes	   et	   al.,	   2002). However, IgG-mediated 
hydrolysis of FIX was detected, together with FVIII hydrolysis, in one of the patients 
who survived from severe sepsis (Lacroix-­‐Desmazes	  et	  al.,	  2005). In the case of CAN, 
FIX hydrolysis was observed by IgG of 3 patients. No satisfactory explanation could be 
provided at the time, although it is possible that the combined hydrolysis of FVIII and 
FIX exerts anti-thrombotic effects and participates in preventing disseminated 
intravascular coagulation, thus protecting the patients.  
Recently, we have found that IgG from some patients with acquired hemophilia may 
hydrolyze FIX in addition to FVIII. The proteolytic activity was a property of the antigen 
binding site, as it was recovered with the purified F(ab’)2 fragments of the patients’ IgG. 
Of note, FIX-hydrolyzing IgG were not detected in inhibitor-positive patients with 
congenital haemophilia B. Taken together, these data suggest that, in contrast to FVIII-
hydrolyzing IgG that are found in congenital as well as acquired hemophilia, the 
spontaneous generation of FIX-hydrolyzing IgG requires the endogenous presence of the 
antigen. Interestingly, the migration profile of IgG-hydrolyzed FIX resembled that of 
activated FIX. Indeed, N-terminal sequencing of the IgG-mediated FIX degradation 
products confirmed cleavage of FIX at the arginine 180 residue and we confirmed that 
IgG-mediated hydrolysis of FIX lead to the activation of the coagulation factor (Wootla	  et	  al.,	  2011). Overall, IgG from 38.5% of the patients included in the cohort were able to 
activate FIX. IgG-mediated FIX activation tended (P = 0.07) to be significantly 
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associated with patient survival 12 months following diagnosis. In vitro assays showed 
that the FIX-hydrolyzing IgG were able to generate an average 0.3 nmol/l of activated 
FIX per 24 h. Such a modest amount of activated FIX was able to restore thrombin 
generation in vitro, provided that a basal level of FVIII ≥3% was present in the assay (Wootla	  et	  al.,	  2011). Although the measured kinetics of IgG-mediated FIX activation 
are low when compared to that of physiological FIX-activating enzymes (i.e., activated 
factor XI), we believe that the low kinetics are compensated by the long half-life and high 
concentration of IgG in the blood. Moreover, a fraction of the circulating FIX upon IgG-
mediated activation may feed in the coagulation cascade and compensate for the loss of 
FVIII activity in patients with acquired hemophilia. 	  	  
5. Catalytic antibody in renal transplant 
A large amount of work during my thesis has been dedicated to studying the evolution of 
catalytic antibodies in patients undergoing renal transplant (Articles 2 and 3). My interest 
was motivated by the earlier finding of the laboratory that circulating levels of catalytic 
IgG may predict chronic allograft rejection (CAN), thus opening the way towards 
translational research and potential use of catalytic antibody detection in clinical practice (Wootla	  et	  al.,	  2008b).  
While initiating the project on catalytic antibodies in renal transplant, I was initially 
pursuing two original objectives. The first one was to confirm the predictive value of the 
presence of catalytic antibodies on CAN in a prospective study involving a large number 
of patients. Conclusions on this end have not been reached as yet, since all data on CAN 
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are not available for the 73 patients that remain following two years of follow-up. Hence, 
the results presented in this thesis are that of an intermediate analysis.  
The other objective that I was interested in was less clinical and more fundamental. Very 
few studies had concentrated on following the evolution with time of catalytic antibodies 
in human beings. The only studies were performed by our research group, either in small 
patient cohort such as patients with septic shock (Lacroix-­‐Desmazes	  et	  al.,	  2005), or in 
large cohorts of patients with rare diseases, such as acquired hemophilia (Wootla	  et	  al.,	  2008a), a disorder that is extremely heterogeneous owing to the variety of underlying 
diseases that pre-exist to the development of the anti-FVIII autoantibody, to the clinical 
manifestations and to the treatments used. Both in septic shock and in acquired 
hemophilia, it was hardly possible to get blood or serum from the patients before the 
disease was diagnosed, and it was thus very complicated to relate heterogeneous levels of 
catalytic antibodies to any particular underlying disorder. Unlike most of the studied 
diseases, the incidence rate of renal transplant is relatively high and the patients are 
routinely followed-up for the evaluation of the graft functions. In collaboration with Ivan 
Peyron, another PhD student of the laboratory, I thus collected in a prospective manner 
the blood from 100 consecutive patients 3 months after they underwent kidney 
transplantation. Blood was also collected 12 and 24 months post-transplantation. 
Unfortunately, plasma samples from only 59 patients could be retrieved retrospectively. 
The questions which I wanted to address where as follows: 
. Is there heterogeneity in the circulating levels of catalytic IgG in patients? Is associated 
with particular underlying pathological conditions? Is it intrinsic to each individual’s 
immune system? 
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. Levels of catalytic IgG have been shown to vary with time (Wootla	  et	  al.,	  2008a). Is it 
possible to evaluate the fluctuations of catalytic IgG in a systematic manner? Can we 
conclude on the stability or plasticity of the “catalytic B cell” repertoire? 
. How do the immunosuppressive treatments dedicated to preventing acute graft rejection 
affect the repertoire of B cells that secrete catalytic antibodies?  
. Our earlier study had shown hydrolysis of FVIII and FIX by patients’ IgG. Is the 
antigen/substrate-specificity of the catalytic IgG pre-determined or is it generated in the 
course of the disease?  
 
5.A. Heterogeneity in the circulating levels of catalytic IgG in patients with end-stage 
kidney failure  
Previous studies from the laboratory had brought to important results (Lacroix-­‐Desmazes	  et	  al.,	  2002;	  Lacroix-­‐Desmazes	  et	  al.,	  2005;	  Wootla	  et	  al.,	  2008a;	  Wootla	  et	  al.,	  2008b): human beings in general had exacerbated levels of circulating catalytic IgG 
under pathological conditions; different patients with the same pathology present with 
heterogeneous levels of catalytic IgG. Indeed, in patients with end-stage renal failure, and 
prior to kidney transplant, the levels of catalytic IgG were significantly higher than that 
of pooled IgG from healthy donors (Article 2). Besides, as observed for patients with 
congenital hemophilia A, with acquired hemophilia and with septic shock, the circulating 
levels of catalytic IgG were extremely heterogeneous prior to transplant. We failed to 
find an association between the levels of catalytic IgG and age or sex (Article 2). This 
indirectly suggests that levels of catalytic IgG are not gender-specific. It also suggests 
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that levels of catalytic IgG are not fluctuating in a systematic manner with ageing. There 
was also no association with number of previous transplants or time of dialysis prior to 
transplant. A lack of association with the number of previous transplant is compatible 
with the fact that the patients recover, 24 months after transplant, similar levels of 
catalytic IgG as that measured prior to transplant (Article 2). It does not say however 
whether the actual repertoire of target antigens have been altered or preserved.  
When we compared patients with different causes for end-stage renal failure, it became 
apparent that patients with uropathy tended to have lower levels of catalytic IgG than the 
other groups of patients, even though the differences were not statistically significant 
owing to the low number of cases in some of the groups (in particular, diabetes, 
vasculopathy) (Article 2). Interestingly, patients with uropathy often develop 
nephropathy due to congenital reasons, and most often due to physical abnormalities. 
Once the kidney has been replaced, nephropahty is not supposed to relapse. In contrast, 
the other disease groups are characterized by inflammatory conditions, vascular problems 
or autoimmune manisfestations. Taken together, the data suggest that dysregulation fo the 
immuno-inflammatory status may lead to a flare up of catalytic Ig-producing B-cell 
clones.  
 
5.B. Fluctuations of circulating levels of catalytic IgG 
There was a drastic decrease in the IgG-mediated hydrolysis of PFR-MCA at 3 months 
post-transplant (Articles 2 and 3). Of note, IgG from all patients at all time points were 
tested for catalytic activity at a constant IgG concentration, hence the catalytic activity 
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observed at different time points was not due to the fluctuations in the total IgG 
concentration but was a reflection of the levels of catalytic IgG in the plasma.  
The cause of the decrease in IgG-mediated catalytic activity is certainly linked to the 
immunosuppressive therapy. Indeed, all patients received classical treatment using 
different combinations of steroids, cyclosporin, tacrolimus and/or mycophenolate mofetil. 
Furthermore, about 90% of the patients received adjunct immuno-suppressive therapy 
under the form of Basiliximab, anti-lymphocyte rabbit serum, Rituximab, plasmapheresis 
and/or IVIg (Article 3). Assessment of the effect of steroids on the decrease of IgG-
mediated catalytic activity was not possible, as almost all patients were administered with 
at least one form of steroid. However, separation of patients into groups based on the use 
of different adjunct therapies revealed a significant exacerbated decrease in catalytic 
activity in patients who were administered with repeated doses of IVIg at the time of 
transplantation. The effect of IVIg on the decrease of IgG-mediated catalytic activity may 
be linked either to a dilution effect of the patients’ endogenous IgG with the administered 
exogenous IVIg, or due to the direct immunomodulatory effects of IVIg on the hosts’ 
immune effectors (Article 3).  
Follow-up of the patients revealed a significant recovery of the levels of PFR-MCA 
hydrolyzing IgG at 12 months, followed by a further increase at 24 months as compared 
to that at 3 months. The recovery after 24 months was substantially high as indicated by 
the absence of significant difference in the mean rates of IgG-mediated PFR-MCA 
hydrolysis in comparison to that of pre-transplant. While the present data do not allow to 
conclude on the plasticity or stability of the repertoire of catalytic antibodies under 
physiological conditions, or in an “un-manipulated” diseased organism (because the 
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patients are treated with immunosuppressive drugs), the data clearly plead for intrinsic 
capacity of the patients’ immune system to express catalytic antibodies at higher than 
physiological levels. In other words, our data suggest that, when fluctuations on the levels 
of catalytic antibodies are imposed on the organism (by drugs), then the organism 
replenishes the depleted pool of catalytic antibodies. Evolution of levels of circulating 
catalytic antibodies may thus be envisaged as a complex process: under physiological 
conditions, B cells secreting catalytic antibodies are controlled and their expression is 
repressed to minimal levels; under some pathological conditions, most probably 
inflammatory or autoimmune, the B cell clones are activated in an individual dependent 
manner – some patients have the intrinsic capacity to mount a strong “catalytic immune 
response” (without presuming of its role, significance, efficiency), other patients mount 
only marginal catalytic immune responses; the levels of circulating catalytic IgG are then 
stable, and are re-established if eliminated by transient immuno-suppressive treatments – 
which may be due to the chronic stimulation of the “catalytic immune system” by a yet 
unidentified disease-related trigger, or to the fact that the repressor mechanisms that were 
at play under physiological conditions have been perturbed and cannot be re-established.  
 
5.C. Is the antigen/substrate-specificity of the catalytic IgG pre-determined or is it 
generated in the course of the disease? 
Chronic allograft nephropathy (CAN) is one of the major causes of late stage renal 
transplant failure. Deregulated activation of the coagulation cascade due to the 
uncontrolled activation of the endothelium drastically impairs graft function and may 
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result in total loss of function due to increased fibrosis of the graft (Matsuyama	  et	  al.,	  2003). The coagulation molecule FVIII plays a central role in the amplification loop of 
thrombin generation. Our previous observation in CAN and sepsis documents that the 
IgG mediated hydrolytic activity is directed against coagulation FVIII and/or FIX (Lacroix-­‐Desmazes	   et	   al.,	   2005). Indeed, IgG-mediated hydrolysis of PFR-MCA 
correlated with that of IgG-mediated FVIII hydrolysis in patients with CAN. Thus, 
circulating hydrolyzing IgG may exert their preventive effect against CAN by disrupting 
the thrombin amplification loop. In the present study, we have observed that FVIII 
hydrolyzing IgG evolves with the general evolution of catalytic activity. The rate of 
FVIII hydrolysis by pre-transplant patients’ IgG is high, however, no correlation is 
observed between the IgG-mediated PFR-MCA and FVIII hydrolysis. After transplant, 
IgG-mediated PFR-MCA hydrolysis tends to correlate with FVIII hydrolysis at three 
months and shows a significant correlation at 12 months. Thus indicating that, in the 
course of the disease, there is a change in the repertoire of catalytic IgG, which is shifting 
towards FVIII specificity. The reason for this shift towards FVIII specificity is unclear 
but it is tempting to speculate that it depends on the changing coagulation status of the 
surrounding endothelium of the graft.  
 
6. Role of constant domain in heme-induced polyreactivity 
Antibody molecules can be divided structurally into a variable and a constant domain. 
The constant region mediates the functions of antibodies by two major mechanisms that 
are: antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent 
cytotoxicity (CDC). Conversely, the variable regions impart their function by binding to 
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the epitopes on antigen or sometimes through enzyme-like catalysis. For a long time, the 
two domains of the antibodies were considered mutually exclusive of each other in terms 
of the functions they perform. However, growing evidences now show that the constant 
region plays an important role in tuning the fine specificity and sensitivity of the binding 
of variable regions to their cognate antigens (Pritsch	  et	  al.,	  1996). Additionally, changes 
in the subclass of antibodies have been associated with a tendency towards polyreactivity, 
resulting in binding to multiple autoantigens (Torres	   et	   al.,	   2007;	   Dam	   et	   al.,	   2008). 
Among the domains within the constant region (CH1– CH4), it is the CH1 domain that is 
considered to be responsible for imparting this effect (Pritsch	  et	  al.,	  1996). Interestingly, 
a recent study describes a huge increment in the antibody-mediated catalytic activity 
when cloned in an IgM scaffold as compared to its IgG or scfv counterparts (Sapparapu	  et	   al.).	   Thus, antibody constant regions may impart conformational changes in the 
variable domains, thereby modulating the antigen-binding functions. Indeed, long range 
interaction between the VH and CH1 region have been proved experimentally to 
structurally influence the antigen-binding site (Torres	  and	  Casadevall,	  2008). 
In the case of induced polyreactive antibodies, the modulation of variable regions by 
protein destabilizing agents is well known. While there is data on the induction of 
polyreactivity in antibodies with different isotypes (IgG, IgM, IgA) upon treatment with 
protein destabilizing agents, the results do not truly state the influence played by the 
constant region, due to the presence of different variable regions in each of the antibody 
isotypes studied (Omersel	  et	  al.;	  Dimitrov	  et	  al.,	  2006;	  McIntyre	  et	  al.,	  2006). Hence, it 
remains unclear whether changes in the constant domain may influence the polyreactivity 
induced by protein destabilizing agents. In this respect, one of the aims of my thesis was 
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to look at the role played by the constant region in heme-induced polyreactivity. For this, 
variable regions obtained from a monoclonal B cell of a patient with splenic marginal 
zone B cell lymphoma (SMZL) was cloned into an IgG scaffold. The binding profile and 
kinetics of interaction with various self and non-self antigens were then compared 
between the circulating IgM isolated from the plasma of the patient and the 
corresponding recombinant IgG. Our data suggest that the change in isotype does not 
modulate the specificity of heme-induced binding to different antigens, however the 
affinity of the variable region in the IgM scaffold for all antigens was approximately 10 
times higher. The higher affinity of the IgM may be due to the avidity effect posed by the 
pentameric structure of IgM. In view of these results, it might be appropriate to compare 
the monomeric form of the IgM with that of the recombinant IgG. The IgM isolated from 
plasma showed a small amount of impurity with IgG when evaluated by ELISA and 
Western blot. To eliminate a possible bias in our results by the contaminating IgG, I have 
now cloned the variable heavy chain genes in an expression vector containing the 
constant region of IgM. Presently, I am in the process of selecting stable clones of 
recombinant IgM-secreting HEK293 cells, which have been simultaneously transfected 
with expression vectors containing the light and heavy chains. The monoclonal 
preparation of IgM will contain largely pentameric but also monomeric forms of the 
recombinant IgM. We will separate the pentameric and monomeric forms through size-
exclusion chromatography and further evaluate the difference in heme-induced 
polyreactivity of the two forms of recombinant IgM and recombinant IgG. 
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a  b  s  t  r  a  c  t
Among  the  numerous  questions  remaining  opened  about  catalytic  antibodies  (abzymes),  the  understand-
ing  of  the  origin  of  the  genes  encoding  them  is  of  vital  signiﬁcance.  An  original  statistical  analysis  of  genes
encoding  abzymes  is  described  in  the  present  report.  Results  suggested  that  these  genes  display  a high
conservation  degree  with  their  germline  counterpart  and  a limited  number  of  amino  acid changes.  Hence,
on  the  contrary  with  high-afﬁnity  antibodies,  maturation  process  by accumulation  of  somatic  hypermu-eywords:
atalytic antibodies
bzymes
utoimmune diseases
omatic  hypermutations
ermlines
tations  is  not  required  for  the  catalytic  function.  We  demonstrated  that  despite  a weak  somatic  mutation
rate,  the physicochemical  properties  of  mutated  amino  acid  (AA)  are  predominantly  dissimilar  with  that
of  the  germline  AA.  Further,  we  developed  a novel  approach  in  order  to analyze  the  nature  of genes  encod-
ing  catalytic  antibodies.  For  the  ﬁrst  time,  an  unexpected  and  signiﬁcant  high  level  expression  of  rare
gene  subgroups  was  noticed  and  emphasized.  The  data  described  in  this  paper  would  lay  the  foundation
for  future  studies  about  origin  of  genes  encoding  catalytic  antibodies.
© 2012 Elsevier Ltd. All rights reserved.. Introduction
Catalytic antibodies are immunoglobulins that are able to accel-
rate a chemical reaction. Originally, catalytic antibodies were
enerated by procedures using transition state analogues (TSA) as
mmunogens (Pollack et al., 1986; Tramontano et al., 1986). Since
hen, a hundred of antibodies with catalytic activity have been
roduced by using optimized strategies based on TSA or alterna-
ive ways (Xu et al., 2004). Catalytic antibodies were also found in
uman beings in the absence of deliberate immunization. Indeed,
he presence of catalytic antibodies has been described in the serum
f healthy individuals (Kalaga et al., 1995; Kit et al., 1996; Paul
t al., 2004; Barrera et al., 2009) and patients suffering from autoim-
une diseases (Shuster et al., 1992; Ponomarenko et al., 2002,
006; Wootla et al., 2008, 2011) as well as other pathological con-
itions (Belogurov et al., 2009). This universal presence of abzymes
aising the question of the mechanisms at stake that mediate the
Abbreviation: TSA, transition state analog.
∗ Corresponding author. Tel.: +33 3 44 23 44 12; fax: +33 3 44 23 39 10.
E-mail address: severine.padiolleau@utc.fr (S. Padiolleau-Lefèvre).
161-5890/$ – see front matter ©  2012 Elsevier Ltd. All rights reserved.
oi:10.1016/j.molimm.2012.01.004selection of the B cell clones producing antibodies with a catalytic
propensity.
Analysis of somatic hypermutations of catalytic antibodies by
comparison to the closest germline genes has been performed on
an individual case basis (Sharma et al., 2009; Zein et al., 2010a,b).
However, this did not provide a general overview of the mech-
anisms implicated to get catalytic features. Hence, it remains
unclear whether the repertoire of variable (V) genes encoding
catalytic antibodies is similar to or different from that encod-
ing binding antibodies. Studies are required to deﬁne the role
of somatic hypermutation in relation with a catalytic function.
In addition, rearrangements of V, diversity (D) and joining (J)
genes are necessary for the synthesis of the VH domains (V–D–J),
and rearrangements of V and J genes for the synthesis of the
VL domains (V–J) of the light chains kappa or lambda (Lefranc
and Lefranc, 2001). Thus, the role of speciﬁc V–D–J or V–J rear-
rangements and the pairing of Vl and VH in the acquisition of
the catalytic activity have to be clariﬁed. Answering to these
questions is complicated because of the presence of catalytic
antibodies both under physiological and pathological conditions
(Belogurov et al., 2009). Though there are numerous reports on
the characteristics of catalytic antibodies, several questions are
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till unanswered. For example, whether the rate of mutation in
he genes encoding catalytic antibodies is less or more or equal
s compared to the genes encoding non-catalytic antibodies? Are
here speciﬁc gene subgroups expressed by catalytic antibodies
s compared to non-catalytic ones? Answers to these questions
ould help to understand the mechanism of generation of catalytic
ntibodies.
In this paper, systematic evaluation of the sequences of the cat-
lytic antibodies referred in literature has been made. We  have
ollected all available sequences of antibodies displaying the abil-
ty of breaking the amide bonds. We  focused on amidase activity
or the following reasons: (i) the catalytic amino acids required for
uch an amidase activity are well characterized, (ii) the hydrolysis
f the amide bond is performed by antibodies that have been asso-
iated with physiological and pathological states in human beings.
n several reports, studies of genes encoding catalytic antibodies
f human or murine origin are based on a single technique (either
y immunization or by phage display selection) (Wedemayer et al.,
997; Yang and Schultz, 1999; Paul et al., 2006; Zein et al., 2010a,b).
n this report, irrespective of the techniques, we dealt with catalytic
ntibodies not only of mouse origin but also from human donors
Table 1). By this way, the bias of production of antibodies by a
ingle technique was minimized.
Herein  we have focused on both the extents of somatic hyper-
utations and the nature of the V genes used to encode catalytic
ntibodies. In particular, on the basis of the germline analysis,
e have evaluated (i) the rate and the nature of somatic hyper-
utations expressed by the catalytic antibodies considering the
stimated role of the amino acid (AA) changes in catalysis, (ii)
he frequency of the immunoglobulin (IG) V gene subgroups that
ncode catalytic antibodies in comparison with those encoding
inding antibodies. A robust statistical analysis was performed
o study the frequency of genes encoding catalytic antibodies in
wo separate sets. First, sequences of murine catalytic antibod-
es speciﬁcally displaying amidase activity were analyzed. Second,
he studies were also extended to the antibody sequences of
oth human and murine origin, regardless of the type of catalytic
ctivity.
. Materials and methods
.1.  Gene analysis
The  published V domain sequences of antibodies displaying the
bility of breaking amide bonds were collected: the latter reactiv-
ty is shared by several enzymatic activities, including protease,
eptidase and -lactamases (Table 2). Gene analysis was further
xtended to catalytic antibodies endowed with other activities, i.e.
NAse, esterase, decarboxylase, transaminase and Diels-Alderase
Table 2). Nucleotide sequences and translations were available
rom the GEDI nucleotide databases (GenBank (http://www.ncbi.
lm.nih.gov/genbank),  EMBL-Bank (http://www.ebi.ac.uk/embl),
NA  Data Bank of Japan (http://www.ddbj.nig.ac.jp/),  and
MGT/LIGM-DB (http://www.imgt.org).  Amino acid sequences
rom three-dimensional (3D) structures were from the RCSB
rotein Databank (PDB) (http://www.rcsb.org/pdb)  and from
MGT/3D structure-DB (http://www.imgt.org).  Sequences
rom antibodies i41-7 and HpU-9-L have been obtained from
. Uda (personal communication), and FT6 and FT12 were from the
orresponding publication (Tanaka et al., 1999).
The germline V and J genes of each sequence were iden-
iﬁed and analyzed by using the IMGT® databases and tools
IMGT®, the international ImMunoGeneTics information system®
ttp://www.imgt.org)  (Lefranc et al., 2009). When nucleotide
equences of V domains were available, we used the IMGT/V-QUESTunology 50 (2012) 160– 168 161
tool  (Brochet et al., 2008; Giudicelli et al., 2011) to identify
the closest germline V and J genes and to determine the per-
centage of nucleotides identity between the V domain and the
germline sequences. When only amino acid sequences were
provided, we used the IMGT/DomainGapAlign tool (Ehrenmann
et al., 2010; Ehrenmann and Lefranc, 2011). The consistency
between the two  tools was  controlled by submitting the
nucleotide sequence to IMGT/V-QUEST and the corresponding
amino acid sequence to IMGT/DomainGapAlign for several anti-
bodies. In each case, both tools suggested the same germline
genes.
2.2. Evaluation of the physicochemical properties modiﬁcations
due  to the AA changes
Amino  acid changes in strands and loops were analyzed accord-
ing to the IMGT/DomainGapAlign tool (Ehrenmann et al., 2010;
Ehrenmann and Lefranc, 2011). This tool allows to estimate the
physicochemical impact of AA changes due to mutations. Eleven
IMGT ‘Physicochemical’ classes of the 20 common amino acids
have been deﬁned by the physicochemical properties of their side
chains. The distinction between hydropathy, volume, chemical,
charge, hydrogen donor or acceptor atoms and polarity properties
of the side chains was taking into account. “Very similar, simi-
lar, dissimilar or very dissimilar” terms were used to qualify the
importance of physicochemical properties modiﬁcations due to AA
changes.
2.3. Location of catalytic amino acids of antibodies displaying
amidase activity
Among  the 23 antibodies displaying an amidase activity, 15 had
been studied by authors at the molecular level in order to iden-
tify or hypothesize the AA implicated in the active sites (in bold
in Table 4). Most of the active sites were deduced from molecu-
lar modeling by sequence homology, except in the case of 43c9,
Yvo (crystallographic data, Protein Data Bank accession codes 43c9
and 2agj, respectively) and of 9G4H9 (conﬁrmed by mutagenesis).
When authors proposed several hypotheses implying catalytic tri-
ads or dyads, we arbitrarily hold the hypothesis of a catalytic triad.
When several catalytic triads were proposed, we retained each
hypothesis.
2.4. Statistical analysis
Statistical  signiﬁcance was  calculated using the following sta-
tistical test, with null hypothesis H0: p1 = p2 against H1: p1 /=  p2
Z# = p1 − p2√
p(1 − p)((1/n) + (1/m))
This  statistic, under H0, is asymptotically normal and the critical
region of rejection of H0 is: (−∞, −z1−˛/2] U [z1−˛/2,  +∞), where
(1 − ˛) 100% is the conﬁdence level of test and z is the quantile of
the standard normal distribution N(0,1).
For instance, for  ˛ = 0.05, z1−˛/2 corresponds to z0.975 = 1.96:where X is the number of cases in the ﬁrst sample and Y is the
number of cases in the second sample.
This test has been developed for comparing two  distinct popu-
lations in terms of proportionality (Hoel et al., 1971).
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Table 1
Source and characteristics of the studied catalytic antibodies.
Name Format and class or subclass Production ways (and references) Activity
Anti-VIP LC derived from IgG BALB/c mice immunization with VIP (Gao et al., 1994)
DM506
scFv, Na Selection on phage library from autoimmune human patients (Bangale et al., 2003)
DM408
ECL2B LC derived from IgG1 BALB/c mice immunization with CCR5 receptor (Mitsuda et al., 2004)
i41-7  IgG1 BALB/c mice immunization with urease H. pylori (Uda and Hifumi, 2004)
HpU-18-L LC derived from IgG1
HpU-9-L LC derived from IgG1 BALB/c mice immunization with urease H. pylori (Hifumi et al., 2005)
HpU-2-H HC  derived from IgG1 BALB/c mice immunization with urease H. pylori (Hifumi et al., 2006)
Yvo Fab derived from IgM Isolated from patients with Waldenström’s macroglobulinemia (Ramsland et al., 2006)
VL2′ -t 2E6 VL heterodimer, Na Selection on phage library from human origin (Taguchi et al., 2008)
VLt′-5D3 VL monomer, Na
UA15-L LC derived from IgG1 BALB/c mice immunization with recombinant urease (Hifumi et al., 2008) Amidase
scFv  E6 scFv derived from IgG Reactive immunization of autoimmune prone mice (Durova et al., 2009)
scFv  E11
hk14 Na Selection on phage library from asthmatic human patients (Paul et al., 2001)
c23.5 LC derived from IgG BALB/c mice immunization with VIP-KLH conjugate (Paul et al., 2001)
6B8E12  IgG Anti idiotypic antibody from immunized BALB/c mice (Pillet et al., 2002)
41S-2-L LC derived from IgG2b BALB/c mouse immunization with a peptide derived from gp41 (Hifumi et al., 2006)
9G4H9 IgG2b Anti idiotypic antibody from immunized Biozzi mice (Avalle et al., 1998)
FT6
scFv,  Na Selection on phage library from BALB/c mouse origin (Tanaka et al., 1999)
FT12
43c9  Na Immunization of mice using TSA (Thayer et al., 1999)
312D6 IgG2a Immunization of BALB/c mice using TSA (Aggarwal et al., 2003)
17E8 IgG2b Immunization of mice using TSA (Zhou et al., 1994)
Esterase
CNJ206 IgG2a Immunization of BALB/c mice using TSA (Charbonnier et al., 1995)
48G7  IgG Immunization of BALB/c mice using TSA (Patten et al., 1996)
7C8  scFv derived from IgG1 Immunization of BALB/c mice using TSA (Gigant et al., 1999)
D2.3  IgG2a Immunization of BALB/c mice using TSA (Gigant et al., 1998; D’Souza et al., 2002)
9A8 Fab derived from IgM Anti idiotypic antibody from immunized Biozzi mice (Kolesnikov et al., 2000)
3F1 scFv, Na Selection on phage library from immunized mice with TSA (McKenzie et al., 2007)
6D9 IgG1 Immunization of BALB/c mice using TSA (Oda et al., 2007)
H11  Na Immunization of BALB/c mice (Brooks et al., 1996)
Diels Alder
39A11 IgG Immunization of mice using TSA (Romesberg et al., 1998)
1E9  IgG1 Immunization of mice using TSA (Xu et al., 1999)
9D9 IgG2a Immunization of mice using TSA (Hugot et al., 2002; Zheng et al., 2004)
13G5  IgG1 Immunization of mice using TSA (Zhu et al., 2004; Debler et al., 2009)
3D8  IgG Immunization of autoimmune prone mice (Kim et al., 2006)
DNAseIg  521 IgG BALB/c mouse immunization with Cucumber mosaic virus (Zein et al., 2010a)
21D8  IgG1 Immunization of 129 GIX+ mice using TSA (Hotta et al., 2000) Decarboxylase
 TSA 
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e15A9 IgG1 Immunization of mice using
he data in grey and white boxes indicate the antibodies from murine and human o
ingle  chain fragment variable; Na: isotype is not available. Nature of various tested
. Results
.1. Deviation of catalytic antibody sequences and their germline
ounterparts
It  is commonly admitted that the maturation of antibodies is
he result of the selective expansion of B cell clones leading to the
xpression of high afﬁnity antibodies. The maturation process of the
mmune system undoubtedly involves hypermutations. The muta-
ion rate of antibodies has been shown to be intimately linked to
he measured afﬁnity constants that characterize antibody–antigen
nteractions, and improves signiﬁcantly the strength of the afﬁnity
Poulsen et al., 2007). Conversely, polyreactive antibodies that are
ound in healthy individuals without deliberate immunization or in
he absence of obvious advert disease, generally display low spe-
iﬁc afﬁnities to a wide variety of self and/or foreign antigens. It is
oteworthy that sequences of polyreactive antibodies are near to
heir germline counterpart (Casali and Notkins, 1989; Zhou et al.,
007). Interestingly, polyreactivity is one of the striking features of
any catalytic antibodies (Kalaga et al., 1995; Tawﬁk et al., 1995;
lanque et al., 2004). It is thus conceivable that the link between the
olyreactivity of antibodies and their catalytic capacity may  ﬁnd its
rigin in the extent of somatic hypermutations. To investigate this
ink, we collected the V domain sequences of 23 catalytic antibodies
ndowed with amidase activity (Table 2).(Golinelli-Pimpaneau et al., 2006) Transaminase
respectively. TSA: transition state analogue; LC: light chain; HC: heavy chain; scFv:
trates is described in corresponding publications.
Using  IMGT/V-QUEST and IMGT/DomainGapAlign as described
in Section 2, we  individually analyzed VH and VL sequences. Data
are gathered in Table 3. Percentages of nucleotide identity suggest
that, for catalytic antibodies endowed with amidase activity, the V-
domains display a high degree of conservation with their germline
counterparts, around 97.5 ± 1.7% for VL and around 97.0 ± 2.7% for
VH. Our results are in concordance with that of previously obtained
on DNAse (Zein et al., 2010a) (99% for VL and 95% for VH) and
esterolytic activities (Sun et al., 2001) (98% for VL and 93% for VH).
Considering the non-silent mutations, we  have calculated an
average of 6.1 and 9.7 AA changes for VL and VH, respectively, yield-
ing an average of 16 AA changes for the VL/VH pairing (Table 4).
Such a rate of AA change is lower when compared to the rate that
characterizes mature high afﬁnity antibodies. For example, an anti-
body displaying afﬁnity in the nanomolar range has evolved from
the germline by acquiring 13 (for VL) and 14 (for VH) AA changes
(Poulsen et al., 2007), yielding 27 AA changes for the VL/VH pairing
of this particular antibody. When extending their study to several
antibodies, the same authors estimated an average number of 21
AA changes from data concerning VL/VH pairing, i.e. more than
31% higher than the average number of AA changes observed in
amidolytic antibodies.Interestingly, using the IMGT/DomainGapAlign tool, we  have
estimated the importance of the modiﬁcations of the physicochem-
ical properties linked to the AA changes. Despite the low rate of AA
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Table 2
Identiﬁcation indexes of the studied catalytic antibodies.
Name References Accession numbers Activity
Anti-VIP Gao et al. (1994) L34775 (LC)
Peptidase
⎫⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎬
⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎭
Amidase
DM506 Bangale et al. (2003) AF509587 (scFv)
DM408 AF509586  (scFv)
ECL2B Mitsuda et al. (2004) Nd
i41-7 Uda and Hifumi (2004) Personal communication
HpU-18-L AB117100 (VL) & AB117101 (VH)
HpU-9-L  Hifumi et al. (2005) Personal communication
HpU-2-H Hifumi et al. (2006) AB117095 (HC)
Yvo Ramsland et al. (2006) 2agj (Fab from IgM)
VL2′ -t 2E6 Taguchi et al. (2008) FJ231715 (VL heterodimer)
VLt’-5D3 FJ231714  (VL monomer)
UA15-L Hifumi et al. (2008) AB286872 (VL) & AB286873 (VH)
scFv  E6 Durova et al. (2009) FJ159155 (VL) & FJ159154 (VH)
scFv  E11 FJ164066 (VL) & FJ164065 (VH)
hk14  Paul et al. (2001) 1850134 (LC)
Protease
c23.5 896288  (LC)
6B8E12 Pillet et al. (2002) EF392666 (VL) & EF392665 (VH)
41S-2-L  Hifumi et al. (2002) D85104 (LC)
9G4H9 Avalle et al. (1998) AJ277812 (VL) & AJ277813 (VH)
-Lactamase
FT6 Tanaka et al. (1999) Nd
FT12 Nd
43c9 Thayer et al. (1999) 43c9
312D6 Aggarwal et al. (2003) AY349608 (VL) & AY351681 (VH) Amidase
17E8 Zhou et al. (1994) 1eap
CNJ206 Charbonnier et al. (1995) 1kno
48G7 Patten et al. (1996) 1aj7
7C8 Gigant et al. (1999) 1ct8 Esterase
D2.3 Gigant et al. (1998) and D’Souza et al. (2002) 1kn2
9A8 Kolesnikov et al. (2000) AF253060 (VL) & AF253061 (VH)
3F1 McKenzie et al. (2007) DQ849033 (scFv)
6D9 Oda et al. (2007) 2dtm
H11 Brooks et al. (1996) L41689 (VL) & L41728 (VH)
39A11  Romesberg et al. (1998) 1a4k
1E9 Xu et al. (1999) 1c1e Diels Alder
9D9  Hugot et al. (2002) and Zheng et al. (2004) 1lo4
13G5 Zhu et al. (2004) and Debler et al. (2009) 1ruq
Ig 521 Zein et al. (2010a) EF672206 (VL) & EF672220 (VH) DNAse
3D8  Kim et al. (2006) AAF79129 (VL) & AAF79128 (VH)
21D8  Hotta et al. (2000) 1c5b Decarboxylase
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a15A9 Golinelli-Pimpaneau et al. (2006) 
cFv: single chain variable fragment; LC: light chain; HC: heavy chain; VL: variab
eposited in database, but available, in the publication.
hanges, most of the modiﬁcations in the physicochemical proper-
ies of the amino acids changes of VL and VH domains (64.5% and
5.1%, respectively) were dissimilar or very dissimilar (Table 4).
As described in Section 2, 15 of the 23 catalytic antibodies dis-
laying an amidase activity were studied by the respective authors
n order to hypothesize their active site (Table 4, in bold). We  have
bserved that 11 among the 15 proposed active sites were exclu-
ively located on the light chain. Active sites of hk14, c23.5 and
pU-2-H were not hypothesized by authors. However, the hk14
nd c23.5 antibody fragments are known to be constituted only
y a light chain (Paul et al., 2001), consequently, their active site
s de facto located on them. Conversely, active site of HpU-2-H is
e facto located on the heavy chain. Hence, the ratio of active sites
xclusively located on light chain becomes 13/18, i.e. around 72%.
Then we have investigated whether the AA implied in the
utative catalytic sites originate from the introduced somatic
utations, or are already present in the V genes in germline
onﬁguration. In a half of the cases, at least one amino acid in
he catalytic triad has been gained upon somatic hypermutation.
mong these catalytic amino acids issued from somatic muta-
ions, around 71% concern dissimilar or very dissimilar AA changes
Fig. 1). Hence, the nature of these AA seems to be important for the
cquisition of the catalytic activity. Moreover, the data in Fig. 1 Transaminase
ain from light chain; VH: variable domain from heavy chain; Nd: sequence not
shows that location of catalytic Amino acids is not necessarily
focused on Complementary Determining Region (CDR) (notably
on the VH CDR3) as one might expect for standard antigen bind-
ing. On the contrary, catalytic amino acids were also noticed in
the framework regions. This suggests that hypermutation mech-
anisms for acquisition of catalytic function could be different from
mechanisms for the improvement of afﬁnity.
3.2. Gene subgroups encoding catalytic antibodies
As previously mentioned, in most of the cases, the putative cat-
alytic site involves amino acid located on the light chains of catalytic
antibodies. Thus we  further focused on the genes encoding light
chains of catalytic antibodies. To this end, the frequencies of the
IGKV germline genes used by catalytic antibodies (Table 3) were
compared with that reported in IMGT/GeneFrequency (Lefranc
et al., 2009).
There are 1553 IGKV cDNA sequences expressing IGKV
of Mus musculus origin from IMGT/LIGM-DB listed in the
IMGT/GeneFrequency tool. Reported IGKV genes have not been
observed with identical frequencies. We  have considered that gene
subgroups are rarely represented when their frequency of appear-
ance in the database is lower than 5%. Rare gene subgroups (IGKV
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Table 3
Germline origin and percentage of nucleotidic sequence identity of catalytic antibodies displaying amidase activity.
Name Species Light chain Heavy chain
V-GENE Id (%) J-GENE Id (%) V-GENE Id (%) J-GENE Id (%) D-GENE
Anti-VIP Musmus IGKV1-135*01 98.30 IGKJ1*01 100.0 –
DM506 Homsap IGKV4-1*01 94.28 IGKJ1*01 97.37 IGHV4-39*03 97.93 IGHJ4*02 89.58 IGHD3-3*01
DM408  Homsap IGLV1-40*01 97.57 IGLJ2*01 78.95 IGHV3-23*04 100.0 IGHJ4*02 95.83 IGHD6-19*01
ECL2B Musmus IGKV1-117*01 98.98 IGLJ1*01 100.0 –
i41-7 Musmus IGKV6-25*01 Na IGKJ5*01 Na IGHV1S135*01 Na IGHJ4*01 Na Na
HpU-18-L  Musmus IGKV1-117*01 97.28 IGKJ4*01 100 –
HpU-9-L Musmus IGKV1-88*01 Na IGKJ2*01 Na –
HpU-2-H Homsap – IGHV1-77*01 93.06 IGHJ3*01 97.87 IGHD2-14*01
Yvo  Homsap IGKV3-20*01 Na IGKJ1*01 Na IGHV2-5*01 Na IGHJ4*01 Na Na
VL2′ -t 2E6 Homsap IGLV2-14*01 98.61 IGLJ2*01 86.84 –
Homsap IGKV1-39*01 98.57 IGKJ1*01 91.67
VLt′-5D3 Homsap IGKV3-20*01 98.23 IGKJ2*01 100.0 –
UA15-L Musmus IGKV1-135*01 99.66 IGKJ1*01 100.0 –
scFv E6 Musmus IGKV9-124*01 99.28 IGKJ1*01 91.89 IGHV1-69*01 95.83 IGHJ2*01 85.37 IGHD3-2*02
scFv  E11 Musmus IGKV19-93*01 97.49 IGKJ2*03 94.87 IGHV1-52*01 95.83 IGHJ2*01 75.61 IGHD2-12*01
hk14  Homsap IGKV1-39*01 Na IGKJ4*01 Na –
c23.5 Musmus IGKV1-135*01 Na IGKJ1*01 Na –
6B8E12 Musmus IGKV4-61*01 94.20 IGKJ5*01 96.88 IGHV5-6-3*01 99.31 IGHJ1*01 91.67 IGHD2-14*01
41S-2-L Musmus IGKV2-137*01 95.92 IGKJ2*01 100.0 –
9G4H9 Musmus IGKV2-137*01 96.26 IGKJ5*01 94.44 IGHV1-39*01 100.0 IGHJ2*01 95.74 IGHD2-14*01
FT6 Musmus  IGKV4-55*01 Na IGKJ2*03 Na IGHV5-6*03 Na IGHJ3*01 Na Na
FT12  Musmus IGKV4-55*01 Na IGKJ5*01 Na IGHV5-9-3*01 Na IGHJ3*01 Na Na
43c9  Musmus IGKV8-24*01 Na IGKJ1*01 Na IGHV2-6-4*01 Na IGHJ3*01 Na Na
312D6  Musmus IGKV3-2*01 97.59 IGKJ1*01 94.12 IGHV1-82*01 94.04 IGHJ2*01 91.49 IGHD1-2*01
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Aata in italic were deduced using the IMGT/DomainGapAlign tool, whereas others w
equences. When germline identiﬁcation is deduced by IMGT/DomainGapAlign tool
–)  depicts antibody fragment that lacks the indicated chain. The data in grey and w, 5, 7, 9, 10, 11, 13, 15, 16, 17 and 19) thus represent 251 sequences
mong the 1553 in IMGT/GeneFrequency, i.e. 16.1% of all sequences.
In the present analysis, 16 murine IGKV genes were identiﬁed
mong the 23 catalytic antibody V-KAPPA sequences (Table 3, grey
able 4
ocation of catalytic amino acids and somatic mutation rates of catalytic antibodies displ
Name Location of catalytic amino acids 
Anti-VIP VL 
DM506  VL 
DM408 VL
ECL2B VL 
i41-7  VL or VH 
HpU-18-L  VL 
HpU-9-L  VL 
HpU-2-Ha VHa
Yvo  VL and VH 
VL2′ -t 2E6 VL 
VLt′-5D3 VL 
UA15-L VL 
scFv  E6 Nd 
scFv  E11 Nd 
hk14# VL#
c23.5# VL#
6B8E12  Nd 
41S-2-L  VL 
9G4H9  VL 
FT6  Nd 
FT12  Nd 
43c9  VL and VH 
312D6  VL and VH 
23  antibodies 11 exclusively on VL 
15  studied active sites 2 de facto on VL (#) 
3  deduced de facto (#) 1 de facto on VH (#)
he data in grey and white boxes indicate the antibodies from murine and human origin
dentiﬁed or hypothesized by authors. For the location of catalytic amino acids, “or” indica
n  both chains were suspected. Nd: Not determined active site.
# Catalytic amino acids were neither identiﬁed nor hypothesized, but the active site is n
A/total AA changes indicates the number of dissimilar or very dissimilar AA changes in sduced using IMGT/V-QUEST. Id (%) indicates the percentage of identity in nucleotide
ercentage is not available (Na) because of the nucleotide sequence is not published.
oxes indicate the antibodies from murine and human origin, respectively.boxes).  Unexpectedly, some of the rare gene subgroups (IGKV2,
IGKV9 and IGKV19) were over-represented (about 4/16, i.e. 25%)
among catalytic antibodies. In particular, the frequency ratios cal-
culated in the case of IGKV2 and IGKV19 were signiﬁcantly different
aying amidase activity.
Light chain Heavy chain
dis&vdis AA/total AA changes dis&vdis AA/total AA changes
3/4 –
7/13 4/5
4/6 3/3
2/2 –
2/2 5/9
2/8 –
2/4 –
– 9/13
6/11 10/18
5/5 –
2/3
1/4 –
1/1 –
2/2 8/11
4/4 8/12
10/14 –
3/5 –
11/14 3/3
6/7 –
5/7 0/0
5/8 10/16
2/6 7/13
4/6 9/13
2/5 6/10
91/141 = 64.5% dis&vdis AA 82/126 = 65.1% dis&vdis AA
141/23 = 6.1 AA changes 126/13 = 9.7 AA changes
, respectively. In bold indicates that active sites of corresponding antibodies were
tes that several hypothesis were proposed, “and” indicates that amino acids located
ecessarily located on the unique chain of the catalytic antibody fragment. dis&vdis
trands and loops (IMGT/DomainGapAlign) out of total amino acid changes.
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Fig. 1. AA changes and catalytic AA in both chains of catalytic antibodies displaying an amidase activity. Amino acid sequences alignment of VL domains (A) and VH domains
(B)  were performed using Multalin. The delimitations between the FR and CDR (in grey boxes) have been deﬁned according to IMGT unique numbering (Lefranc et al.,
2003; Lefranc, 2011). # indicates that the catalytic AA were neither identiﬁed nor hypothesized by authors. In the case of VL2′ -t 2E6, because this antibody fragment is a VL
heterodimer, the ﬁrst light chain is named VL2′ -t 2E61, and the second one is named VL2′ -t 2E62. Here, the active site has been hypothesized to be located on the VL2′ -t 2E62
monomer. Catalytic AA are deﬁned according to the authors’ hypotheses and are highlighted in yellow. When two  hypotheses were proposed by the authors, the second
one is highlighted in blue. If a AA is suspected to belong to the two  potential active sites, it is highlighted in green. Amino acid changes due to somatic mutations are red.
Underlined AA are considered as dissimilar or very dissimilar AA changes (according to 
supposed  to be implicated in the active site, results from a somatic hypermutation, and t
of the references to color in this ﬁgure caption, the reader is referred to the web version o
Fig. 2. Comparison of murine IGKV rare gene subgroups frequency. Rare IGKV
groups  were arbitrarily designed as having a frequency lower than 5%. The “IMGT
data”  gather 1553 IGKV rearranged sequences from murine origin together, irre-
spective of their antigen speciﬁcity. The “catalytic antibody population, restricted to
amidase activity” concerns the 16 mouse V sequences displaying an amidase activ-
ity and listed in Table 3 (grey boxes). The “catalytic antibody population, irrespective
of activity” concerns the 33 mouse V sequences displaying catalytic activity (the
16 previous sequences + the 17 ones referred in Table 4).the IMGT/DomainGapAlign criteria). For example, amino acid H30 from AntiVIP is
his mutation implies a dissimilar or very dissimilar AA change. (For interpretation
f the article.)
(p < 0.01 and p < 0.05, respectively) when calculated among the pop-
ulation of catalytic antibodies and in IMGT/GeneFrequency (Fig. 2).
The small sample size – that could be considered as a possible
source of error – is checked and validated by the statistical anal-
ysis. It suggests that rare subgroups such as IGKV2 and IGKV19 are
preferentially selected for the catalytic expression.
The nature of the catalytic function may not have a particular
relevance for the study of gene frequency. Further, the analy-
sis was  extended to the catalytic antibodies endowed with other
activities, like DNAse, esterase, decarboxylase, transaminase and
Diels-Alderase (Table 1). Altogether, 33 murine catalytic antibod-
ies (16 murine V-KAPPA with amidase activity and the 17 murine
V-KAPPA with other activities) were included in the analysis. Under
such conditions, rare IGKV gene subgroups were used by 33.3% of
the catalytic light chains versus 16.1% for the overall antibody pop-
ulation (p < 0.01) (Fig. 2). This trend was  conﬁrmed when extending
the analysis to the study of human V-KAPPA.
Among the 3664 cDNA sequences (1553 murine and 2111
human origin) listed in the IMGT/GeneFrequency tool, 255, i.e. 6.9%
sequences (251 murine and 4 human origin) are found to derive
from rare gene subgroups. Signiﬁcantly, 11 sequences (28.9%,
p < 0.001) have been observed to derive from rare gene subgroups
among the population of 38 catalytic antibodies, i.e. 33 murine
V-KAPPA sequences (Table 1, grey boxes) and 5 human V-KAPPA
sequences (Table 3, white boxes). The present data thus conﬁrm
that rarely represented IGKV gene subgroups are more frequently
associated with the expression of antibody V-KAPPA domains with
catalytic activity.
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. Discussion
Several papers published to date deal with V gene rearrange-
ents of catalytic antibodies produced by following a unique
roduction pathways (Zein et al., 2010a; Sun et al., 2001). This
ay introduce a bias in the expression proﬁle of V genes. We
herefore, compare the expression features of reported catalytic
ntibodies regardless of their mode of elicitation, namely, delib-
rate immunization with a TSA, idiotypic pathway and selection
n phage library from patients or disease animal models (Table 1).
s shown in Table 1, a large majority of the listed catalytic anti-
odies has undergone class switching into IgG, indicating that
he maturation process of the immune response has been acti-
ated. This process is further analyzed by investigating the rate
f somatic mutations. For this purpose, we identiﬁed a population
f 23 catalytic antibodies endowed with peer activities (protease,
midase and peptidase). We  highlighted a high percentage of iden-
ity between the nucleotide sequences of these 23 antibodies and
heir closest germline V genes, indicating a weak rate of somatic
utation and a low rate of AA change. Nevertheless, mutations
ere observed to induce important modiﬁcations in physicochem-
cal properties of a large majority of the AA changes. Thus, the AA
hange rate is low in terms of quantity, but seems to be impor-
ant in terms of quality. Among the 23 amidolytic antibodies, 15
ctive sites were hypothesized, whereas the active sites of the 8
thers have been neither characterized nor hypothesized. In spite
f the localization of most of the active sites on the light chain (i.e.
2%), a higher level of AA changes was observed on the VH domain.
his may  be in order to maintain the speciﬁc recognition of the
ubstrate.
Erhan and Greller (1974) have previously suggested that all anti-
ody light chains may  have protease-like features. Uda and Hifumi
2004) have further investigated the relationships between the
tructure of the catalytic triad Asp-Ser-His and the IGKV germline
y referring to 49 randomly extracted clones from the Protein
ata Bank (PDB) and to 35 clones from their laboratory. They have
emonstrated that most of the prospected catalytic triads of these
lones were encoded by the corresponding germline amino acids.
n the present report, the results suggest that 50% of the hypothe-
ized catalytic triads possess at least one amino acid derived from
he process of hypermutation.
Otherwise,  the catalytic activities of matured antibodies and
heir germline counterparts have been compared in various reports
Patten et al., 1996; Ulrich et al., 1997; Gololobov et al., 1999;
omesberg et al., 1998; Xu et al., 1999). The contradictory results
ed to suggest that a systematic rule cannot be applied generally.
ndeed Ulrich et al. (1997) and Gololobov et al. (1999) demonstrated
hat the antibodies encoded by germline genes were endowed with
n equal or greater activity than the matured ones. In contrast,
omesberg et al. (1998) demonstrated that the matured antibody
ndowed a greater activity than its germline counterpart. Indeed,
hey have shown that the catalytic antibody 39A11 that catalyzes a
iels Alder reaction is weakly mutated, but a single somatic muta-
ion on the light chain appear to be largely responsible for the
atalytic activity. Interestingly, this single mutation (Ser91Val, i.e.
er107Val according to the IMGT numbering) is considered as a very
issimilar AA change according to the IMGT criteria. Xu et al. (1999)
lso suggested that subtle mutational steps were able to inﬂuence
atalytic efﬁciency. In the same way, Patten and collaborators sug-
ested that the activity of the germline antibody was  lower than
he matured one. However, these authors have observed that none
f the AA changes was implicated in the active site. On the contrary,
hese AA changes were involved in the conformational structure of
he antibodies (Patten et al., 1996).
Finally, the subtle equilibrium between a weak mutation rate
ut nonetheless leading to modiﬁcations of the physicochemicalunology 50 (2012) 160– 168
properties should also be considered in light of the following obser-
vations: (i) catalytic antibodies are mainly polyreactive (Kalaga
et al., 1995; Tawﬁk et al., 1995; Planque et al., 2004), (ii) polyre-
active antibodies (but not catalytic) are known to be derived from
slightly mutated or unmutated germline V genes (Zhou et al.,
2007), and (iii) a decline in the occurrence of catalytic antibodies
was observed when repeated versus short immunization protocols
were performed (Tawﬁk et al., 1995). This latter point suggests that
the maturation process have to be moderated for the acquisition of
the catalytic function. All together, these observations tend toward
the same conclusion, i.e. the somatic mutations characterizing cat-
alytic antibodies are quantitatively rare but could be qualitatively
signiﬁcant.
It is commonly accepted that high afﬁnities are related to the
somatic mutations appearing during the course of the immune
response. Because the catalysis mechanism involves both regen-
eration of catalysts and product release, abzymes have to show
some ﬂexibility properties, and thus must not display high afﬁni-
ties towards antigens. Herein, we  showed that the genes encoding
catalytic antibodies and the CDR in particular are globally weakly
mutated. The catalytic proﬁciency may  be probably more linked to
the overall plasticity of weakly mutated V regions versus those of
maturated ones. Indeed, somatic mutations generally reduce the
conformational freedom of CDR, thus conferring higher afﬁnities
(Patten et al., 1996; Wedemayer et al., 1997; Venkateshrao et al.,
2004). Conversely, a weak rate of mutations may maintain the pos-
sibility of adopting many conformations by CDR which appears to
be more compatible with the catalysis mechanisms (i.e. substrate
recognition, catalyst regeneration and product release) (Ma  and
Nussinov, 2010).
The  gene subgroups encoding catalytic antibodies were further
investigated. Since many sequences of catalytic antibodies are now
accumulated in databases, this analysis is from now on statistically
relevant. The statistical analysis showed that catalytic antibodies
are signiﬁcantly and preferentially expressed by rare genes sub-
groups. This observation could ﬁnd an explanation in a more or less
sensitivity of genes to the mutation mechanisms. Indeed, Berek and
Milstein (1987) suggested that all V genes might not be equally sub-
jected to somatic hypermutation process. Since then, the somatic
hypermutation processes were investigated and various results
suggest that mechanisms involved notably depend on the sequence
of DNA (Wang et al., 2010; Ganesh and Neuberger, 2011). This could
explain the observations of Berek and Milstein suggesting that
some V genes are more or less sensitive to hypermutation process.
The fact that rare gene subgroups are overexpressed by catalytic
antibodies may  reﬂect a different susceptibility or accessibility of
certain genes to mutation processes. It would suggest that more
accessible genes being more “mutable” and less accessible genes
being less mutable. The immune system is intended to produce high
afﬁnity antibodies. Consequently, the genes that are more sensitive
to hypermutation process would be expressed more frequently. On
the contrary, genes unfavorable to hypermutation process would be
rarely expressed. On that account, a catalytic repertoire not requir-
ing high level of mutations could more frequently express the “less
sensitive” genes. This hypothesis is supported by the results in the
present paper.
Finally, the idea that some rare events might be activated in a
particular immunological context is innovative, but results from
convergence of observations. Indeed, R. Lerner recently proposed
that an “S.O.S component” of the human immunological reper-
toire could explain the activation of rare events leading to the
over representation of a speciﬁc set of genes (Lerner, 2011). Library
approaches seems favor such observations (Smirnov et al., 2011).
Whatever the reason, i.e. an emergency situation leading to an
unusual accommodation of the immune system, or an autoimmune
pathology inducing a deregulation of the immune response, a new
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oncept emerges and may  lays the foundations of a new ﬁeld of the
mmunology.
This study illustrates the complexity of the immune system.
t underlines the characteristics of the various repertoires of
xpressed V genes: mutated in high afﬁnity antibodies versus
nmutated in low-afﬁnity antibodies (with polyreactive or catalytic
roperties). A tendency emerges, showing a higher expression fre-
uency of rare subgroup genes for catalytic antibodies. In this
ontext, the special case of the high occurrence of catalytic antibod-
es in autoimmunes diseases (Shuster et al., 1992; Ponomarenko
t al., 2002, 2006; Wootla et al., 2008, 2011) could be explained by
 deregulation of the immune response that leads to the favorable
xpression of usually rare expressed gene subgroups.
In conclusion, we showed that catalytic antibodies displayed a
ow rate of somatic mutations. A signiﬁcant modiﬁcation in physic-
chemical properties due to AA changes of mutated was observed.
emarkably, we noticed that the catalytic antibodies are more
requently expressed by rare genes subgroups than binding anti-
odies. The results herein discussed are not only innovative but also
ssential to understand the origin of genes encoding catalytic anti-
odies. By highlighting astonishing rare events occurred in immune
esponse, this paper would provide a basis for future studies in the
haracterization of genes encoding catalytic antibodies.
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a b s t r a c t
Anti-factor VIII (FVIII) inhibitory IgG may arise as alloantibodies to therapeutic FVIII in patients with
congenital hemophilia A, or as autoantibodies to endogenous FVIII in individuals with acquired
hemophilia. We have described FVIII-hydrolyzing IgG both in hemophilia A patients with anti-FVIII
IgG and in acquired hemophilia patients. Here, we compared the properties of proteolytic auto- and
allo-antibodies. Rates of FVIII hydrolysis differed signiﬁcantly between the two groups of antibodies.
Proline-phenylalanine-arginine-methylcoumarinamide was a surrogate substrate for FVIII-hydro-
lyzing autoantibodies. Our data suggest that populations of proteolytic anti-FVIII IgG in acquired
hemophilia patients are different from that of inhibitor-positive hemophilia A patients.
 2009 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.
1. Introduction
Acquired hemophilia is a rare bleeding disorder, caused by the
spontaneous occurrence of autoantibodies directed against endog-
enous factor VIII (FVIII) that inhibit the procoagulant activity of
FVIII and are referred to as FVIII inhibitors [1]. About 50% of the
cases are associated with underlying pathological conditions. The
remaining cases arise during the post-partum period or are
idiopathic. FVIII inhibitors also arise in patients with congenital
hemophilia A as alloantibodies directed to therapeutically admin-
istered exogenous FVIII in the course of replacement therapy [2].
Autoantibodies and alloantibodies against FVIII share similar
properties [3,4], but may differ in their kinetics of FVIII inactivation
[5].
We have reported that IgG from hemophilia A patients and from
patients with acquired hemophilia both may hydrolyze FVIII [6,7].
In the case of hemophilia A, FVIII-hydrolyzing IgG were detected in
50% of inhibitor-positive patients [8]. FVIII-hydrolyzing IgG from
these patients inactivated FVIII with kinetics of FVIII degradation
that are compatible with a pathogenic role towards therapeutical
FVIII [9]. The rates of IgG-mediated FVIII hydrolysis correlated with
the inhibitory activity measured in patients’ plasma. Cleavage sites
for IgG on FVIII were spread over the heavy and light chains of
FVIII. In the case of acquired hemophilia, autoimmune FVIII-hydro-
lyzing IgG were found in 47% of the patients [7]. We failed to ﬁnd a
correlation between the rates of IgG-mediated FVIII hydrolysis and
the inhibitory titer in plasma or the survival of the patients one
year following diagnosis of the disease. The levels of IgG-mediated
FVIII hydrolysis co-evolved with the inhibitory titers measured
during the course of the treatment [7].
Here, we decipher the properties of auto-immune FVIII-hydro-
lyzing IgG and compare them to that of alloimmune FVIII-hydro-
lyzing IgG. The data suggest that populations of FVIII-hydrolyzing
0014-5793/$36.00  2009 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.
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ical situation that prevails when they are generated.2. Materials and methods
2.1. Patients
Plasma samples from 45 patients with acquired hemophilia
were obtained from CHU de Rouen (Etude Sacha), Caen, Compiè-
gne, from Hôpital Cochin (Paris), Hôpitaux du Kremlin-Bicêtre
(Bicêtre) and Rennes (France), in accordance with the local ethical
regulation. Patients’ clinical characteristics included in the cohort
have been published [7]. Plasma was obtained at the time of diag-
nosis. Age at time of diagnosis was 68.3 ± 17.6 years (mean ± S.D.,
ranging from 25 to 92). Patients included 28 males and 13 females
(not documented in the case of 4 patients). Inhibitory titer and
residual FVIII activity in plasma at time of diagnosis were
84.1 ± 174.0 BU/ml and 5.6 ± 6.2%, respectively. Survival one year
after diagnosis, documented for 35 patients, was 60%. In the case
of 8 patients, blood samples were obtained sequentially over peri-
ods of 6–140 days. For these 8 patients, the underlying treatments
included cortico-therapy, therapeutic FVIII, recombinant activated
factor VII and/or intravenous immunoglobulins (IVIg).
2.2. IgG puriﬁcation
IgG was isolated from plasma on protein G Sepharose (Amer-
sham). A therapeutic preparation of pooled normal human immu-
noglobulin (IVIg, Sandoglobulin, CSL-Behring, Switzerland) was
used as a source of normal IgG. To exclude potentially contaminat-
ing proteases, size-exclusion chromatography of patients’ IgG and
IVIg was performed on a superose-12 column (Amersham) equili-
brated with 50 mM Tris, 8 M urea and 0.02% NaN3 (pH 7.7), at a
ﬂow rate of 250 ll/min. IgG was dialyzed against PBS–0.01%
NaN3 for 48 h at 4 C, followed by dialysis against 50 mM Tris
(pH 7.7), 100 mM glycine, 0.02% NaN3, 5 mM CaCl2 (catalytic buf-
fer) for 24 h at 4 C.
2.3. Hydrolysis of biotinylated antigens
Commercially available recombinant human FVIII (Kogenate
FS, Bayer HealthCare, France) and activated factor VII (FVIIa, Novo-
Seven, Novo Nordisk, Chartres, France) were biotinylated [7]. Bio-
tinylated FVIII and FVIIa (185 nM) were incubated in catalytic
buffer with IgG (67 nM) for 24 h at 37 C. Samples were subjected
to 10% sodium dodecyl sulfate–polyacrylamide gel electrophoresis
followed by Western blotting and detection using streptavidin-
coupled alkaline phosphatase (KPL, Gaithersburg, MD, USA) and
the BCIP/NBT substrate. The rates of hydrolysis of FVIII were mea-
sured as described [7]. Results were expressed as millimoles of
FVIII protein hydrolyzed per minute per moles of IgG. Signiﬁcant
differences between the rates of hydrolysis by patients’ IgG and
by IVIg were assessed using an ANOVA post hoc test (Ficher PLSD).
Reported P values are one-sided.
2.4. Pro-Phe-Arg-MCA hydrolysis
IgG (67 nM) was mixed with proline-phenylalanine-arginine-
methylcoumarinamide (PFR-MCA, Peptide Inc., Osaka, Japan) at
100 lM in 40 ll catalytic buffer and incubated in the dark for
24 h at 37 C. Hydrolysis was determined by the ﬂuorescence of
the leaving group (aminomethylcoumarin; kem 465 nm, kex
360 nm). Fluorescence values were compared to a standard curve
of free MCA to compute corresponding quantities of released
MCA. At each time point, background release of MCA, measured19for each PFR-MCA concentration in wells containing the substrate
alone, was subtracted from the value observed in the presence of
the antibodies.
2.5. Calculation of Ki
IgG (67 nM) was incubated with 60, 120 and 180 lM of PFR-
MCA in the presence of increasing amount of FVIII (0.013–
3.3 lM), for 24 h at 37 C. For each FVIII concentration, a double re-
ciprocal graph was plotted: the reciprocal of the rate of PFR-MCA
hydrolysis versus that of the substrate concentration (PFR-MCA).
The slopes of the curves were calculated by linear regression anal-
ysis, and plotted as a function of inhibitor concentration (i.e., FVIII).
Intersection with the X-axis of the linear regression curve obtained
with the latter data, indicates the Ki value.
2.6. Determination of the quantity of catalytic antibodies in plasma
IgG from patients 1, 2, 15, 20, 22, 38, 42, 43, 45 were allowed to
react with Pefabloc (0–0.05 lM) (Roche Diagnostics, Mannheim,
Germany), an irreversible inhibitor of serine proteases, for 1 h at
37 C. Mixtures were incubated with PFR-MCA (100 lM) for 24 h
at 37 C. Residual PFR-MCA hydrolysis was measured. Inhibition
data (total inhibition values) obtained were curve-ﬁtted to obtain
single linear regression curves that represent IgG with low PFR-
MCA hydrolyzing activity (QL). Values calculated from the linear
regression curve at each Pefabloc concentration were subtracted
from total inhibition values; obtained data were curve-ﬁtted to ob-
tain a second single linear regression curve that represents IgG
with high PFR-MCA hydrolyzing activity (QH). Theoretically, the
amount of inhibition by Pefabloc is a reﬂection of the quantity
of catalytic sites in the IgG pool. Intersection of each generated
regression curve with the X-axis indicates the amounts of IgG with
low and high PFR-MCA hydrolyzing activity, respectively.3. Results
3.1. IgG from patients with acquired hemophilia hydrolyze FVIII
Hydrolytic patterns of FVIII and FVIIa incubated in buffer alone
or with puriﬁed IgG from ﬁve patients are depicted in Fig. 1A. FVIII
(185 nM) incubation with IgG (67 nM) from patients 2, 10, 16 and
32 resulted in FVIII hydrolysis. The FVIII migration proﬁle exhibited
minimal spontaneous degradation when it was incubated in buffer
alone (Ctl). In parallel, trypsin (>0–41.7 nM) incubated with FVIII
displayed a different hydrolytic pattern as compared to that of FVIII
hydrolysis by IgG (data not shown). IgG from acquired hemophilia
patients did not hydrolyze FVIIa or human serum albumin (Fig. 1A
and [7]). Speciﬁc rates of FVIII hydrolysis by the IgG from 45 ac-
quired hemophilia patients were calculated using the densitomeric
analysis of the hydrolyzed bands. IVIg exhibited a hydrolytic activ-
ity of 0.06 ± 0.03 mmol/min/mol (Table 1 and Fig. 1E). IgG from 21
of the 45 patients (46.6%) exhibited a FVIII-hydrolyzing activity
signiﬁcantly higher than that of IVIg (Table 1, P < 0.05). The mean
hydrolytic activity of IgG of these 21 patients was
0.22 ± 0.09 mmol/min/mol (coefﬁcient of variation: 0.29 ± 0.20)
[7].
3.2. IgG-mediated PFR-MCA hydrolysis correlates with rates of FVIII
hydrolysis
An excess of FVIII neutralized in a dose-dependent manner the
auto-immune IgG-mediated hydrolysis of PFR-MCA (Fig. 1B). The
Ki calculated in the case of IgG from patient 1 was
4.45 ± 0.49 lM. An excess of PFR-MCA inhibited FVIII hydrolysis9
Fig. 1. (Panel A) Hydrolysis of FVIII by IgG puriﬁed from the plasma of patients with acquired hemophilia. Biotinylated FVIII and FVIIa (185 nM) were incubated alone (Ctl) or
in the presence of IgG (67 nM) from patients 2, 10, 16, 20 and 32 for 24 h at 37 C. IVIg was used as a source of normal IgG and as a negative control. Migration proﬁles on a
10% SDS–PAGE are depicted. (Panel B) Inhibition of hydrolysis of PFR-MCA by puriﬁed IgG in the presence of FVIII. IgG (67 nM) from patient 1 was allowed to react with
increasing concentrations of FVIII (0–3.3 lM) for 30 min at 37 C. The mixtures were then incubated in the presence of PFR-MCA (60 lM) for 24 h at 37 C. The ﬁgure depicts
the inhibition of IgG-mediated PFR-MCA hydrolysis in the presence of FVIII, measured in two independent experiments. The Ki was calculated as described in the materials
and methods and was equal to 4.45 ± 0.49 lM. (Panels C and D) Correlation between the hydrolysis of FVIII and PFR-MCA by IgG from patients’ IgG. Biotinylated FVIII
(185 nM) and the peptide PFR-MCA (100 lM) were incubated alone or in the presence of IVIg or of IgG (67 nM) puriﬁed from the plasma of 45 patients with acquired
hemophilia (Panel C) or 22 patients with congenital hemophilia A (Panel D, [9]), for 24 h at 37 C. Rates of hydrolysis of FVIII and of PFR-MCA were calculated as explained in
Materials and Methods and are expressed as mmoles of substrate hydrolyzed per min per moles of IgG. Data were plotted for all patients (open squares and circles). In each
panel, the solid curve represents the linear regression analysis of the data. The signiﬁcance of the correlations between the FVIII- and PFR-MCA-hydrolyzing activities were
assessed using the nonparametric Spearman rank correlation. (Panels E and F) IgG-mediated hydrolysis of FVIII and of PFR-MCA. Rates of hydrolysis of FVIII (Panel E) and of
PFR-MCA (Panel F) were measured in the case of IgG puriﬁed from the plasma of 45 patients with acquired hemophilia, 22 patients with congenital hemophilia A and 9
healthy donors (panel E, 10 healthy donors in the case of panel F). Hydrolysis mediated by IVIg in the case of both substrates is indicated. The thick lines represent the
arithmetic means and the thin lines the standard deviations. Signiﬁcance between differences were assessed using the nonparametric Mann–Whitney test.
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Table 1
Speciﬁc rates of hydrolysis of FVIII and of PFR-MCA by IgG puriﬁed from the plasma of 45 patients with acquired hemophilia.
Patient number Inhibitory titer in plasmaa (BU/ml) Hydrolysis of FVIIIb (mmol/min/mol) Hydrolysis of PFR-MCAc (mmol/min/mol)
1 40 0.45 ± 0.2* 3.78 ± 1.4*
2 63 0.15 ± 0.0 4.34 ± 0.5*
3 128 0.14 ± 0.1 2.00 ± 0.9*
4 114 0.13 ± 0.1 1.31 ± 0.7*
5 380 0.17 ± 0.0 0.57 ± 0.1
6 32 0.12 ± 0.1 0.82 ± 0.6*
7 49.4 0.08 ± 0.0 0.96 ± 0.1*
8 3.1 0.38 ± 0.2* 5.68 ± 1.8*
9 42 0.13 ± 0.0 1.08 ± 0.1*
10 6 0.17 ± 0.0 0.71 ± 0.1*
11 14 0.08 ± 0.0* 0.55 ± 0.1*
12 2 0.12 ± 0.1 2.61 ± 0.8*
13 40 0.16 ± 0.1* 0.78 ± 0.7
14 2 0.22 ± 0.0* 3.56 ± 0.6*
15 80 0.18 ± 0.0* 6.90 ± 0.6*
16 52 0.14 ± 0.0* 1.86 ± 0.2*
17 100 0.36 ± 0.1* 3.74 ± 0.7*
18 10 0.09 ± 0.0 1.57 ± 0.3*
19 1.4 0.10 ± 0.0 1.84 ± 0.1*
20 18 0.08 ± 0.0 5.96 ± 0.9*
21 1050 0.15 ± 0.1* 2.94 ± 0.3*
22 330 0.14 ± 0.1* 2.95 ± 1.1*
23 18 0.30 ± 0.1* 4.12 ± 0.7*
24 1.3 0.05 ± 0.0 2.94 ± 0.5*
25 60 0.06 ± 0.0 5.14 ± 0.2*
26 1 0.06 ± 0.0 1.75 ± 0.8*
27 4 0.10 ± 0.1 1.16 ± 0.3*
28 56 0.07 ± 0.0 1.54 ± 0.1
29 4.5 0.13 ± 0.0* 0.77 ± 0.2*
30 1.5 0.08 ± 0.0 0.62 ± 0.2*
31 3 0.11 ± 0.1* 0.53 ± 0.0
32 7 0.19 ± 0.0* 7.17 ± 0.3*
33 362.7 0.08 ± 0.0 2.16 ± 0.1*
34 249.2 0.09 ± 0.1 1.19 ± 0.3*
35 62 0.32 ± 0.0* 3.31 ± 0.1
36 54 0.21 ± 0.1* 2.47 ± 0.1*
37 1 0.13 ± 0.1* 0.78 ± 0.2*
38 105.4 0.10 ± 0.0 1.24 ± 0.3*
39 92.5 0.09 ± 0.0 0.65 ± ± 0.2
40 26.6 0.10 ± 0.1 1.36 ± 0.2*
41 10 0.17 ± 0.0* 2.83 ± 0.6*
42 29.9 0.10 ± 0.0 1.48 ± 0.1*
43 4.9 0.30 ± 0.2* 3.13 ± 1.3*
44 13 0.10 ± 0.0 1.97 ± 0.1*
45 58.2 0.17 ± 0.0* 1.71 ± 0.3*
IVIg 0 0.06 ± 0.03 0.06 ± 0.03
a Inhibitory titers were measured in the plasma using the Bethesda assay.
b The results are mean ± S.D. of four independent experiments. Rates of factor VIII hydrolysis were calculated by densitometric analysis of Western blots. Spontaneous
hydrolysis that occurred upon incubation of factor VIII in the presence of buffer alone was subtracted from each analysis. The mean coefﬁcient of variation was 0.37 ± 0.21
(coefﬁcients of variation vary between 0.05 and 0.92).
c The results are mean ± S.D. of ﬁve independent experiments. Spontaneous hydrolysis that occurred upon incubation of PFR-MCA in the presence of buffer alone was
subtracted from each analysis. The mean coefﬁcient of variation was 0.37 ± 0.21 (coefﬁcients of variation vary between 0.05 and 0.92).
* P < 0.05 for the comparison with intravenous immunoglobulin (IVIg), using an analysis of variance post hoc test.
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PFR-MCA hydrolysis of patients’ IgG was 2.4 ± 1.7 mmol/min/mol
(Table 1 and Fig. 1F). IgG from 35 patients (77.8%) displayed signif-
icantly higher hydrolytic rates of PFR-MCA than IVIg
(0.06 ± 0.03 mmol/min/mol, P < 0.05). FVIII hydrolysis rates and
PFR-MCA hydrolysis rates by IgG from the 45 patients were posi-
tively correlated (Fig. 1C, Spearman rank correlation, rho = 0.395,
P = 0.008), which was not the case for IgG from 22 with hemophilia
A patients (Fig. 1D, rho = 0.05, P = 0.8, [9]). Taken together, the re-
sults suggest that PFR-MCA is a suitable alternative substrate for
autoimmune FVIII-hydrolyzing IgG.
3.3. Kinetics of PFR-MCA hydrolysis by catalytic antibodies
Using PFR-MCA as a substrate, we quantiﬁed the number of en-
zyme active sites in the polyclonal pool of IgG from patients with
acquired hemophilia. Co-incubation of PFR-MCA with IgG from pa-20tient 20 with the protease inhibitors E-64 (28 lM), EDTA (1.3 lM),
or pepstatin (10 lM) did not inhibit the hydrolytic activity. Con-
versely, aprotinin (0.3 lM), leupeptin (100 lM) and Pefabloc
(100 lM) inhibited in a dose-dependent way PFR-MCA hydrolysis,
suggesting that IgG possess serine protease-like activity (data not
shown). In order to calculate the enzyme active sites in the IgG pool,
5.3 pmoles of IgG from patients 1, 2, 15, 20, 22, 38, 42, 43 and 45
were reacted with Pefabloc (0–0.05 lM) prior to incubation with
PFR-MCA (100 lM) (Fig. 2A). IgG with low and high catalytic activ-
ity represented approximately 53 ± 11% and 9 ± 4% of total IgG,
respectively (Table 2, calculated as explained in Section 2).
Incubation of patients’ IgG (67 nM) with increasing concentra-
tions of PFR-MCA (0–2 mM) led to the saturation of hydrolytic
activity towards PFR-MCA (Fig. 2B for IgG from patient 2). Fitting
the experimental data to Michaelis–Menten equation allowed der-
ivation of the apparent Vmax and average Km of the reactions (Table
3). The computed kinetic parameters were heterogeneous among1
Fig. 2. (Panel A) Quantiﬁcation of IgG with serine protease activity within the
polyclonal pool of IgG from a patient with acquired hemophilia. The IgG puriﬁed
from the plasma of patient 2 was allowed to react with increasing concentrations of
Pefabloc prior to be incubated in the presence of PFR-MCA. The obtained data were
ﬁtted to a double linear regression model to obtain the quantity of catalytic IgG
with high PFR-MCA-hydrolyzing activity (QH) and the quantity of catalytic IgG with
low PFR-MCA-hydrolyzing activity (QL),as explained in Section 2. (Panels B and C)
Kinetic parameters of PFR-MCA hydrolysis. PFR-MCA (0-2 mM) was incubated in
the presence of IgG from patient 2 (Panel B, 66.6 nM) or trypsin (Panel C, 0.42 nM)
for 24 h at 37 C. The plotted values represent the rate of hydrolysis of PFR-MCA
determined at each concentration of PFR-MCA. The solid curve depicts the ﬁt of the
experimental data to the Michaelis–Menten equation.
Table 2
Quantity of catalytic IgG within the polyclonal pool of total IgG from patients with
acquired hemophilia.
Patients’
IgG
Quantity of PFR-MCA hydrolyzing IgG
Low hydrolyzing activity, pmol
(%)
High hydrolyzing activity,
pmol (%)
1 3.0 (56) 0.4 (8)
2 2.3 (43) 0.5 (10)
15 2.4 (44) 0.5 (10)
20 2.7 (51) 0.3 (7)
22 3.1 (59) 0.3 (6)
38 3.5 (66) 0.2 (3)
42 2.1 (40) 0.2 (5)
43 2.5 (48) 0.7 (14)
45 3.9 (73) 0.8 (15)
Mean ± S.D. 2.84 ± 0.58 (53 ± 11) 0.46 ± 0.21 (9 ± 4)
The values are expressed as pmoles of catalytic IgG per 5.3 pmoles of puriﬁed
polyclonal total IgG. Values in round brackets represent the mean % of catalytic IgG
with low and high activity. The results are representative of three individual
experiments.
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average Km of 427.4 ± 143.6 lM. Kinetic parameters of PFR-MCA
hydrolysis were also calculated for a model serine protease, tryp-202sin, tested at 0.42 nM (Fig. 2C). Vmax and Km for trypsin were
201.4 ± 3.6 fmol/min and 414.6 ± 10.0 lM. The average computed
catalytic efﬁciencies calculated on the basis of the proportion of
IgG with catalytic activity (60.6 ± 60.3 M1 min1) in the pool of
polyclonal IgG showed a 477-fold difference with that of trypsin
(28 922.3 M1 min1), thus providing evidence for the lack of con-
tamination by conventional serine proteases among the puriﬁed
polyclonal IgG preparations. Based on the derived Kcat values, cat-
alytic IgG cleaved 5–114 molecules of PFR-MCA in 24 h, indicating
capacity of turnover.
3.4. Evolution with time of the catalytic activity of IgG
We have demonstrated previously that 3/4 patients followed
over the course of the disease had FVIII hydrolysis rates that co-
evolved with inhibitory titers in plasma, suggesting that IgG-med-
iated FVIII hydrolysis participates in part in FVIII inactivation. Here,
we followed eight patients over the course of the disease. Plasma
was collected at the time of diagnosis and during the course of
the disease for periods of time ranging from 6 to 140 days. At the
time of diagnosis, inhibitory titers in plasma were 42, 6, 14, 2,
60, 56, 7 and 62 BU/ml, respectively (Table 1). At the time of the
last sampling, all patients had detectable inhibitory titers of 18,
0.7, 3.5, 0.6, 30, 67, 1.6 and 19 BU/ml, respectively (Fig. 3). Thus,
in the case of 7 patients, inhibitory titers had decreased by 2.0–
8.6-folds, while one patient presented with a steady inhibitory titer
(patient 28). IgG was puriﬁed from each of the plasma samples and
assessed for serine protease activity towards PFR-MCA. At the time
of diagnosis, hydrolytic activities of IgG from patients 9, 10, 11, 14,
25, 28, 32 and 35, were 1.08, 0.71, 0.55, 3.56, 5.14, 1.54, 7.17 and
3.31 mmol/min/mol, respectively (Table 1). At the time of the last
sampling, the hydrolytic activities of patients’ IgG were 1.72, 0.43,
0.79, 4.62, 0.84, 1.51, 2.99 and 1.51 mmol/min/mol (Fig. 3), respec-
tively. Thus, in the case of 4 patients, the hydrolytic activity of IgG
had decreased by 3.1 ± 2.0-folds. IgG from the remaining patients
demonstrated stable (patient 28) or increased (patients 9, 11 and
14) hydrolytic activities. Overall, hydrolysis rates of PFR-MCA
and Bethesda titers in plasma evolved following similar trends in
the case of 6 patients (Fig. 3).
4. Discussion
While inhibition of FVIII by IgG-mediated hydrolysis is a feature
shared by allo- and auto-antibodies to FVIII, FVIII-hydrolyzing
alloantibodies presented heterogeneous FVIII hydrolysis rates,
Table 3
Kinetic parameters of the hydrolysis of PFR-MCA by IgG of patients with acquired hemophilia.
Patients/Control Vmaxa (fmol/min) Kmb (lM) Kcatc (min1) Catalytic efﬁciencyd (M min)1
1 46.1 ± 7.7 376.4 ± 169.8 0.013 38.5
2 74.9 ± 14.2 500.4 ± 90.9 0.027 53.6
15 111.9 ± 5.1 466.7 ± 33.2 0.039 83.1
20 112.5 ± 12.6 545.5 ± 152.5 0.037 69.4
22 20.1 ± 2.5 163.0 ± 38.1 0.004 24.0
38 31.8 ± 6.8 273.4 ± 178.7 0.005 21.1
42 189.5 ± 11.6 399.7 ± 118.4 0.079 209.6
43 41.0 ± 17.3 484.3 ± 391.5 0.013 31.2
45 44.0 ± 6.0 637.2 ± 170.0 0.009 15.2
Trypsin 201.4 ± 3.6 414.6 ± 10.0 12.0 28 922.3
a,b PFR-MCA was incubated at increasing concentrations (0–2 mM) with IgG (67 nM) of nine patients with acquired hemophilia or of trypsin (0.42 nM), for 24 h at 37 C.
Hydrolysis rates were computed as explained in Materials and Methods. The data were ﬁtted to the Michaelis–Menten equation (r2P 0.94) and Vmax and Km were derived.
The data represent the mean of three independent experiments.
c In the calculation of Kcat, in the case of patients’ IgG, the quantity of catalytic IgG sites within the pool of IgG was estimated to be equal to 3.3 ± 0.8 pmol per 5.3 pmol
(Table 2).
d The catalytic efﬁciency is the ratio of Kcat to the corresponding Km.
Fig. 3. Follow-up of the inhibitory and hydrolytic activities of patients’ IgG. Plasma samples were collected from eight patients with acquired hemophilia during periods of
time comprised between 6 and 150 days. Four to 7 samples were collected for each patient. For each sample, the inhibitory titer towards FVIII was measured in plasma (BU/
ml, closed circle). IgG was puriﬁed from each plasma sample and assessed for PFR-MCA hydrolysis (mmol/min/mol, open circle). The graphs depict for each of the 8 patients
the evolution with time of the inhibitory titer (left y-axis) and of the rates of IgG-mediated PFR-MCA hydrolysis (right y-axis).
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those measured for FVIII-hydrolyzing autoantibodies (Fig. 1E,
P = 0.033). Previous studies have failed to distinguish FVIII inhibi-
tory IgG that arise under autoimmune conditions from those that
develop in an alloimmune context, with respect to the isotypic dis-
tribution and to the epitopes targeted on FVIII [3–5,10]. Anti-FVIII
allo- and autoantibodies have however been found to differ in their
kinetics of FVIII inactivation, and capacity to be neutralized by
anti-idiotypic antibodies (reviewed in [11]), suggesting the exis-
tence of subtle differences in the epitopes recognized by the two
groups of antibodies and in the structures of their variable regions.
Whether such differences account for the differences in FVIII
hydrolysis rates of allo- and auto-immune IgG remains hypotheti-
cal. Alternatively, the differences in proteolytic behavior of allo-
and auto-antibodies may reﬂect the different immunological
contexts under which FVIII-hydrolyzing IgG have been generated.
In particular, while development of anti-FVIII alloantibodies may20result from the inability of the patients’ immune system to estab-
lish tolerance to a harmless exogenous antigen [12], appearance of
anti-FVIII autoantibodies results from a break in tolerance to an
endogenous molecule.
Our initial attempts to determine the kinetic parameters of
FVIII-hydrolyzing IgG were hindered by the limited maximal con-
centration of FVIII available. To overcome this limitation, we have
used a generic tri-peptide synthetic substrate, PFR-MCA [9], previ-
ously used to screen catalytic IgG, directed against antigen sub-
strates such as vasoactive intestinal peptide [13] and
thyroglobulin [14]. The cleavage of the amide bond between the
amino acid arginine and the ﬂuorescent moiety MCA justiﬁes for
a peptide bond hydrolysis, but may not essentially mimic the
hydrolysis of a complex protein antigen. Indeed, alloimmune
FVIII-hydrolyzing antibodies did not present a signiﬁcant correla-
tion between FVIII and PFR-MCA hydrolysis rates. Conversely, in
the case of autoimmune FVIII-hydrolyzing IgG, and despite the3
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autoimmune FVIII inhibitors, the FVIII hydrolysis rates correlated
with PFR-MCA hydrolysis rates. The apparent Vmax
(74.7 ± 54.4 fmol/min) and average Km (427.4 ± 143.6 lM) calcu-
lated for PFR-MCA hydrolysis in the case of IgG from nine patients
with acquired hemophilia, differed from that previously published
for ﬁve hemophilia A patients (12.7 ± 4.0 fmol/min and
846.6 ± 351.6 lM, respectively) [9], possibly accounting for the
above mentioned discrepancy. However, the estimated Kcat
(0.05 ± 0.02 min1 in the case of alloantibodies [9] and
0.03 ± 0.02 min1 in that of autoantibodies) and the average cata-
lytic efﬁciencies (71 ± 32 and 61 ± 60 M1 min1, respectively)
did not allow to discriminate between the two groups of patients.
Recently, we described the co-evolution of the titers of IgG-
mediated FVIII hydrolysis with the inhibitory titers measured in
the plasma of acquired hemophilia patients during the course of
the treatment. Here, we have performed a follow-up study in the
case of eight patients. In the case of 6 out of 8 patients, we ob-
served similar trends of co-evolution between the catalytic activity
of IgG measured towards PFR-MCA and the measured Bethesda ti-
ters in plasma. The data demonstrate the reliability of PFR-MCA as
a surrogate substrate for autoimmune FVIII-hydrolyzing IgG, and
highlight the different natures of FVIII-hydrolyzing allo- and
auto-antibodies.
Paul et al., reported that IgG from patients with systemic lupus
erythematosis (SLE) and autoimmune thyroiditis (ATh), presented
with signiﬁcantly increased thyroglobulin-cleaving activities, as
compared to IgG from healthy individuals or from patients with
asthma or HIV infection [15]. Conversely, PFR-MCA hydrolysis
was detected among IgG from healthy donors, but was extremely
low or undetectable among IgG from SLE, ATh and rheumatoid
arthritis patients [15,16]. Here, we document that IgG from alloim-
mune and autoimmune patients are endowed with greater levels
of hydrolysis towards both FVIII and PFR-MCA, than IgG from
healthy donors. Our results conﬁrm that pathological conditions,
whether alloimmune or autoimmune, are associated with in-
creased levels of proteolytic IgG targeted towards cognate anti-
gens. They however do not support the hypothesis of a universal
occurrence of polyspeciﬁc catalytic activity in healthy donors that
diminishes under autoimmune/inﬂammatory conditions.
We have previously reported on the absence of contaminating
proteases among IgG puriﬁed from the serum of the different pa-
tients, that would account for the observed proteolysis of the dif-
ferent substrates [7]. Here, we have compared the data on the
modiﬁcation rates of puriﬁed catalytic IgG from patients to that
of a conventional serine protease, trypsin. There was a 2.7-fold dif-
ference in the apparent Vmax calculated between patients’ IgG and
trypsin (Table 3), while average Km were in the same range. The
catalytic efﬁciencies, calculated on the basis of the proportion of
IgG with high catalytic activity in the polyclonal IgG pool, showed
a 477-fold difference between patients’ IgG and trypsin. Taken to-
gether, the data indicate that the modiﬁcation rates calculated for
puriﬁed IgG in our assay widely differ from that calculated for a
conventional serine protease, thus suggesting that the architecture
of the active site of FVIII-hydrolyzing molecules in our prepara-
tions is different from that of a conventional enzyme.
The occurrence of FVIII-hydrolyzing IgG has been reported in
patients with hemophilia A [6], acquired hemophilia [7], sepsis
[17] and renal transplantation [18]. FVIII-hydrolyzing IgG may thus
be endowed with pathological roles; in inhibitor-positive patients
with congenital hemophilia A, they inactivate therapeutic FVIII and
hamper the control of hemorrhage. Alternatively, IgG-mediated
FVIII hydrolysis may be beneﬁcial in other pathological situations.
Thus, patients with sepsis develop disseminated intravascular
coagulation that may lead to organ failure [19]. Similarly, in pa-
tients with kidney transplant, uncontrolled activation of coagula-204tion by the stressed endothelium of the graft is thought to play a
role in the pathophysiology of chronic allograft nephropathy [20–
22]. In both situations, IgG-mediated FVIII inactivation, within lim-
its that are compatible with normal coagulation, may be beneﬁcial
by disrupting the ampliﬁcation loop of thrombin generation which
is dependent, at least in part, on factor VIII. The identiﬁcation of the
molecular immunological mechanisms underlying the selection of
B lymphocytes secreting FVIII-hydrolyzing IgG under such a vari-
ety of pathological conditions remains the subject of intense
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 PAbzymes are immunoglobulins endowed with enzymatic activities. The catalytic activity of an abzymeresides in the variable domain of the antibody, which is constituted by the close spatial arrangement of
amino acid residues involved in catalysis. The origin of abzymes is conferred by the innate diversity of the
immunoglobulin gene repertoire. Under deregulated immune conditions, as in autoimmune diseases, the
generation of abzymes to self-antigens could be deleterious. Technical advancement in the ability to generate
monoclonal antibodies has been exploited in the generation of abzymes with deﬁned speciﬁcities and activ-
ities. Therapeutic applications of abzymes are being investigated with the generation of monoclonal abzymes
against several pathogenesis-associated antigens. Here, we review the different contexts in which abzymes
are generated, and we discuss the relevance of monoclonal abzymes for the treatment of human diseases.
© 2012 Published by Elsevier B.V.356C
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1. Introduction: A history of catalytic antibodies
One central concept in catalysis is the transition-state theory. Any
chemical reaction may be viewed graphically in terms of free energy
changes of the reactants as a function of a reaction coordinate. The
most unstable chemical species appear at the highest point on the
reaction coordinate, which is called the transition state. The rate of
a chemical reaction is proportional to the free energy of activation
which corresponds to the difference in free energy between that of
the starting reactants and the transition state. Linus Pauling postu-
lated that enzymes achieve catalysis because of their complementar-
ity to the transition state for the reaction being catalyzed [1].
Antibodies are proteins produced by the immune system that bind
and neutralize antigens. Each antibody binds to its molecular target
similar to a key ﬁtting in a lock or a substrate binding to an enzyme.
In most cases, antibodies tightly bind the antigen, but do not speciﬁ-
cally alter its chemical nature. The hypothesis proposed by Pauling in
1946 that the active center of an enzyme is targeted against the struc-
ture of the transition state, rather than to the native conformation
of the substrate molecule [2], led Jencks in 1969 to propose that
antibodies generated in an anti-hapten immune response against
chemically stable analogs of the transition state of a reaction of inter-
est could potentially display an enzymatic activity [3,4]. Indeed, in
1985, a general method for generating catalytic monoclonal anti-
bodies (mAbs) against transition-state analogs, and a way to use
those antibodies to accelerate chemical reactions, was ﬁrst described.
In 1986, using this approach, Richard Lerner and Peter Schultz inde-
pendently reported antibody catalysis for the ﬁrst time: monoclonal
antibody-mediated hydrolysis of aryl esters and of carbonates, re-
spectively [5,6].
Since 1986, catalytic antibodies, or abzymes, catalyzing more than
100 distinct chemical reactions have been obtained using TSA. Many
catalytic antibodies achieve rate accelerations in the range 103 to 106.
The rates of reactions catalyzed with abzymes, as measured by kinetic
parameters such as KM and Vmax, are up to a million-fold greater than
the corresponding uncatalyzed reactions. Inmany cases, however, cata-
lytic antibodies have not yet approached the rates of reactions catalyzed
by natural enzymes, owing either to the strong binding to the products
of the reaction that greatly inhibits effectiveness, or to the difﬁculty to
synthesize the proper immunogens.
This article reviews the different contexts in which abzymes may
be generated, and discusses the relevance of monoclonal abzymes
for the treatment of human diseases.
2. Strategies for deliberate induction of abzymes
2.1. Immunization with transition state analogs (TSA)
Making antibodies with binding pockets complementary to transi-
tion states is complicated by the fact that true transition states and
most reaction intermediates are unstable. Thus, true transition states
or intermediates cannot be isolated or used as haptens for immuniza-
tion. Instead, so-called transition-state analog (TSA) molecules are
used. Transition-state analog molecules are stable molecules that
simply resemble a transition state (or intermediate) for a reaction
of interest in terms of stereochemistry and charge distribution. To
the extent that the transition-state analog molecule resembles a
true reaction transition state or intermediate, the elicited antibodies
will also be complementary to that transition state or intermediate
and thus lead to the catalytic acceleration of that reaction (Fig. 1A).
Abzymes catalyzing the hydrolysis of amides and esters, as well as re-
actions of cyclization [7–9], decarboxylation [10–12], lactonization
[13], peroxidation [14], photochemical thymine dimer cleavage, bi-
molecular amide-bond formation, and other reactions not known to
be catalyzed by natural enzymes have been described. Some abzymes
have been produced that require cofactors for activity, similar toPlease cite this article as: Mahendra A, et al, Antibody-mediated catalysis:
dx.doi.org/10.1016/j.autrev.2012.10.009
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standard enzymes [15]. Later, in 1995 a new concept of “reactive
immunization” emerged, wherein organisms are immunized with
highly reactive haptens designed to make covalent link with the nu-
cleophilic B-cell receptor (BcR) on the B cells, thus forming a TSA
[16]. The catalytic efﬁciencies of aldolase abzymes, generated by reac-
tive immunization, are only 40-fold lower than most studied aldol-
ases [17,18].
2.2. Manipulation of the idiotypic network
Generation of abzymes using the idiotypic network was inspired by
the “idiotypic network theory” proposed by Niels Jerne in 1974 [19].
According to this theory, immunization of an animalwith an antigen re-
sults in the production of a 1st generation antibody (Ab1), with an
antigen-binding site speciﬁc for an epitope on the antigen. Immuniza-
tion with the variable region of the Ab1 induces the production of 2nd
generation antibodies (Ab2), the antigen-binding domain of which is
complimentary to the variable domain of Ab1 and, in some cases, pos-
sesses the internal image of the antigen epitope. If the initial antigen
is an enzyme, some of the Ab2s will present with an internal image of
the catalytic site of the enzyme, and will thus be catalytic (Fig. 1B).
Manipulation of the idiotypic network has led to the generation of
monoclonal abzymes with esterase activity [20], amidase activity [21],
carboxypeptidase activity [22], protease activity [23] and recently
allinase activity [24].
2.3. Immunization with electrophilic covalent reactive analog (CRA)
First reported in the year 2000, phosphonate diester molecules have
been extensively used as a bait toﬁsh-out antibodieswith catalytic activ-
ity [25]. Covalent reactive analogs are haptenic phosphonates that bind
covalently to a nucleophilic residue in the active site of an abzyme or
of the BcR of the abzyme-producing B cells (Fig. 1C). S. Paul and
co-workers have obtained monoclonal abzymes against the gp120 coat
protein of HIV-1 virus using CRA-coupled gp120 as an immunogen
[26], and against the amyloid-β peptide by screening an scFv library
against a CRA-derivatized amyloid-βpeptide [27]. Likewise, Tramontano
and colleagues have successfully used covalently reactive phosphonate
esters to isolate catalytic scFv from a semi-synthetic scFv phage display
library [28].
2.4. Immunization with ground state antigens
Immunization of normal or autoimmune-prone mice with ground
state antigens has allowed to generate several monoclonal abzymes
with catalytic activities against vasoactive intestinal peptide [29],
CCR5 [30], HIV-1 coat protein gp41 [31], gp120 [32], Helicobacter py-
lori urease [33] and TNFα [34].
2.5. De novo generation of abzymes by site-directed mutagenesis of
antibodies
De novo elicitation of catalytic activity in antibodies has been
performed by introduction of amino acid residues with known cata-
lytic functions into the antigen-binding site of antibodies (Fig. 1D).
This approach is advantageous because the antibody, which is to be
modiﬁed into an abzyme, is of a predetermined speciﬁcity. Fletcher
et al. were able to introduce ribonuclease activity in a scFv variant
of a Fab, which was speciﬁc for RNA [35]. In another instance, Liu
et al. were able to induce protease activity in a scFv speciﬁc for the
bacterial protein HPr. Introduction of 4 mutations in the antigen-
binding domain resulted in induction of protease activity with no
loss in speciﬁcity for HPr [36]. In a similar approach, peptidase activity
has been introduced into a light chain expressed at the yeast cell sur-
face, by substituting two residues Ser27a and Asp1. The substitutionsInduction and therapeutic relevance, Autoimmun Rev (2012), http://
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Fig. 1. Different methods to generate monoclonal abzymes. A. Stable transition state analogs (TSA) of known chemical reactions are synthesized and used as haptens to immunize
mice. Monoclonal antibodies are selected based on high binding to the TSA. Some of the high binders exhibit good complementarity with the transition state, thus enabling the
acceleration of catalysis when incubated with the substrate. B. Abzyme generation by manipulation of the idiotypic network requires generation of a neutralizing antibody
(Ab1) that is directed against the active site of the enzyme (E) of interest. In the course of immunization, the paratope of the Ab1 provides an inverse image of the active site of
the enzyme, which acts as a template for synthesis of the mirror image of the active site in the anti-idiotypic antibody (Ab2). Ab2s with an enzymatic activity similar to that of
the enzyme are referred to as Abzymes. C. An antigen (Ag) coupled to a covalent reactive analog (CRA) of a reaction-based enzyme inhibitor is injected in mice. The spleen is iso-
lated to generate hybridomas from the B cells or to construct a library of scFv-expressing phages. The catalytic B cells or scFvs are then selected based on covalent binding to the
CRA-coupled antigen. D. Catalytic activity can be conferred de novo to a non-catalytic monoclonal antibody, by introduction of a serine protease-like catalytic triad in the paratope of
the antibody.
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were done for the elicitation of a serine protease-like catalytic triad
with a His93; already present within the CDR [37].
2.6. Isolation of abzymes by targeting speciﬁc germline genes
Several abzymes possess variable region-encoding genes in the
germline conﬁguration [38]. In line with this observation, the presence
of the Asp1, Ser27a and His93 catalytic triad was investigated in mouse
kappa light chain of a total of 84 clones by the group of Uda: pseudo cat-
alytic triads were found mainly in the bb1, cr1, cs1, bl1, bj2 and bd2
germline kappa genes [39]. In parallel, the same group screened genes
encoding human kappa light chains, upon structural prediction using
a strict spatial arrangement of the catalytic residues Ser, His and Asp.
Nine germline genes belonging to subgroup II showed a highprevalence
of pseudo catalytic triads. Cloning and expression of these genes from
circulating B cells of a healthy individual vaccinated against rabies
virus, allowed the generation of virus-speciﬁc abzymes [40].
3. Abzymes as therapeutic tools
The antibody scaffold provides a unique combination of antigen
speciﬁcity and functional activity to generate novel enzymes. Nowadays,
attempts are made to take advantage of these synergistic properties for
the treatment of human diseases.
3.1. Abzymes against infectious agents
Several virus-speciﬁc abzymes have been developed in the recent
years. Thus, the HIV-1 coat proteins gp120 and gp41 have been targeted
because of the key role they play in infecting CD4+ T lymphocytes.
Three monoclonal abzymes able to cleave gp120 in a site-speciﬁc man-
ner were generated upon immunization of mice with a CRA-coupled
gp120 [26]. Because HIV-1 is known to escape from the host immune
system by undergoing repeatedmutations in its coat proteins, abzymesPlease cite this article as: Mahendra A, et al, Antibody-mediated catalysis:
dx.doi.org/10.1016/j.autrev.2012.10.009
210E
were also generated from a phage library established from lupus pa-
tients that cleaved the conserved superantigenic region 421–433 [41].
In parallel, the group of Uda has generated abzyme light chains by
ground state immunization of the conserved region of gp41 [31].
Catalytic kappa light chains have been isolated from an individual
vaccinated against rabies virus; the light chains cleaved small peptide
substrates and, in some cases, diminished the infectivity of rabies
virus (CVS-11) in mouse NA cells and protected mice upon intracere-
bral inoculation with CVS-11 [40].
Lastly, the group of Uda has isolated a light chain abzyme (UA15-L)
speciﬁc for the urease of H. pylori [33]. UA15-L was able to hydrolyze
both recombinant UreB and the whole urease, and degraded urease
in the intact bacterium, thus signiﬁcantly decreasing colonization by
H. pylori in the stomach of mice.
3.2. Abzyme prodrug therapy
The ﬁrst documentation of abzyme-mediated activation of a
prodrug was provided in 1993, when Miyashita et al. showed the
activation of a non-bioactive chloramphenicol ester by an abzyme
generated against a phosphonate TSA [42]. Later in 1996, Wentworth
et al. generated an abzyme that activated the carbamate prodrug into
its cytotoxic form, nitrogen mustard, that was able to decrease the vi-
ability of human colonic carcinoma cells in vitro [43]. The most stud-
ied abzyme for prodrug therapy is 38C2 that was generated by
reactive immunization with the 1,3 diketone hapten, and possesses
an aldolase activity [17]. 38C2 activates the prodrug form of the
anti-cancer drugs doxorubicin and camptothecin [44]. It was shown
to inhibit the growth of human colon carcinoma and prostrate cancer
cell lines and to reduce tumor growth in an animal model of neuro-
blastoma [45]. 38C2 also showed therapeutic potential in diabetes
upon activation of an aldol-modiﬁed insulin [46]. More recently, a
catalytic nanobody with alliinase activity was obtained upon manipu-
lation of the idiotypic network. The abzyme nanobody suppressedInduction and therapeutic relevance, Autoimmun Rev (2012), http://
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3143.3. Abzymes in inﬂammation
A potential beneﬁcial role of abzymes has been investigated in
Alzheimer's disease by virtue of their capacity to proteolytically de-
grade amyloid aggregates. Proteolytic cleavage of amyloid-β by re-
combinant light chains [47], heterodimeric light chains and single
chain abzymes [27] was documented with exceptionally elevated
hydrolysis rates. It was proposed that single chain variant abzymes
may combine efﬁcient Aβ clearance and prevention of Fc-mediated
inﬂammation caused by phagocytic cells.
Amonomeric heavy chain abzyme speciﬁc for the pro-inﬂammatory
cytokine tumor necrosis factor-α (TNF-α)was recently developed upon
immunization with the ground state molecule [39]. In the context of
the treatment of autoimmune and inﬂammatory diseases by anti-TNF
therapy [48–51], the capacity of abzymes to turnover should allow to
diminish the requirement for bolus doses of therapeutic antibodies
that are usually required for the clearance of TNF-α.T
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3283.4. Abzymes for gene silencing
Gene silencing by targeting mRNA has been achieved by conven-
tional small interfering RNA (siRNA) technique. Alternatively, inhibition
of intracellular proteins by cell penetrating antibodies (TransMabs) is
also being investigated [52]. In a novel approach, Lee et al. have
achieved gene silencing by abzymes speciﬁc for the mRNA of Her2, a
protein that is overexpressed in breast cancer cells [53]. The abzymes
are variants of a DNA/RNA-hydrolyzing antibody light chain 3D8,
obtained by generating a synthetic library by randomization of amino
acids. The abzyme variants selectively hydrolyzed the Her2 mRNA,
resulting in decreased surface expression of Her2 and induction of apo-
ptosis, with a cytotoxic potential greater than that of siRNA. C
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We have demonstrated in the past the hydrolysis of coagulation
factor VIII (FVIII) by IgG puriﬁed from the serum of patients with con-
genital and acquired hemophilia A [54–58], suggesting that catalytic an-
tibodies may interfere with hemostasis under pathological conditions.
Interestingly, IgG-mediated catalytic activity was higher in the plasma
of patients who survived septic shock as compared to those who de-
ceased [59]: indeed, IgG from some patients hydrolyzed FVIII and factor
(FIX), potentially modulating disseminated vascular thrombosis. Simi-
lar observations were seen in patients with chronic allograft nephropa-
thy (CAN) where IgG from patients' plasma were shown to hydrolyze
FVIII and FIX. Patients with higher IgG-mediated catalytic activity had
better graft survival, and low catalytic activity measured at 3 months
post-transplantation was predictive of CAN 2 years later [60].
In contrast to these observations where the IgG-mediated hydro-
lysis of coagulation factors is presumed to hamper coagulation, we
have recently described that hydrolytic IgG from some patients with
acquired hemophilia activates## FIX and restore thrombin genera-
tion in vitro, provided that a basal level of FVIII is present in the
assay [61]. The presence of FIX-activating catalytic IgG tended to be
signiﬁcantly associated with patient survival 12 months following
diagnosis. Although the measured kinetics of IgG-mediated FIX acti-
vation are low, this may be compensated by the long half-life and
substantial concentration of IgG in the blood. Thus, a fraction of
the circulating FIX upon IgG-mediated activation may “feed in” the
coagulation cascade and compensate for the loss of FVIII activity in
patients with acquired hemophilia.Please cite this article as: Mahendra A, et al, Antibody-mediated catalysis:
dx.doi.org/10.1016/j.autrev.2012.10.009
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4. Conclusion
Abzymes appear as a double-edge sword. They have been described
in a number of human diseases, including autoimmune disorders,
alloimmune responses to protein therapeutics, and viral or bacterial in-
fections [61]. However, it is unclear as yet whether catalytic antibodies
that develop in pathological conditions play a pathogenic role or reﬂect
an attempt of the organism to re-establish homeostasis. Conversely,
monoclonal abzymes demonstrate an extraordinary potential as a
novel class of therapeutic molecules. They combine high substrate/
antigen speciﬁcity, with turnover, relatively low catalytic efﬁciency
and elevated half-life. In certain cases, expression of the variable
catalytic domains in the absence of the Fc portion may advantageously
reduce risks for activation of the inﬂammatory machinery. It is antici-
pated that the recently developed strategies to generate highly proﬁ-
cient abzymes will have implications in close future for the treatment
of infectious, alloimmune and autoimmune disorders.
Take-home messages
• Abzymes are antibodies that behave like enzymes.
• Abzymes are found under pathological conditions, although their
pathogenic or beneﬁcial role remains unclear.
• Abzymes with pre-deﬁned speciﬁcity and activity may be generated
a façon using an increasing number of biotechnological approaches.
• By virtue of combining high substrate/antigen speciﬁcity, enzyme-like
turnover, relatively low catalytic efﬁciency and elevated half-life,
abzymes reveal as promising therapeutic tools for human disorders.EAcknowledgments
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Summary
Acquired haemophilia A (AHA) is a rare bleeding disorder
characterized by the sudden generation of autoantibodies against
factor VIII (FVIII) in individuals with no previous history of
abnormal haemostasis. Understanding the pathogenesis of this
disease has been hampered by the rarity of the patients and the
difficulty in obtaining biological material from untreated
patients. Still, progress has been made recently in understanding
the pathogenesis of AHA. In particular, the importance of CD4+
T cells in AHA development has been documented and the
epitopes targeted by T cells on FVIII have been delineated.
Accordingly, a polymorphism in the cytotoxic T-lymphocyte-
associated protein 4 gene (CTLA4), known to participate in the
regulation of CD4+ T-cell responses, and a preferential usage of
certain human leukocyte antigen class II haplotypes, have been
associated with the disease. Recent findings have documented
the presence of immunoglobulin G (IgG) with proteolytic
activity against FVIII and factor IX (FIX) in patients with AHA.
While FVIII-hydrolysing IgG has been shown to inactivate
FVIII, FIX-hydrolysing IgG from AHA patients activate FIX in
vitro. Here, we describe the latest findings on the immuno-
pathogenesis of AHA, with a special focus on the potential role
played by antibodies endowed with proteolytic properties.
Keywords: Acquired haemophilia A, factor VIII, factor IX,
factor VIII inhibitors, catalytic antibodies.
Acquired haemophilia A (AHA) is a bleeding disorder that
occurs following the development of a neutralizing autoim-
mune response against the endogenous coagulation factor VIII
(FVIII). AHA occurs at an overall incidence rate of 1Æ48 per
million/year and it mainly affects the elderly, with an incidence
rate as high as 14Æ7 per million/year seen in patients above
85 years (Collins et al, 2007). The clinical feature of AHA is the
occurrence of sudden bleeding episodes in individuals without
previous bleeding history. Bleeding is life threatening in about
80% of the cases, especially in the early stage of the disease or
in cases of excessive bleeding following trauma, surgery or
cerebral haemorrhages (Collins et al, 2007). The bleeding
patterns in AHA include a high prevalence of haemorrhages in
skin, muscle or soft tissue and mucous membrane (Green &
Lechner, 1981; Boggio & Green, 2001).
Acquired haemophilia A is a disease with a complex aetiology.
In 50% of cases, AHA is not associated with any pertinent
disease, while the remaining cases of AHA are associated with
autoimmune diseases (17–18% of patients) (Green & Lechner,
1981; Yee et al, 2000), post-partum (7–21%) (Franchini, 2006),
solid cancers, monoclonal haemopathies, skin disorders, use of
drugs, infection and even vaccination. While much information
on the clinical aspects is available, a thorough dissection of AHA
pathogenesis at the cellular and molecular levels has been
challenging due to limited access to biological samples. How-
ever, an appreciable progress has been made in recent years and
the properties of the inhibitory anti-FVIII autoantibodies have
been delineated both at the functional and structural levels.
Similarly, the implication and epitope specificity of CD4+ T
lymphocytes have been studied in detail. More recently, a few
polymorphisms in genes implicated in the control of the
immune response have been associated with the occurrence of
AHA. Further, interesting findings in AHA on the pathogenic
and beneficial role of antibodies with proteolytic properties have
shed light on new parameters of auto-immune response. In the
present review, we describe the latest findings on the immuno-
pathogenesis of AHA, with a special focus on the potential role
played by proteolytic antibodies.
Immune response to FVIII in AHA
Immune responses to FVIII
Immune responses to FVIII are found in three different
immunological contexts. Anti-FVIII allo-antibodies develop in
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some patients with congenital haemophilia A following
replacement therapy with exogenous FVIII (Ehrenforth et al,
1992). This allo-immune response is believed to reflect a
classical immune response to a foreign antigen, although it
remains unclear why some patients develop an immune
response to FVIII while others do not, and why some patients
develop an immune response at all, given the fact that
therapeutic FVIII is administered intravenously, a notoriously
non-immunogenic route of antigen administration.
Acquired haemophilia A results from the spontaneous
development of autoantibodies against endogenous FVIII.
The context of the initiation of the autoimmune response to
self-FVIII is not understood. We believe that two different
immune contexts may pre-exist for the development of
autoimmune FVIII inhibitors, which will be addressed below.
Lastly, anti-FVIII antibodies of the immunoglobulin G (IgG)
isotype have been described in healthy individuals (Algiman
et al, 1992; Moreau et al, 2000); these antibodies are referred
to as natural anti-FVIII autoantibodies and have been shown
to inhibit the pro-coagulant activity of FVIII in vitro following
purification from serum by affinity-chromatography (Moreau
et al, 2000). In vivo, natural anti-FVIII autoantibodies are
neutralized by the presence of anti-idiotypic antibodies that
control their inhibitory potential towards FVIII (Rossi et al,
1988; Kazatchkine et al, 2000). Accordingly, natural FVIII-
reactive CD4+ T cells are found within peripheral blood
mononuclear cells of healthy donors, which are controlled by
the presence of regulatory CD4+CD25+ T cells (Kamate et al,
2006).
We shall summarize below the information that is currently
available regarding the involvement of CD4+ T cells in the
pathological autoimmune anti-FVIII response and will
describe the properties of FVIII inhibitors found in patients
with AHA.
Requirement for T-cell help in the anti-FVIII autoimmune
response
A classical immune response to an antigen requires several
sequential steps: the antigen is endocytosed by antigen
presenting cells (APCs), such as dendritic cells or macrophag-
es. The APCs process the antigen and present antigen-derived
peptides at their surface in complex with major histocompat-
ibility complex (MHC) class II molecules. The peptide-MHC
complexes are recognized by the T-cell receptor (TcR) of CD4+
T lymphocytes. If T cells simultaneously receive co-stimulatory
signals from the APCs, they are activated and differentiate into
effector T cells that will then assist antigen-specific B lympho-
cytes. In turn, the antigen-specific B lymphocytes are activated,
differentiated into memory cells or into plasma cells that
produce the antibodies. A strong T-cell dependent immune
response generally leads to the production of high affinity
antigen-specific antibodies of the IgG isotype.
As mentioned above, natural anti-FVIII IgG and natural
FVIII-reactive CD4+ T cells are found in healthy individuals.
This demonstrates that, under physiological conditions,
endogenous FVIII is internalized by APCs and presented to
T cells that receive strong enough co-stimulatory signals to
assist B cells. However, regulatory T cells that control natural
autoreactive anti-FVIII T cells have also been identified
(Kamate et al, 2006). In patients with AHA, the autoimmune
response results from a break of tolerance towards self-FVIII.
The requirement for T cells in the pathogenesis of AHA
probably depends on the underlying disorder, which precedes
the emergence of AHA.
In the literature, a few cases of AHA have been associated
with monoclonal gammapathies, as seen in patients with
Waldenstro¨m macroglobulinemia (Castaldi & Penny, 1970) or
myeloma (Glueck & Hong, 1965; Sallah et al, 2000; Holme
et al, 2005; Sari et al, 2009). It is probable that FVIII inhibitors
in these patients do not result from the development of a
classical immune response, but from the stochastic ‘tumou-
rogenization’ of B-cell clones that encode FVIII-specific
immunoglobulins that may be of the IgM, IgG or IgA isotypes
(Glueck et al, 1989). In the large majority of AHA patients
however, the immune response to FVIII is polyclonal and is
characterized by the production of polyclonal IgG. In these
patients, the disease is idiopathic or associated with autoim-
mune, inflammatory or infectious conditions, or develops
post-partum. The reasons for which an innocuous self-antigen
is suddenly ‘seen’ by the immune system as foreign and
‘undesired’, are not clear. As for most autoimmune diseases,
mimicry with foreign (viral or bacterial) antigens may evoke
immune dysregulation or excessive inflammation. Concrete
evidence is however scarce. The available literature suggests
that, under these conditions, CD4+ T cells play a role in the
pathogenesis of the disease.
Reding et al (1999, 2000) dissected the specificity of FVIII-
reactive CD4+ T cells in patients with AHA. These authors
isolated circulating mononuclear cells from the blood of about
10 patients with AHA. The cells were incubated with human
recombinant FVIII or with arrays of peptides spanning the
heavy and light chains of FVIII. The in vitro proliferation of
the memory CD4+ T cells was assessed upon incorporation of
tritiated thymidine (Reding et al, 1999, 2000). Memory CD4+
T cells from AHA patients were shown to proliferate in the
presence of intact FVIII. The use of overlapping peptides
demonstrated proliferation of the T cells against peptides
originating from the A2, A3 and C2 domains (Reding et al,
2000). More detailed analyses indicated that peptides from the
C2 domain, spanning the amino acids 2191–2210, 2241–2290
and 2291–2330, were the most prone to induce CD4+ T cell
proliferation. Interestingly, these peptide regions are also
known to overlap with inhibitor-binding sites (Reding et al,
2003). T cells from healthy individuals also proliferated in
response to the peptide spanning amino acids 2241–2290. In
the case of the A3 domain, a peptide spanning the amino
acids 1831–1850 was found to significantly induce the
proliferation of T cells from AHA patients (Reding et al,
2004).
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Anti-FVIII autoantibodies in AHA
Fulcher et al (1987) reported the presence of FVIII-specific
antibodies of the IgG1 and IgG4 subclasses in 5 patients with
AHA (Fulcher et al, 1987). Further, a more recent study
documented the presence of inhibitory IgG4 antibodies in 18
patients with AHA (Scandella, 1999). Additionally, Reding
et al (2002) documented a correlation between high levels of
anti-FVIII IgG4 antibodies and elevated inhibitory titres.
Conversely, at least half of the AHA patients with low inhibitor
titres, predominantly had IgG1 and IgG2 anti-FVIII autoan-
tibodies in this study (Reding et al, 2002).
The available information regarding the IGHV genes that
encode inhibitory anti-FVIII autoantibodies in AHA comes
from studies by the group of J Voorberg (van den Brink et al,
2000a,b, 2001, 2002). In this work, several scFv libraries were
generated using the circulating memory B cells of patients with
mild and severe haemophilia A, as well as from one patient
with AHA. In their experimental set-up, the patients’ IgG4-
specific IGHV gene repertoire was amplified and combined
with a variable light chain (IGLV) gene repertoire of non-
immune origin. The scFv displayed at the surface of filamen-
tous phages were then selected for binding to different
domains of the FVIII molecule. In the case of the only AHA
patient studied, four clones were isolated that bound to the C2
domain of FVIII. The isolated scFv clones had IGHV genes
encoded by the germline gene segments DP-10, DP-14 and
DP-88, that all belong to the IGHV1 gene family. The clones
harboured extensive hypermutations (11–16 amino acid
substitutions), indicating that the autoimmune anti-FVIII
humoral response in AHA undergoes affinity maturation,
indirectly confirming the help provided by FVIII-specific
CD4+ T cells. Interestingly, other monoclonal C2-specific anti-
FVIII IgG have been derived either from a scFv library
prepared from cells of a patient with mild haemophilia A (van
den Brink et al, 2002), or from the Epstein–Barr virus-
transformed memory B cells of a patient with severe haemo-
philia A (Jacquemin et al, 1998); all anti-C2 antibodies were
shown to be encoded by IGHV genes that were also
homologous to the IGHV1 gene family. Whether all
C2-specific IgG in AHA are encoded by IGHV1 genes remains
to be confirmed upon analysis of a large repertoire of patients.
Such a result would pave the way towards the development of
therapeutic approaches aimed at specifically targeting B cells
expressing restricted families of IGHV genes, for instance
using anti-idiotypic strategies (Kazatchkine et al, 2000; Gilles
et al, 2004).
Epitope specificity of anti-FVIII autoantibodies in AHA
Available data on the epitope specificity of FVIII inhibitors
show that the main target domains for anti-FVIII IgG of
patients with AHA are the A2 and C2 domains, while the
A1, A3 and C1 domains are rarely targeted. In a cohort of
21 AHA patients, Prescott et al (1997) showed that anti-
bodies from 13 patients were exclusively directed against
either the C2 or the A2 domain with a majority (IgG from
10 patients) being directed to the C2 domain. Another
study, which included 22 AHA patients (Scandella, 1999),
showed a mixed specificity of autoantibodies towards the A2
and C2 domains. Importantly, high inhibitory titres have
been associated with recognition of either the A2 or C2
domains of FVIII. This is in agreement with similar studies
performed on inhibitor-positive patients with congenital
haemophilia A.
As was reported in the case of anti-FVIII alloantibodies
found in patients with congenital haemophilia A; C2
domain-specific autoantibodies in AHA patients inhibit the
binding of FVIII either to von Willebrand factor (VWF) or
to phospholipids, thus preventing the protective effect that
VWF plays on FVIII catabolism or the role played by
phospholipids in FVIII activity (Gawryl & Hoyer, 1982; Arai
et al, 1989). Further, antibodies from AHA patients, similar
to those from patients with congenital hemophilia A, may
also inhibit the activation of FVIII by thrombin and activated
factor X; as shown by their ability to prevent the binding of
C2 domain-specific non-classical (type II inhibitors) anti-
bodies (Meeks et al, 2007, 2008). Lastly, binding of anti-
FVIII autoantibodies to the A2 and A3 domains prevents the
interaction of FVIII with thrombin, activated factor IX and/
or factor X, thus hampering the formation of the tenase
complex (Fay & Scandella, 1999; Scandella, 1999; Gharagoz-
lou et al, 2009).
Kinetics of FVIII inhibition
Anti-FVIII inhibitory antibodies have been classified into type
I and II antibodies, based on their kinetics of FVIII inactiva-
tion. Antibodies with type I kinetics inhibit the pro-coagulant
activity of FVIII in a dose-dependent manner; in other words,
the amount of FVIII activity measured in the Bethesda assay is
proportional to the dilution of the plasma tested. In contrast,
type II antibodies exhibit non-linear inactivation patterns, and
total FVIII inactivation is generally not reached even when
plasma is tested undiluted. A preventive role for VWF has been
attributed to the partial inactivation of FVIII by type II
inhibitors. Thus, it was demonstrated that some type II
inhibitors compete with VWF for binding to FVIII (Gawryl &
Hoyer, 1982), although this is not the case for all type II
inhibitors (Jacquemin et al, 2000). In rare cases, VWF has been
shown to be required to allow certain type II antibodies to
exert their inhibitory activity, by reducing the rate of
dissociation of activated FVIII from VWF (Peerlinck et al,
1999). Interestingly, while alloantibodies from patients with
congenital haemophilia A generally behave like type I
antibodies, autoantibodies to FVIII more frequently exhibit
type II kinetics of FVIII inactivation. Rather than differences in
epitope specificities, differences in binding affinities for FVIII
may be the discriminatory feature between type I and II
inhibitors.
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Risk factors for AHA
The development of autoimmunity represents a breakdown in
the balance between immunogenic and tolerogenic signals that
constantly trigger the immune system. The fine-tuning of this
balance is under the control of multiple factors. In this respect,
the onset of AHA probably results from a combination of
genetic and environmental factors, together with a decline in
immune tolerance that is associated with ageing, or that
accompanies the postpartum period. A couple of genes have
been proposed to be associated with the development of AHA;
these include genes encoding HLA molecules and some co-
stimulatory molecules that are essential in the cross-talk
between antigen presenting cells and CD4+ T lymphocytes.
Polymorphisms in CTLA4 in AHA patients
The cytotoxic T-lymphocyte-associated protein 4 (CTLA4)
gene is an important co-stimulatory molecule present at the
surface of activated CD4+ T lymphocytes and of regulatory T
cells. It is involved in the preservation of T-cell homeostasis
and peripheral tolerance by down-regulating effector T-cell
responses. Interestingly, two studies have demonstrated the
association of single nucleotide polymorphisms (SNPs) in the
CTLA4 gene with inhibitor development in patients with
congenital severe haemophilia A (Astermark et al, 2007;
Pavlova et al, 2009).
The frequencies of different SNPs in CTLA4 have been
reported in AHA patients (Pavlova et al, 2008). Genetic
polymorphisms of CTLA4 were studied at three positions:
)318 C/T, +49 A/G and CT60 A/G. The CTLA4 49 A/G
polymorphism occurred at a significantly higher frequency in
patients with AHA compared with controls. A sub-cohort
analysis showed a higher frequency of the G allele in groups of
patients with idiopathic AHA and in AHA patients with
underlying autoimmune diseases (Pavlova et al, 2008). The
CTLA4 49 A/G polymorphism has been shown to change a
threonine into an alanine at position 17 of the leader peptide
sequence (Ligers et al, 2001; Maurer et al, 2002). This alter-
ation causes an improper compartmentalization of the
molecule in the endoplasmic reticulum, resulting in hampered
mobilization of the molecule at the cell surface. The ensuing
decreased expression of CTLA4 has been shown to hamper the
CTLA4-driven down-regulation of T-cell activation.
The effect of the CTLA4 polymorphism has not been shown
at the protein level in AHA patients. However, with reference
to other studies (Ligers et al, 2001; Maurer et al, 2002), we
may speculate that AHA patients bearing such polymorphisms
have inadequate peripheral tolerance towards endogenous
FVIII. This would result in an inappropriate control of FVIII-
specific CD4+ T cells, leading to facilitated B-cell activation
and development of inhibitors.
Of interest, seminal work by Astermark et al (2006a,b) have
documented strong associations between a SNP in the TNF
and IL10 genes, with inhibitor development in severe congen-
ital haemophilia A patients. Both polymorphisms had been
previously associated with increased transcription and secre-
tion of the respective cytokine, thus leading to inflammation in
the case of TNF, or to B-cell activation in that of IL10 (Wilson
et al, 1997; Zheng et al, 2001). To our knowledge, associations
between polymorphisms in TNF and IL10 and the onset of
AHA have not been reported as yet.
HLA haplotypes in AHA patients
A recent study including 57 AHA patients investigated associ-
ations between the development of the disease and HLA class I
and class II haplotypes (Pavlova et al, 2010). While there was no
association of AHA with HLA class I haplotypes, a significantly
higher frequency of the HLA class II molecules DRB1*16 and
DRB1*0502 was found in AHA patients as compared to healthy
controls. In contrast, the HLA class II molecules DRB1*15 and
DQB1*0602 were detected at significantly lower levels. Interest-
ingly, a similar analysis performed in a population of inhibitor-
positive and inhibitor-negative patients with severe congenital
haemophilia A yielded completely opposite results (Pavlova
et al, 2010). The alleles found to be susceptible in AHA were
identified as low inhibitor risk alleles in congenital haemophilia
A. Conversely, DRB1*15 and DQB1*0602, identified as protec-
tive alleles in AHA, were found to be high inhibitor risk alleles in
congenital haemophilia A (Pavlova et al, 2009). DRB1*15 is
particularly suited to the presentation of the FVIII-derived
peptide 1706–1721 to CD4+ T lymphocytes, and has been
proposed to participate in the alloimmunization process against
exogenous FVIII in severe haemophilia A (Pavlova et al, 2009). It
is tempting to speculate that, in AHA, high affinity HLA alleles
such as DRB1*15 are mostly involved in conferring tolerance to
the endogenous FVIII; the DRB1*15 HLA class II allele would
play amajor role in presenting processed FVIII peptides to newly
arising T cells in the thymus, thus favouring the elimination of
autoreactive FVIII-specific CD4+ T lymphocytes and the
generation of regulatory T cells in the thymus or at the periphery.
Polymorphisms in the F8 gene in AHA patients
One intriguing field of study regarding genetic predisposition
to AHA is related to particular polymorphisms in the FVIII
gene (F8). Indeed, a novel SNP C.8899G > A was found at
the 3¢UTR region of exon 26 in two Korean patients with
AHA (Hwang et al, 2011). While this has not been reported
by other groups in the case of AHA as yet, a similar
correlation between a SNP in the 3¢UTR of F9 and levels of
circulating factor IX in haemophilia B has been proposed (de
la Salle et al, 1993). More recently, several polymorphisms
have been reported in the coding sequence of F8, which are
differently distributed between patients of different ethnic
origins. Whether particular combinations of the different
SNPs in F8 facilitates the development of pathogenic auto-
immune responses to FVIII remains to be investigated (Viel
et al, 2009).
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Proteolytic activity of antibodies in AHA
Generation of catalytic antibodies
Catalytic antibodies are immunoglobulins endowed with
enzymatic activities. This possibility was first postulated by
Pauling (1946), and demonstrated 30 years later (Satterthwait
& Jencks, 1974). The first molecular analysis of catalytic
antibodies became possible in the 1980’s with the production
of the monoclonal antibodies using hybridoma technology
(Pollack et al, 1986; Tramontano et al, 1986). The catalytic
activity of immunoglobulins is associated with the antigen-
binding site, which has been shown to mimic structurally and
functionally the active site of enzymes (Fig 1).
Several experimental protocols have been used to generate
monoclonal catalytic antibodies (for review, see Lacroix-
Desmazes et al, 2006a). Historically, the first attempts were
performed upon immunization of mice with transition-state
structural analogues of substrate molecules, which represent
chemical structures, as seen in enzyme-catalysed reactions
(Thomas, 1994). Alternative strategies have been based on the
use of covalent reactive analogues (CRA) of suicide inhibitors
for serine proteases, such as phosphonate diesters. The CRA
molecules bind covalently to the active site serine residue after
engaging into a nucleophilic-electrophilic electron attack. As a
bait, the CRA moieties are coupled to the amino acid
corresponding to the cleavage site on the target antigen/
substrate, and the CRA-peptide chimera are used to immunize
mice or screen phage libraries for fishing out catalytic
antibodies (Paul et al, 2003; Taguchi et al, 2008). In an
original approach, one group has exploited the idiotypic
network to generate monoclonal catalytic antibodies. The
‘idiotypic approach’ first requires the generation of a mono-
clonal antibody, referred to as Ab1, which binds to the active
site cleft of the enzyme of interest. Secondary monoclonal
antibodies, referred to as Ab2, are then generated against the
variable region of the Ab1. While the antigen binding site of
the Ab1 represents an ‘inverse’ image of the active site of the
enzyme, some of the generated Ab2 carry an internal image of
the active site of the enzyme, and are thus endowed with
similar enzymatic activities: antibodies with esterase, lactamase
and amidase activities have thus been produced (Izadyar et al,
1993; Avalle et al, 1998; Ponomarenko et al, 2007).
Catalytic antibodies in physiological and pathological
conditions
Catalytic antibodies also arise spontaneously in humans,
without deliberate immunization. The first description was
provided by Paul et al (1989) who documented the presence of
IgG with the ability to hydrolyse the vasoactive intestinal
peptide in patients with asthma. A few years later, the presence
of DNA-hydrolysing IgG was demonstrated in patients with
systemic lupus erythematosus (Shuster et al, 1992), and we
demonstrated the presence of thyroglobulin-hydrolysing IgG
in a patient with Hashimoto thyroiditis (Li et al, 1995). Since
then, catalytic antibodies have been associated with a range of
pathologies, including multiple myeloma, rheumatoid arthri-
tis, multiple sclerosis, and HIV-related immune thrombocy-
topenia (Paul et al, 1995; Baranovskii et al, 2001; Nardi et al,
2001; Ponomarenko et al, 2002). Catalytic antibodies are also
found under physiological conditions in humans. Thus,
catalytic antibodies of the IgG and IgM isotypes form part of
naturally occurring antibodies (Kalaga et al, 1995; Planque
et al, 2004) and have been suggested to participate in the
removal of metabolic waste and protection from bacterial
infections (Friboulet et al, 1999; Nathan, 2002; Wentworth
et al, 2002). Interestingly, the presence of IgG with amidolytic
activity has been positively associated with survival or positive
outcome in severe sepsis (Lacroix-Desmazes et al, 2005).
Antibodies with hydrolytic properties have been shown to
target a large number of self or exogenous antigens; target
antigens of particular interest to the present review are proteins
involved in blood coagulation – FVIII and FIX (Lacroix-
Desmazes et al, 1999, 2002; Wootla et al, 2008).
FVIII-hydrolysing IgG
In our early work, we demonstrated the presence of IgG with
proteolytic activity towards exogenous therapeutic FVIII in
inhibitor-positive patients with severe congenital haemophilia
A (Lacroix-Desmazes et al, 1999). FVIII-hydrolysing IgG were
detected in about 50% of the patients included in the study
(Lacroix-Desmazes et al, 2002). Further, the rates of IgG-
mediated FVIII proteolysis measured in vitro were positively
correlated to the inhibitory activity measured in the plasma of
the patients (Lacroix-Desmazes et al, 2002), although it is
Fig 1. Antigen hydrolysis by catalytic antibodies. The antigen-binding domain of a catalytic antibody mimics the active site of an enzyme. Similar to
the enzyme-mediated catalysis of a substrate into its product, catalytic antibodies interact with their antigen (e.g., FVIII) and mediate its hydrolysis.
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obvious that the different anti-FVIII IgG in the polyclonal
antibody population of a single patient may simultaneously
neutralize therapeutic FVIII by several means: classical steric
hindrance and proteolysis. Importantly, the proteolysis of
FVIII by IgG was demonstrated to lead to FVIII inactivation in
vitro (Lacroix-Desmazes et al, 2006b). The protease activity
was similar to that of serine proteases, as more than 80% of the
identified cleavage sites on FVIII occurred after a lysine or an
arginine (Lacroix-Desmazes et al, 2006b).
More recently, we observed that IgG from about 47% of
AHA patients also hydrolysed FVIII (Wootla et al, 2008). A
longitudinal study, performed on four AHA patients to
evaluate the relationship between FVIII hydrolysis and FVIII
inhibition, suggested a co-evolution of the catalytic activity
with the inhibitory titre over time. However, despite the
inhibitory potential of FVIII-hydrolysing IgG in AHA patients,
no correlation was found between the presence/absence of
proteolytic IgG and the clinical parameters of the patients, or
the survival status of the patients 1 year after diagnosis. The
results of this study did not enable us to attribute the epitope
specificity or the type I/II kinetics of FVIII inhibition to the
presence of FVIII-hydrolysing IgG.
The nature of the anti-FVIII autoimmune response respon-
sible for AHA differs in several aspects from that of the
alloimmune response that develops in patients with congenital
haemophilia A; differences in the kinetics of FVIII inactivation
and in the capacity to be neutralized by anti-idiotypic
antibodies (Lacroix-Desmazes et al, 2000) have thus been
suggested. The capacity of patients’ IgG to hydrolyse FVIII
identified one additional distinctive criteria between the two
pathological situations. Indeed, IgG-mediated FVIII hydrolysis
in congenital haemophilia A is characterized by a higher
average hydrolytic rate than that scored in AHA patients
(Wootla et al, 2009). Further, a significant and positive
correlation was found between the hydrolysis of FVIII and of
a synthetic chromogenic peptide substrate (proline-phenylal-
anine-arginine-MCA) in the case of anti-FVIII autoimmune
IgG, which was not found with alloantibodies, thus suggesting
fine differences in epitope specificity.
Factor IX-hydrolysing IgG
Our initial work on FVIII-hydrolysing IgG in congenital
haemophilia A failed to detect hydrolysis of other self-antigens,
such as human serum albumin and human recombinant FIX
used as controls (Lacroix-Desmazes et al, 2002). However,
IgG-mediated hydrolysis of FIX was detected, together with
FVIII hydrolysis, in one of the patients who survived from
severe sepsis (Lacroix-Desmazes et al, 2005). No satisfactory
explanation could be provided at the time, although it is
possible that the combined hydrolysis of FVIII and FIX exerted
anti-thrombotic effects and prevented disseminated intravas-
cular coagulation, thus protecting the patient.
Recently, we have found that IgG from some patients with
AHA may hydrolyse FIX in addition to FVIII (Wootla et al,
2011). The proteolytic activity was a property of the antigen
binding site, as it was recovered with the purified F(ab’)2
fragments of the patients’ IgG. Of note, FIX-hydrolysing IgG
were not detected in inhibitor-positive patients with congenital
haemophilia B. Taken together, these data suggests that, in
contrast to FVIII-hydrolysing IgG that are found in congenital
as well as AHA, the spontaneous generation of FIX-hydroly-
sing IgG requires the endogenous presence of the antigen.
Interestingly, the migration profile of IgG-hydrolysed FIX
resembled that of activated FIX (Fig 2). Indeed, N-terminal
sequencing of the IgG-mediated FIX degradation products
confirmed cleavage of FIX at the arginine 180 residue and we
confirmed that IgG-mediated hydrolysis of FIX lead to the
activation of the coagulation factor (Fig 3) (Wootla et al,
2011). Overall, IgG from 38Æ5% of the patients included in the
cohort were able to activate FIX. IgG-mediated FIX activation
tended (P = 0Æ07) to be significantly associated with patient
survival 12 months following diagnosis. In vitro assays showed
that the FIX-hydrolysing IgG were able to generate an average
0Æ3 nmol/l of activated FIX per 24 h. Such a modest amount of
activated FIX was able to restore thrombin generation in vitro,
provided that a basal level of FVIII ‡3% was present in the
assay (Wootla et al, 2011). Although the measured kinetics of
IgG-mediated FIX activation are low when compared to that of
physiological FIX-activating enzymes (i.e., activated factor XI),
we believe that the low kinetics are compensated by the long
half-life and high concentration of IgG in the blood. Moreover,
a fraction of the circulating FIX upon IgG-mediated activation,
Fig 2. Hydrolysis of factor IX by purified IgG from a patient with
AHA. Human recombinant factor IX (FIX), human recombinant
activated factor IX (FIXa), IgG purified from the plasma of a patient
with AHA, and FIX incubated in the presence of the patient’s IgG were
subjected to 4–12% sodium dodecyl sulphate polyacrylamide gel
electrophoresis. Proteins were stained by colloidal Coomassie blue.
Incubation of FIX with patient’s IgG resulted in the generation of a
band corresponding to the size of FIXa.
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may feed in the coagulation cascade and compensate for the
loss of FVIII activity in AHA patients.
Conclusion
AHA is a serious disease with a high mortality rate. The
reasons for the elevated mortality are mostly related to the old
age of the patients, to particular underlying pathologies (e.g.,
cancer) or to the difficulty to re-establish haemostasis and
immune homeostasis in the patients. The data accumulated in
the recent past emphasizes the association of certain gene
polymorphisms with AHA development, as well as the
importance of autoreactive CD4+ T lymphocytes in the
generation of the FVIII inhibitors. The observations however
do not open obvious avenues towards better management of
the patients. An original finding in the last year is the
observation of FIX-hydrolysing IgG that activates the molecule
in about a third of AHA patients. In vitro data suggest that the
generation of activated FIX by IgG re-establishes thrombin
generation in a situation where some residual FVIII activity is
present. To date, haemorrhages in patients with AHA are
treated with FVIII, activated factor VII, or activated
prothrombin complexes, all of which are hampered by short
half-life and/or risk for thromboembolic complications. Our
recent findings raise the issue of the therapeutic relevance of
the passive administration of FIX-activating IgG. Proteolytic
antibodies would advantageously combine properties of
enzymes, which is ‘turnover’, and properties of antibodies,
that is long half-life. Moreover, FIX-activating antibodies
would pose low risk for thrombotic complications because of
their low catalytic rates of FIX activation.
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Conclusion: 
Antibodies are versatile molecules known to play a plethora of functions. Indeed it is the 
inherent diversity installed in the immunoglobulin repertoire that enables antibodies to 
perform several functions. Our present knowledge on antibody functions have extend 
from binding to single cognate antigen, to polyreactivity and even catalytic activity.  
Although it has been 25 years since the development of the first catalytic antibody, our 
knowledge on their physiopathological role is still rudimentary. During my PhD, I tried 
to understand some of the basic questions regarding catalytic antibodies. Intially thought 
to be deleterious in disease, they are now considered to be molecules involved in 
maintaining immune homeostasis. Our study on acquired hemophilia and renal transplant 
provides newer insights into the beneficial aspects of catalytic antibodies. We observed a 
novel function of FIX activation by patients’ IgG, which showed a tendency towards 
better survival of the patients. We believe that FIX activating antibodies can be a good 
therapeutic tool for treating patients with acquired hemophilia. In addition our study on 
patients with renal transplant provided an insight on the evolution of catalytic antibodies 
during the course of the disease. The results of this study will have implication in future 
in the utility of catalytic antibodies as a predictive tool for chronic allograft nephropathy. 
Finally our results on polyreactivity have provided greater insight on the mechanism of 
heme-induced polyreactivity. In perspective we wish to revisit the phenomenon by re-
cloning the variable region genes in an IgM cloning vector.   
 
 
